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Chapter I 
 
INTRODUCTION 
 
Hemozoin: Biomineralization in Disease
1
 
 
 
In nature, biomineralization is observed across the entire biosphere.  These 
biologically synthesized materials can consist of carbonate, phosphate, oxalate, silica, 
iron, gold and many other diverse compositions of organic or inorganic materials.  The 
most well-known examples of biomineralization are those that lend structural support to a 
species, including the formation of bones in vertebrates and the shells of eggs.  The 
formation of these biominerals generally occurs under physiological conditions in a 
highly controlled and organized sequence of events.  Another biomineral, hemozoin, is a 
heme crystal synthesized by the malaria parasite as a survival mechanism to escape heme 
related toxicity.  The discovery of this detoxification biomineral actually precedes the 
discovery of the malaria parasite itself.  Although hemozoin has been studied since the 
18
th
 century, scientists have only begun to obtain a detailed understanding of the structure 
and formation of this biomineral in the last 25 years.  Hemozoin formation is an 
important drug target in antimalarial drug discovery and development.  In fact, 
chloroquine, arguably the most successful antimalarial developed to date, acts by 
disrupting formation of hemozoin.  Unfortunately, chloroquine is now ineffective as an 
antimalarial due to the emergence of multidrug-resistant strains of the parasite, though 
hemozoin remains a viable drug target in antimalarial drug discovery.  In order to 
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develop new antimalarial compounds that target the formation of hemozoin, it is 
important to have a sound understanding of the formation of this biocrystal. 
 
Malaria Overview 
 
Malaria is an ancient disease that has affected mankind throughout human 
history.
2
  Malaria is caused by several species of intracellular protozoan parasites of the 
Plasmodium genus.  Of this genus, there have been at least 200 species identified.  Four 
species, including falciparum, vivax, malariae and ovale, are known to infect humans.  
However, the primary causative agent of human malaria, P. falciparum, is responsible for 
the vast majority of deaths that occur as a result of malaria.  During the mid-1900s, the 
WHO proposed an ambitious strategy to eradicate malaria worldwide.
3
  This eradication 
campaign dramatically lowered malarial infections worldwide through a combination of 
vector control methods and drug treatment using the antimalarial chloroquine.  In several 
areas with seasonal transmission or temperate climates, such as Europe and North 
America, the elimination was successful.  Unfortunately, no significant improvements 
were made in sub-Saharan Africa where over 90% of malaria deaths occur.  
After two decades the focus of these efforts shifted to a less ambitious goal of 
malaria control due in part to the emergence of chloroquine-resistant parasites and safety 
concerns with vector control methods.  Recently, resurgence in malaria cases has been 
observed, primarily in underdeveloped, poverty-stricken countries.
4,5
  While it has been 
over 50 years since resistance to chloroquine was first reported, no affordable, widely 
available replacement has been developed.  It is currently estimated that there are over 
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300 million cases of malaria each year, resulting in nearly one million deaths.
6
  The 
majority of these deaths occur among children under the age of five living in sub-Saharan 
Africa.  The increase of drug-resistant strains of the malaria parasite creates a critical 
need for the development of new antimalarial treatments.       
 
Lifecycle of Plasmodium and the Significance of Hemoglobin Degradation 
 
During the intraerythrocytic stage of infection, the malaria parasite consumes host 
hemoglobin as a source of amino acids.
7
  As a result, toxic free heme is released. In 
humans, several detoxification mechanisms are in place to protect against the drastic 
toxic effects of free heme.  Primarily, heme detoxification is carried out by the heme 
oxygenase (HO) systems (HO-1, HO-2 and HO-3), and by extra-HO systems less 
frequently, including hemopexin and albumin.
8
  These HO enzymes play a large role in 
protecting cells from the oxidative stress caused by free heme by working with NADPH–
cytochrome P450 to break down the porphyrin ring into equimolar amounts of free iron, 
biliverdin, and carbon monoxide.
9
  In this process, HO transfers reducing equivalents to 
the α-methene bridge of heme from NADPH-cytochrome P-450 reductase to open the 
tetra-pyrrolic ring, freeing CO and biliverdin.  Biliverdin is then coverted to bilirubin by 
biliverdin reductase conjugated to glucuronic acid, and excreted from the body.  The HO 
systems are very efficient at detoxifying free heme and restoring homeostasis in the 
organisms that have them, but organisms that lack the HO systems have developed 
alternative mechanisms to protect themselves from free heme toxicity. 
 4 
One organism lacking a HO system is the parasite responsible for malaria. The 
lifecycle of the malaria parasite is quite complex (Figure 1).  Plasmodium sporozoites are 
transmitted to humans through the saliva of a female Anopheles mosquito during a blood 
meal.  Once in the host’s bloodstream, sporozoites invade hepatocytes and undergo a 
phase of growth and differentiation followed by the release of merozoites into the 
bloodstream.  The merozoites then enter host red blood cells, referred to as the 
intraerythrocytic stage of infection.  This stage is characterized by the onset of the 
symptoms of a malaria infection.  Inside the erythrocyte, the parasite goes through three 
distinct growth phases that can be distinguished under a light microscope (Figure 2).  The 
ring stage is first, lasting about 24 hours.  The second stage is the very active trophozoite 
stage.  It is during this stage that most of the erythrocyte cytoplasm is consumed.
7
  Third, 
the parasite undergoes 4-5 cycles of binary divisions, producing merozoites that 
eventually rupture the red blood cell membrane, and enter the bloodstream to infect new 
red blood cells.  During this intraerythrocytic cycle, the host cytoplasm is consumed, and 
an estimated 60-80% of available hemoglobin is degraded for use as a nutrient source and 
to create room for growth.
7
  During this degradation process, the amino acids obtained 
from hemoglobin catabolism are incorporated into Plasmodium proteins and used for 
energy metabolism.
10
   The amino acids Plasmodium cannot obtain from hemoglobin are 
readily scavenged from the environment.
11
 
 
 
 5 
 
Figure 1.  The lifecycle of the malaria parasite is complex.  Upon taking a blood meal, 
the infected female Anopheles mosquito transmits Plasmodium into the bloodstream of 
the human host.  The parasite travels to the liver where it matures and differentiates 
within hepatic cells.  Upon rupturing of the hepatic cells, the parasite enters the 
bloodstream and infects host red blood cells.  The parasite can develop into the sexual 
form (gametocytes) and can be picked up by a feeding mosquito before being transmitted 
to another human host.
12
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Figure 2.  During the intraerythrocytic stage of infection, the malaria parasite goes 
through three distinct growth phases (ring, trophozoite and schizont, respectively) that 
can be distinguished using a light microscope. 
 
 
The malaria parasite obtains hemoglobin from the cytosol through invagination of 
the parasitophorous vacuolar and plasma membrane, creating a double membrane vesicle 
(Figure 3). These vesicles fuse together, creating a single membrane digestive food 
vacuole.  Once formed, the digestive food vacuole becomes the primary site of 
hemoglobin digestion. This specialized organelle maintains an acidic environment, 
estimated pH of 4.8.
11
  Inside this organelle, aspartic and cysteine protease activities have 
been detected that are the primary enzymes responsible for globin proteolysis.
13
  Aspartic 
proteases make up about 60-80% of enzyme activity, while cysteine proteases make up 
20-40%.  The process of hemoglobin degradation has been found to occur in a specific 
order, requiring an initial aspartic protease cleavage, followed by secondary aspartic 
protease and cysteine protease cleavages.  Vacuolar degradation produces small 
polypeptides, but no free amino acids. This suggests that cleavage of the small peptide 
fragments occurs in the cytoplasm, outside of the digestive vacuole.
14
  During this 
process of hemoglobin degradation, large quantities of free heme are released and can 
reach concentrations of 400 mM if heme detoxification is prevented.
7
  The presence of 
free heme within the digestive food vacuole has several undesirable consequences.  Heme 
concentrations as low as 10-20 µM have been shown to inhibit several proteases present 
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within the digestive food vacuole including the plasmepsins and falcipains.
15
  In addition 
to inhibiting enzymatic activity, the presence of free heme is detrimental to the stability 
and deformability of the parasite vacuolar membrane.
16
  The resulting hemolysis is likely 
caused by perturbations to the membrane structure from the insertion of lipophilic heme 
into the phospholipid bilayer.  A further consequence of free heme accumulation is the 
increase in oxidative stress on the parasite.
17,18
  Since the malaria parasite does not have 
HO like vertebrates, the parasite detoxifies free heme by converting soluble, toxic free 
heme into an insoluble, nontoxic crystal called hemozoin.  This process is essential to 
parasite survival, as inhibition of hemozoin formation results in parasite death.
7,18
  
Indeed, the most successful antimalarial ever developed, chloroquine, has been shown to 
inhibit this detoxification pathway supposedly by binding free heme and preventing its 
insertion into the growing hemozoin crystal.
19,20
  Unfortunately, due to resistance 
mechanisms developed by the parasite, chloroquine no longer has clinical efficacy.  
However, hemozoin remains a valid drug target as resistance is a result of efflux, and 
resistant strains of the parasite still produce hemozoin normally.
21-24
  Therefore, it is 
essential that the formation of this biocrystal is better understood in order to promote the 
discovery of new antimalarials that target hemozoin formation. 
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Figure 3.  Within the erythrocyte, the malaria parasite relies on host hemoglobin as a 
source of amino acids.  Hemoglobin degradation occurs within an acidic organelle known 
as the digestive food vacuole.  Here, hemoglobin is degraded by proteolytic enzymes.  As 
a consequence, toxic free heme is released.  In order to survive, the toxic free heme is 
sequestered into a biomineral known as hemozoin.  Hemozoin is shown above as brown 
rods, encapsulated within a neutral lipid droplet, the suspected site of heme 
crystallization.  
 
 
Characterization of Hemozoin 
 
 Lancisi reported the discovery of hemozoin, the dark brown-black malarial 
pigment, in 1717.
25
  As these deposits are quite pronounced in the brains, spleens and 
livers of malaria victims, the discovery of hemozoin actually precedes the discovery of 
the malaria parasite itself by over 150 years.  For many years, it was hotly contested as to 
whether or not pigment was the actual cause of malaria, but in 1890, Golgi presented a 
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photograph of a pigmented parasite in the blood of a malaria patient, forging the 
connection between hemozoin and malaria.
26
 The composition and structure of hemozoin 
remained a subject of intense debate until 2000 when X-ray powder diffraction methods 
were used to identify the structure of β-hematin, the synthetic equivalent of hemozoin.27 
Once thought to consist of polymeric strands of O-Fe(III) linked heme units, XRD 
revealed a centrosymmetric triclinic unit cell comprised of reciprocal head-to-tail dimeric 
units of heme bound through propionate O-Fe(III) with a bond distance of 1.866(2) Å  
(Figure 4).  The propionic acid groups of the heme dimer then hydrogen bond with other 
dimers to form the extended crystal.  Morphologically, β-hematin and hemozoin crystals 
are needle-like and vary in size from several hundred nanometers to ~1 µm.  
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Figure 4.   The structure of hemozoin/β-hematin.  The unit cell is composed of head-to-
tail dimers of heme bound through propionate O-Fe(III).  The extended crystal is then 
formed from hydrogen bonding of the propionic acid groups of neighboring dimeric 
units.  
 
 
 
Synthetic Hemozoin, β-hematin 
 
Understanding the mechanism by which the parasite converts soluble, toxic free 
heme into an insoluble and non-toxic crystal is valuable for antimalarial drug-discovery, 
as perturbations to this crystallization process can result in parasite death.  However, 
studying the formation of hemozoin in vivo has proven challenging to researchers. β-
hematin, the abiological version of hemozoin, has been utilized as a tool to study 
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hemozoin formation in vitro.  For such comparisons to be meaningful, it had to be 
unequivocally established that these entities are isostructural.  Chemical, spectroscopic, 
and crystallographic evidence have been used to conclude the similarity of these two 
materials.   
Chemically, both hemozoin and β-hematin are composed of insoluble, head-to-tail 
dimers of Fe(III)PPIX (Figure 4).
27-29
 Spectroscopically, the similarity of hemozoin and 
β-hematin dimeric units can be confirmed from the infrared spectrum, that exhibits 
fingerprint vibrations around 1664 and 1211 cm
-1
 corresponding to the C=O and C-O 
stretching from coordination of the propionate O atom to the Fe(III) metal center of the 
neighboring heme molecule.
29
 Furthermore, the Fe(III) spin state of each species is 
identical, confirmed by variable temperature EPR that has shown that both β-hematin and 
hemozoin exist in the high spin S=5/2 state, a paramagnetic complex.
30
  This observation 
is in agreement with Mӧssbauer data where the isomer shift and quadrupolar splitting 
values suggest that the Fe(III) exists in a high-spin state. Morphologically, SEM images 
reveal that both BH and hemozoin are composed of needle-like crystals with tapered 
habits.  The crystal structure of each species is nearly identical.  Synchrotron x-ray 
powder diffraction patterns have demonstrated that the crystal structure of hemozoin is 
identical to its synthetic counterpart.  However, a more recent study suggests hemozoin 
may contain slightly more disorder in the Fe-O bonds than β-hematin formed under 
nonaqueous equilibrium conditions.
31
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Hemozoin as a Target for the Development of Antimalarials 
 
The malaria parasite contains several unique metabolic pathways that may be 
exploited for the discovery of new antimalarials.  These include targeting the synthesis of 
DNA precursors, fatty acid synthesis, glycolysis, and de novo heme biosynthesis, among 
others.
32-34
  Of relevance here, however, is inhibition of the formation of hemozoin.  One 
of the earliest effective treatments for malaria dating from the 17
th
 century was prepared 
from bark of Cinchona spp.
35
  The most active component of “Jesuit’s bark” was later 
identified as quinine, a potent inhibitor of β-hematin formation.  Chloroquine, arguably 
the most successful antimalarial developed to this day, is an analogue of quinine and is 
thought to share a similar mechanism of action: inhibition of hemozoin formation.
36
  
Unfortunately, the efficacy of chloroquine has widely diminished in endemic areas due to 
rampant drug resistance.  These resistant strains of P. falciparum exhibit several 
mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT), a 
transmembrane vacuolar protein.
22
  In resistant strains the accumulation of chloroquine 
within the digestive food vacuole is significantly less than in wild-type strains, as it is 
actively transported out of the digestive food vacuole.
37
  Nevertheless, hemozoin 
formation remains a valid drug target, as resistance is the result of diminished vacuolar 
accumulation of chloroquine, rather than changes to the hemozoin formation pathway 
itself.  Importantly, the interactions of hemozoin and antimalarial inhibitors of this 
pathway have been studied in great detail, lending a wealth of information that can 
facilitate the drug discovery process.  In utilizing hemozoin formation as a drug target, it 
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is important to gain insights regarding the mechanism of hemozoin formation utilized by 
the parasite. 
 
Mechanism of Hemozoin Formation 
 
 The identification of the biological mediator responsible for hemozoin formation 
has been a topic of intense debate.  Proteins, membrane lipids and neutral lipids extracted 
from the Plasmodium parasite have each shown to mediate β-hematin formation in vitro.  
Indeed, many biological components within parasite lysates are quite capable of 
promoting the formation of β-hematin in vitro.  One of the earliest studies of these lysates 
was conducted by Slater and Cerami who examined trophozoite extracts.
38
  The 
formation of β-hematin in the presence of these extracts was dependent on pH, time and 
concentration. The authors concluded that the presence of an enzyme, a heme 
polymerase, was responsible for mediating the formation of β-hematin, as activity of 
these lysates was sensitive to both heat and treatment with 1% SDS.  However, 
subsequent work contradicted this hypothesis, demonstrating that heat treated parasite 
lysates retained activity and therefore are not dependent on the presence of an enzyme.
39
  
It was suggested that β-hematin formation in these experiments was actually due to the 
presence of hemozoin crystals within the lysates.  In fact, the authors showed that 
preformed β-hematin crystals were sufficient to seed the process of crystallization in 
vitro.  While these studies demonstrated that an enzyme is not necessary for hemozoin 
formation, the mechanism of hemozoin crystallization remained unanswered.  
 14 
Polar membrane lipids were also implicated as a possible mediator of hemozoin 
formation.  Bendrat et al. first implicated these polar lipids when acetonitrile extracts of 
authentic hemozoin were found to promote the formation of β-hematin.40  MS analysis of 
these extracts identified the presence of the methyl esters of oleic, palmitic and stearic 
acids and low yields of phospholipids within the active fractions.  Further, it seemed that 
these studies were in agreement with a previously published TEM image of an intact 
parasite showing aligned parallelepiped crystals of hemozoin present within the digestive 
food vacuole of the parasite.  These observations supported the hypothesis that 
crystallization occurs via epitaxial nucleation of hemozoin at the lipid layer of the 
vacuolar membrane.
41
  Despite the strength of this argument, it was later revealed that 
axenic parasite cultures lacking a parasitophorus vacuolar membrane still produce 
hemozoin, ruling out any role for these membrane lipids in the parasite’s mechanism of 
heme detoxification.
42
  While these polar membrane lipids are capable of promoting β-
hematin formation in vitro, they are not responsible for the in vivo formation of 
hemozoin. 
More recently, the focus has shifted to the role played by neutral lipids in the 
process of hemozoin formation.  Neutral lipid droplets (also called neutral lipid particles, 
bodies or nanospheres) can be found concentrated within the digestive food vacuole of 
the parasite and are located in close proximity to crystals of hemozoin.
43,44
  These lipid 
droplets were subsequently extracted from the parasite by Sullivan and coworkers and 
found to consist of a mixture of mono and di-acylglycerols.
43
   Further, molecular 
dynamic simulations have demonstrated that the lipophilic environment of the lipid body 
would serve to stabilize the hemozoin precursor dimer and that formation of hemozoin 
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would be favored at the lipid/aqueous interface.
45
  However, the precise details regarding 
the mechanism of hemozoin formation have yet to be determined. 
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Chapter II 
 
INVESTIGATIONS INTO THE MECHANISM OF HEMOZOIN FORMATION
122 
 
Introduction 
 
 The mechanism by which the parasite converts soluble, toxic free heme into an 
insoluble, inert crystal has been the topic of intense debate.  Although hemozoin has been 
studied since the 18
th
 century, scientists have only begun to obtain a detailed 
understanding of the structure and formation of this biomineral in the last 25 years.  
Hemozoin formation is an important drug target in antimalarial drug discovery and 
development.  Therefore, understanding the mechanism by which hemozoin formation 
occurs within the parasite is valuable for the development of new antimalarials that target 
this parasite-specific pathway. 
 Proteins, membrane lipids and neutral lipids extracted from the Plasmodium 
parasite have each shown to mediate β-hematin formation in vitro.39,40  Indeed, many 
biological components within parasite lysates are quite capable of promoting the 
formation of β-hematin in vitro.  Recently, the focus has shifted to a role for neutral lipid 
droplets (NLDs, also known as neutral lipid particles/bodies or neutral lipid nanospheres) 
in the process of hemozoin formation.  TEM images have revealed that these NLDs are 
concentrated within the digestive food vacuole of the parasite and are located in close 
proximity to crystals of hemozoin.
44
  These NLDs were extracted from the parasite and 
characterized by Sullivan and coworkers in 2007.
43
  Analysis of these lipid droplets by 
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mass spectrometry identified a specific blend of monostearic, monopalmitic, dipalmitic, 
dioleic and dilinoleic glycerols in a 4:2:1:1:1 ratio, referred to as the “lipid blend”.  In 
vitro studies have further shown that a solution containing these neutral lipids support the 
conversion of free heme to β-hematin.43,46   
 Many lipophilic mediators of in vitro β-hematin formation have been identified 
including lipophilic extracts from the parasite as well as lipophilic detergents and 
solvents.
40,47,48
  It has been estimated that the maximum half-life required for hemozoin 
formation must be no more than 40 minutes in order for the parasite to escape free heme 
toxicity.
49
  Therefore, if the NLD is the site of hemozoin formation, then it must be 
capable of promoting the formation of hemozoin at a kinetically competent rate.  Here, a 
system of studying synthetic NLDs (SNLDs) is utilized in a physiologically relevant 
context to 1) examine the interactions that occur between SNLDs with free heme and 2) 
determine if SNLDs are a kinetically competent site for β-hematin formation. 
 
Experimental Methods 
 
Preparation of SNLDs 
 A 50 mM citric acid buffer was prepared.  The pH was adjusted to 4.8 using 
sodium hydroxide pellets.  Five lipid components were obtained for these studies:   rac 1-
monopalmitoylglycerol (MPG), rac 1-monostearoylglycerol (MSG), 1,3-dioleoylglycerol 
(DOG), 1,2-dipalmitoylglycerol (DPG) and 1,3-dilinoleoylglycerol (DLG).  Each lipid 
was prepared at a 16.2 mM stock concentration by solubilizing the lipid in a 1:9 
acetone/methanol solvent system.  The “lipid blend” refers to the biological lipid 
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components found to comprise the NLDs within the digestive food vacuole of the 
parasite (4:2:1:1:1 ratio of MSG:MPG:DOG:DLG:DPG prepared at final concentration of 
16.2 mM lipid content).  Citric buffer (5 mL) was added to 15 mL Falcon polypropylene 
conical tubes and allowed to equilibrate in a water bath for 15 min.  A 200 µL aliquot of 
stock lipid was then carefully deposited onto the surface of the citric buffer using a 22.5 
gauge needle.  The tubes were not disturbed following addition of the lipid.  If deposited 
carefully and correctly, the lipids will form an emulsion (Figure 5).  As the lipids’ 
environment becomes dominantly aqueous, the molecules aggregate in the form of solid 
particles.  As the organic solvent system becomes primarily aqueous, the solubilized 
neutral lipids spontaneously form SNLDs in order to maximize lipophilic interactions. 
 
 
Figure 5.  The lipid emulsion (red arrow) containing SNLDs is formed after carefully 
depositing solubilized neutral lipids in acetone/methanol onto the aqueous surface in a 5 
mL Falcon tube. 
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Kinetics of β-Hematin Formation 
 Fe(III)PPIX (heme) stock was prepared by solubilizing 2 mg of heme in 0.4 mL 
of 0.1 M NaOH.  This solution was then vortexed thoroughly to solubilize free heme.  
Next, 0.6 mL of a 1:9 acetone:methanol solution was added so that the final concentration 
of heme stock was 2 mg/mL.  To generate a lipid:heme stock, 2 µL of heme stock is 
added to 200 µL of lipid stock followed by vortexing for 5 sec.  This “premix” is then 
pre-warmed and carefully added to the surface of the citric buffer as described above.  β-
hematin formation was analyzed using the pyridine-ferrochrome method developed by 
Egan and coworkers.
50
  A solution of 50% pyridine, 20% acetone, water and 200 mM 
HEPES buffer (pH 7.4) was added to each tube followed by vortexing.  The final 
concentration of pyridine was 5%.  Each tube was then centrifuged at 3500 rpm for 10 
min to remove precipitated lipids.  200 μL was then transferred to a clear bottom 
microtiter plate and was then read at 405 nm on a Biotek H4 plate reader. 
 
Linear Range of Nile Red 
 The linear range of Nile Red (NR) signal in acetone was established using a 
Varian Cary Eclipse fluorescence spectrophotometer.  Excitation/emission wavelengths 
of 545/605 were used with 10 nm slit widths.  A stock concentration of 20 μM NR in 
acetone was prepared in a 5 mL falcon tube placed in an ice bath in order to limit the 
evaporation of acetone.  NR was added to a 96-well black fluorescence plate in a 
concentration range from 0-20 µM.  Acetone was used to correct for volume differences.  
The plate was quickly read to establish the linear range of NR signal.  An optimal 
concentration of 3.3 μM NR was established. 
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Interactions Occurring Between Heme and Nile Red 
 A stock of 3.3 µM NR was prepared in acetone and added to a black fluorescence 
plate as described above.  A 2 mg/mL solution of heme was prepared in 2:3 ratio of 0.1M 
NaOH:acetone.  This heme stock was titrated into the microtiter plate (0-500 μM) 
containing NR.  The plate was allowed to sit on ice for 2 minutes then quickly read to 
quantitate NR signal quenching as a function of free heme concentration. 
 This procedure was then adapted to incorporate SNLDs into the system (Scheme 
1).  A solution of 100:1neutral lipid blend: NR was prepared (as suggested by literature 
methods) and briefly vortexed.  This stock (60 µL) was then added citric buffer and 
vortexed briefly before adding the solution to a 96-well fluorescence plate.  Since NR 
fluorescent signal is quenched by water, the only signal observed in this sample is SNLD-
associated NR.  Next, the wells were titrated with free heme stock in a concentration 
range from 0-500 μM.  Since the NR signal is associated with SNLDs, then any 
quenching of the fluorescent signal would suggest heme is in close proximity with the 
SNLDs.    
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Scheme 1.  SNLDs were labeled with NR and combined with a pH 4.8 citric buffer then 
added to a fluorescence plate.  Following addition of the NR-labeled SNLDs to the plate, 
a heme titration was performed to monitor interactions occurring between heme and the 
SNLDs (heme was shown to quench NR signal). 
 
 
  
Characterization of SNLDs using Confocal Microscopy 
 The morphology of the SNLDs was observed using confocal microscopy.  A 1 
mL solution of NR-labeled SNLDs was prepared in a 100:1 ratio of lipid blend: NR as 
described above.  The stock was briefly vortexed and 168.5 μL was transferred and 
diluted with citric buffer (50 mM, pH 4.8) to 1 mL total volume and vortexed briefly.  
The final concentration of lipid in this solution was 300 µM.  From this NR-labeled lipid 
blend stock, 180 µL was transferred to a glass bottom microwell dish (MatTek 
Corporation, 14 mM microwell dish).  Confocal measurements were made using a Zeiss 
LSM 510META upright confocal microscope with a 63x oil immersion objective.  A 488 
nm argon laser with 505-550 nm band pass filter was used for imaging.  Z-stacking was 
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performed to examine the interior of the SNLDs to ensure that they were continuous 
throughout.   
 
Partitioning of Free Heme into SNLDs 
 A confocal microscope was used to analyze the interactions that occur between 
the SNLDs and free heme in real-time.  SNLDs were labeled with NR and transferred to 
a microwell dish in the manner described in the previous section.  Next, 20 μL aliquots of 
heme stock were carefully added every 30 seconds to the surface of the microwell dish 
containing the NR-labeled lipid blend until quenching was observed.  Extreme care was 
taken to not disturb the SNLDs in the focal plane.  A time series application was used to 
monitor changes in NR fluorescence every ten seconds.  Z-stacking was used at the 
beginning and end of the experiment to ensure that the lipids had not been displaced as a 
result of heme titration.  Proper controls were utilized to ensure photobleaching did not 
play a major role in NR quenching.    
  
Characterization of SNLDs using Dynamic Light Scattering 
 Dynamic Light Scattering (DLS) was used in order to establish the size 
distribution of SNLDs.  Following deposition of the lipid stock onto the surface of the 
citric buffer, the system was allowed to equilibrate for a period of time (5, 20, 40, and 60 
min, 37⁰C) resulting in the formation of a lipid emulsion (Figure 5).  A pipette was then 
used to carefully transfer 500 µL of the lipid emulsion to a cuvette and analyzed using a 
Malvern Zetasizer with a lower limit of 0.1 nm and an upper limit of 6 μm.  Each 
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measurement was repeated in triplicate to monitor the stability and size distribution of 
these SNLDs as a function of incubation time.   
 
Differential Scanning Calorimetry 
 Each lipid was weighed with a microbalance (2.4 – 3.2 mg samples).   Samples 
were sealed in aluminum capsules and analyzed over a temperature range from 80⁰ to -
80⁰C using a TA Instrument DSC Q200.  A cooling rate of 10⁰C/min and heating rate of 
15⁰C/min was used to measure exothermic and endothermic peaks. 
 
Characterization of β-Hematin 
 Product obtained from the kinetics experiments was characterized to confirm that 
the product formed was β-hematin.  Prior to characterization, the product was washed 
thoroughly with 5% pyridine to remove free heme contamination.  pXRD was conducted 
using Cu Kα radiation (λ = 1.541 Å), with data collection on a Philips PW1050/80 
vertical goniometer in the 2θ range of 5–40°.  Scanning electron microscope (SEM) 
images were obtained using a Hitachi S-4200 instrument to confirm the crystal habit of 
the product was similar to hemozoin.   
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Results and Discussion 
 
Characterization of SNLDs 
 The SNLDs were produced by depositing solubilized neutral lipids onto the 
surface of a buffer under physiologically relevant pH (4.8) and temperature conditions 
(37°C) in order to mimic the NLDs observed within the digestive food vacuole of the 
parasite.  Under these conditions, a lipid emulsion spontaneously forms (Figure 5).  The 
resulting emulsion was characterized to establish the size, stability and morphology of the 
SNLDs.  Upon generating the lipid emulsion, particle size was measured using DLS for 1 
h in 20 min intervals.  The DLS measurements revealed two distinct populations of 
particles - the largest population of SNLDs was ~50-200 nm in diameter, with a smaller 
population of ~1-10 µm in diameter.  The stability of this size distribution was found to 
be stable.  Confocal imaging of the Nile Red (NR) labeled SNLDs visually confirms the 
presence of spherical particles that range from approximately one hundred nanometers to 
a few micrometers in diameter.  Orthogonal projections reveal that the particles have a 
spherical morphology and are continuous (not hollow) (Figure 6).  These observations are 
in agreement with the characterization of the NLDs found within the digestive food 
vacuole of the parasite.
44
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Figure 6.  Orthogonal projections of NR-labeled SNLDs reveals the presence of 
spherical, continuous particles. 
 
 
Interactions Occurring Between Free Heme and Nile Red 
 If the digestive vacuole-associated NLDs are indeed the mediator of hemozoin 
formation utilized by the parasite, then it would follow that free heme would interact with 
these lipids.  To examine these interactions, the fluorescent probe, NR, was utilized.  
Fluorescence calibration measurements revealed a linear relationship between the 
concentration of NR and measured fluorescence intensity (Figure 7A) and revealed the 
linear range of NR signal intensity.  Using this fluorescent property, we then explored the 
interactions that occur between free heme (in a lipophilic solvent) and NR and revealed 
that heme quenches NR in a concentration-dependent manner (Figure 7B).  Addition of 
β-hematin did not quench the NR signal.  Next, NR-labeled SNLDs were generated under 
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physiologically relevant pH conditions and titrated with free heme (Scheme 1).  Under 
these conditions, NR that exists in the bulk aqueous solution is quenched, and the 
observed fluorescent signal is a result of NR enveloped within the SNLDs.  Upon 
addition of free heme, the NR signal is quenched, indicating the association of heme with 
the SNLDs (Figure 7C).   
 
 
 
 
Figure 7.  (A) Fluorescence calibration measurements revealed a linear relationship 
between the concentration of NR and measured fluorescence intensity.  (B) A 3.3 μM 
solution of NR in acetone was titrated with heme.  Fluorescence quenching was observed.  
(C) NR-labeled SNLDs were titrated with free heme.  Fluorescence quenching of NR was 
observed as a function of increasing heme concentration. 
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 To further examine NR/heme interactions in real-time, confocal microscopy was 
employed to visualize the transport and partitioning of free heme into the SNLDs.  We 
observed that upon careful addition of 20 μL aliquots of heme, the fluorescent signal of 
the SNLDs are rapidly quenched throughout (Figure 8A,B).  Z-stacking measurements 
confirmed that the quenching not only occurred on the surface of the SNLDs, but 
occurred within the interior of the lipid droplet as well.  As crystals of hemozoin have no 
effect on NR signal, these observations would suggest that free heme rapidly partitions 
into the SNLDs prior to crystallization.  The partitioning of heme into the SNLDs was 
pH dependent in a manner that mirrors the pH-dependence of β-hematin formation 
(Figure 8C,D).  The notion that NLDs serve as a reservoir for free heme are supported by 
previous reports that indicate these lipids may help protect heme from peroxide 
degradation, which would lead to parasite toxicity.
43
  In the absence of these lipids, a 50 
mM H2O2 solution degraded 50% of dilipidated hemozoin, while a 90 mM concentration 
of peroxide was necessary to reduce encapsulated hemozoin by 50%, suggesting that the 
lipids serve as a protective reservoir for free heme preceding its incorporation into the 
nontoxic hemozoin crystal.   
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Figure 8.  (A) NR-labeled SNLDs  (B) Fluorescence/DIC overlay of NR-labeled SNLDs 
demonstrate that heme-quenching is observed throughout the lipid bodies.  (C) 
Fluorescence quenching of NR-labeled SNLDs occurs in a pH dependent process, 
mirroring the observed (D) pH dependence of β-hematin formation.  Data in (D) was 
obtained by Dr. Anh Hoang 
 
 
Characterization of β-Hematin 
 Morphological and structural analysis of the product collected from depositing a 
solution of the lipid blend and heme to an aqueous surface confirmed the formation of β-
hematin.  SEM imaging of the product obtained revealed needle-like crystals resembling 
hemozoin in their crystal habit (Figure 9a). Infrared spectra (Fig 9b) of the product 
displayed prominent IR peaks at 1662 cm
-1
 and 1210 cm
-1
, indicating the formation of the 
C=O stretching vibration and the C-O stretching vibration of hematin linked dimers. 
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These findings are confirmed by XRD (Fig 9c) showing the expected diffraction peaks of 
-hematin.  
 
 
 
Figure 9.  Data obtained by former lab member Dr. Anh Hoang.  (a) The crystal habit of 
SNLD-mediated β-hematin crystals are similar to that observed for hemozoin.  (b) 
Characteristic IR peaks are observed at 1662 cm
-1
 and 1210 cm
-1
, indicating the 
formation of the C=O stretching vibration and the C-O stretching vibration of hematin 
linked dimers.  (c) XRD shows the expected diffraction peaks for β-hematin. 51 
 
 
Kinetics of β-Hematin Formation Mediated by SNLDs 
 It has been estimated that the in order to escape heme-associated toxicity, the 
parasite must convert free heme to hemozoin with a half-life of less than 40 min.
49
  
Therefore if NLDs are the mediator of in vivo hemozoin formation, crystallization would 
be expected to occur rapidly.  Here, SNLDs have been utilized to determine if these lipids 
serve as a kinetically competent site for β-hematin formation.  Each individual lipid 
component, as well as the biological lipid blend was examined as a mediator of β-
hematin formation under physiologically relevant conditions (pH 4.8, 37⁰C).  The half-
life for each reaction was determined.  β-hematin formation in the presence of the 
individual lipid components as well as the neutral lipid blend all revealed half-lives of <5 
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min (Figure 10a).  To examine this system further, the activation energy of β-hematin 
formation was determined for each component as well as the lipid blend.   
 The formation of β-hematin as mediated by SNLDs follows Arrhenius behavior 
(Figure 10b).  Half-lives of crystallization were examined at 25, 37, 45 and 60⁰C for 
individual lipid components and the lipid blend.  This analysis revealed that the 
monoglycerides exhibit higher energy barriers that the diglycerides.  MSG and MPG 
have calculated values of 74.8 ± 5.3 and 60.4 ± 7.1 kJ/mol, respectively, while DLG, 
DPG, and DOG exhibited lower values of 44.5 ± 15.4, 35.2 ± 9.4, and 37.7 ± 3.3 kJ/mol, 
respectively (Figure 10c).  When the lipid blend is utilized, a lower activation barrier of 
27.8 ± 3.4 kJ/mol is calculated. 
 
 
 
 
Figure 10.  (a) The half-life of β-hematin formation mediated by the neutral lipid blend is 
1.9 ± 0.01 min.  (b) SNLD-mediated β-hematin formation follows Arrhenius behavior.  
(c) The activation energy of β-hematin formation was calculated for each individual 
component as well as the neutral lipid blend.
51
  Data obtained in collaboration with Dr. 
Anh Hoang.   
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Differential Scanning Calorimetry Measurements of the Lipids 
 The activation barrier for β-hematin formation is reduced by utilizing the lipid 
blend compared to the individual lipid components.  This would suggest that the lipid 
blend provides a unique environment for crystallization to occur compared to the lipid 
components.  One explanation for this observation is that the heterogeneous lipid 
composition of the neutral lipid blend would facilitate better packing of lipid molecules 
through unique intermolecular interactions that are not observed between homogeneous 
lipid components.  These new interactions would result in a detectable change in heat 
flux necessary to break these new interactions.  Therefore, differential scanning 
calorimetry (DSC) was employed to measure the phase transition peaks of the neutral 
lipid components compared to the lipid blend.  MSG, MPG and DPG (saturated lipids) 
had higher melting points than DLG and DOG (Figure 11).  Specifically, negative heat 
flow peaks were observed at 76, 74 and 74⁰C MSG, MPG and DPG when the samples 
were heated.  When these samples were cooled, a positive heat flow at 69, 63 and 63⁰C 
was observed corresponding to crystallization peaks of MSG, MPG and DPG, 
respectively.  For the unsaturated diglycerides, different phase transition measurements 
were observed.  For DOG and DLG, melting temperatures of 25 and 4⁰C were measured.  
Positive heat flow peaks at 14 and -5⁰C were measured upon cooling the samples.   
 Each of these resultant plots were overlaid (Figure 11f, normalized to their 
biologically relevant ratio) for comparison to the phase transitions observed for the 
neutral lipid blend obtained experimentally (Figure 11g).  When comparing these two 
plots, there are distinct differences.  In the experimental DSC plot, the lipid blend 
exhibits three melting peaks at 5, 20, and 63⁰C that are not observed in the overlay.  
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Further, only two crystallization peaks (5 and 45⁰C) are observed in the blend compared 
to four crystallization peaks in the overlay.  These data suggest that unique intermolecular 
interactions, not present within the individual lipid components, exist in the blend of 
lipids located in the parasitic digestive food vacuole.   
 
 
 
Figure 11.  DSC measurements of (a) MSG, (b) MPG, (c) DPG, (d) DOG, (e) DLG, (f) 
an MSG/MPG/DOG/DLG/DPG overlay with components normalized to the lipid blend 
ratio of 4:2:1:1:1, and (g) the lipid blend. 
51
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Conclusions 
 
 
 If heme-associated toxicity is to be avoided, the malaria parasite must convert free 
heme to hemozoin with a half-life of less than 40 min.  Recent evidence has implicated 
neutral lipids in the formation of hemozoin.  If these neutral lipids are indeed the 
biological mediator of hemozoin formation, we expect 1) the lipids to support rapid 
formation of β-hematin and 2) free heme to interact with the neutral lipids.  Here, we 
have utilized SNLDs as a mediator of β-hematin formation under physiologically relevant 
conditions to examine the partitioning of heme and kinetics of crystallization.  By adding 
heme to a solution containing SNLDs, we have confirmed that crystals of β-hematin that 
are chemically, spectroscopically and morphologically identical to authentic hemozoin 
are formed.  Further, we have shown that SNLDs support formation of β-hematin with a 
half-life of less than 5 min.  Additionally, we have revealed that the lipid blend found 
within the digestive food vacuole of the parasite has a lower activation barrier for β-
hematin formation compared to the individual lipid components.  This data suggested that 
the lipid blend offers a unique intramolecular environment not supported by the 
individual lipid components.  We examined these interactions using DSC and confirmed 
that new phase transitions are observed for the lipid blend that are not seen in the 
individual lipid components, indicative of unique molecular interactions that exist in the 
heterogeneous lipid blend.  Finally, using NR-labeled SNLDs, we have demonstrated that 
not only does free heme interact with the surface lipids, but rapidly partitions throughout 
the lipid.  This would suggest that the neutral lipids serve as reservoirs for lipophilic, 
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toxic free heme.  Taken together, these data support a role for neutral lipid bodies in the 
process of hemozoin formation. 
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Chapter III 
 
DETERGENT-MEDIATED FORMATION OF β-HEMATIN123 
 
Introduction 
 
 During the intraerythrocytic stages of malarial infection, Plasmodium spp. 
catabolizes 60-80% of the red blood cell hemoglobin content to serve as a source of 
amino acids and to create space for growth.
7
  This process of hemoglobin degradation 
occurs within an acidic compartment (pH ~ 4.8) known as the digestive food vacuole.   
As a consequence of hemoglobin degradation, toxic amounts of free heme are released.  
Lacking an enzymatic method of detoxification, the parasite has developed a mechanism 
by which it converts the toxic, free heme into a nontoxic, insoluble biomineral known as 
hemozoin.  Once thought to consist of polymeric strands of O-Fe(III) linked heme units, 
XRD revealed a centrosymmetric triclinic unit cell comprised of reciprocal head-to-tail 
dimeric units of heme bound through propionate O-Fe(III) with a bond distance of 
1.866(2) Å  (Figure 4).
27
  The propionic acid groups of the heme dimer then hydrogen 
bond with other dimers to form the extended crystal.  Though this dark brown-black 
material was discovered in the tissues of malarial victims as early as 1717, the precise 
mechanism by which hemozoin formation occurs is not yet fully understood.
25
 
 Current evidence indicates a role for digestive vacuole-associated neutral lipids in 
the process of hemozoin formation (Chapter II).
43-46,51-53
 Specifically, neutral lipid 
droplets (also known as particles, nanospheres) present within the digestive food vacuole 
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of the parasite have been imaged in close proximity to crystals of hemozoin.  The 
composition of these lipids were identified by mass spectrometry and found to consist of 
a specific blend of neutral lipids in a 4:2:1:1:1 ratio of monostearic, monopalmitic, 
dipalmitic, dioleic and dilinoleic glycerols.  Synthetic neutral lipid droplets (SNLDs) 
consisting of this biologically relevant blend of lipids support the rapid conversion of free 
heme to β-hematin (half-life of 1.9 ± 0.01 min), the synthetic equivalent of hemozoin.46,51  
Furthermore, heme has been shown to rapidly localize within these lipid droplets in a pH 
dependent manner that mirrors the pH dependence of β-hematin biomineralization. 
 In addition to neutral lipids, several lipophilic abiological mediators of β-hematin 
formation have been identified including detergents, solvents, alcohols and acids.
54-57
  
Data obtained from these studies indicate that the lipophilicity of the abiological 
mediators facilitate the solubilization of free heme, the rate limiting step in β-hematin 
formation.
56,58
  As heme itself is quite hydrophobic and insoluble in aqueous solution, it 
would be expected that heme solubility would increase of a function of increasing 
hydrophobicity of the surrounding environment. 
Detergents possess a hydrophobic head group and a lipophilic tail, similar to 
lipids.  If the concentration of a detergent is above a certain threshold (CMC, critical 
micellar concentration), the detergent will spontaneously organize into spherical 
nanostructures known such as micelles or vesicles.  Here, we aim to investigate the 
ability of detergent nanostructures to serve as a surrogate for neutral lipid bodies in the 
process of β-hematin formation.  Eleven detergents were examined in their ability to 
solubilize free heme and competently facilitate formation of β-hematin. 
  
 37 
Experimental Methods 
 
Materials 
 Nonidet P-40 (NP-40) was purchased from Pierce Biotechnology, Rockford, Il.  
Flat bottom, 384-well plates (3680, Corning) were purchcased from Fisher.  Hemin 
(≥98%, Fluka), amodiaquine, sodium acetate trihydrate, Tween-20, Tween-80, Sodium 
dodecyl sulfate and pyridine were obtained from Sigma-Aldrich, St. Louis, MO.  All 
Triton X-detergents (45, 114, 165, 305, 102 and 100) were also purchased from Sigma-
Aldrich.   
 
Determination of Optimal Detergent Concentration 
The optimal concentration that promotes maximum product formation was 
determined for each detergent.  The range of concentrations tested varied from 0-400µM.  
Each detergent was solubilized in water (800 µM) and added in the appropriate volume to 
a 384-well flat bottom clear microtiter plate.  The total volume in each well was then 
adjusted to 25 µL using water.  A 25 mM stock solution of hematin was prepared by 
dissolving hemin chloride in DMSO followed by one minute of sonication.  The heme 
solution was then filtered through a 0.22 µM PVDF membrane filter unit.  From this 
solution, the heme suspension (100 µM) was added to a 2 M acetate buffer at pH 4.9 and 
vortexed for ~5 sec to make the ‘heme stock’ solution.  25 µL of this heme stock was 
rapidly added to each detergent well. The plate was then incubated in a shaking water 
bath for 24 hours at 37°C at 45 rpm.  Following incubation, the microtiter plate was 
removed from the water bath and the assay was analyzed using the pyridine-ferrochrome 
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method developed by Egan and coworkers.
50
  Following the addition of 15 µL of acetone 
to each well of the plate, 7 µL of pyridine solution (50% pyridine, 20% acetone, water 
and 200 mM HEPES, pH 7.4) was added so that the final concentration of pyridine was 
5% (v/v).  Following a 30 minute interval of shaking to facilitate the solubilization of free 
heme, the absorbance of the resulting complex was measured at 405 nm on a BioTek H4 
plate reader.       
 
Kinetics of Detergent Mediated β-Hematin Formation 
The half-life of β-hematin formation was determined for each detergent.  Stock 
solutions of each detergent were prepared at 2x the optimal concentration determined 
previously (all Triton X-detergents were analyzed at 50 µM concentration).  To 1.5 mL 
eppendorf tubes, 400 µL of the detergent stock was added.  The tubes were pre-incubated 
at 37°C for 15 minutes, followed by the addition of 400 µL of a 100 µM heme stock in 
2M acetate buffer (pH 4.9) was added to each tube.  The tubes were shaken at 45 rpm.  
Triplicate sample tubes were removed from the water bath at regular intervals and β-
hematin formation was analyzed using the heme-ferrochrome method of quantification 
described above.
50
       
 
Characterization of Detergent Nanostructures 
Dynamic Light Scattering (DLS) was used in order to establish the size 
distribution of detergent nanostructures.  Each detergent was prepared in 1 M acetate 
buffer at the optimal concentration of detergent to determine whether or not detergent 
micelles or vesicles were present at this concentration (each of the Triton X-detergents 
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was analyzed at 50 µM).  The detergents were equilibrated for 15 min at 37°C.  A pipette 
was then used to carefully transfer the solution to a cuvette and analyzed using a Malvern 
Zetasizer with a lower limit of 0.1 nm and an upper limit of 6 µm.  Triplicate samples 
were prepared to ensure the detergent nanostructure size distribution was stable. 
 
Characterization of β-Hematin Product 
Product obtained from the kinetics experiments was characterized to confirm the 
product was β-hematin.  Prior to characterization, the product was washed thoroughly 
with 5% pyridine to remove free heme contamination.  pXRD was conducted using Cu 
Kα radiation (λ = 1.541 Å), with data collection on a Philips PW 1050/80 vertical 
goniometer in the 2Ɵ range of 5-40°.  Scanning electron microscope (SEM) images were 
obtained using a Hitachi S-4200 instrument to confirm the crystal habit of the product 
was similar to hemozoin. 
 
Data Analysis 
 The kinetics of β-hematin formation were analyzed using linear least-squares 
fitting methods with Graphpad Prism 5.0.  The data were fit to the Avrami equation
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: 
 
          –zXn) 
 
where Y is the mass percentage of β-hematin formed, c is the maximum percentage of β-
hematin formed at the end of the reaction, z is the rate constant, X is time and n is the 
Avrami constant.  Kinetics data were fit to n = 1, 2, 3 and 4.  The curve that represented 
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the best fit based on the r
2
 value was reported as the appropriate Avrami constant that 
represents the crystallization process. 
 
Results 
 
Selection of Detergents 
 A collection of five detergents were initially selected for this study based on cost, 
availability and structural diversity.  These detergents include: NP-40, Tween-20, Tween-
80, sodium dodecyl sulfate (SDS) and 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS).  Ionic SDS and the zwitterionic detergent CHAPS were 
obtained to examine the effects of charge on β-hematin formation.  Tween-20 and 
Tween-80 are both nonionic detergents with identical polyoxyethylene hydrophilic head 
groups.  These two detergents can be distinguished by the length of the fatty acid ester 
moiety.  The 11 carbon hydrophobic tail of Tween-20 is saturated, while the 17 carbon 
tail of Tween-80 contains a double bond.   The detergent NP-40 (Nonidet P-40) was 
selected due to the polyethylene oxide hydrophilic portion, which is similar to the 
glycerol hydrophilic portion of neutral lipids.  After examining each of these detergents, 
we noted that NP-40 behaved most similarly to the biological blend of neutral lipids 
found within the malaria parasite.  Based on these observations, six additional detergents 
were selected so that a systematic analysis of the NP-40 polyethylene oxide portion of the 
detergent could be examined in relation to formation of β-hematin.  These detergents, 
known as the Triton X- detergents, vary with NP-40 based on the size of the polyethylene 
oxide side chain (Table 1).   
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Table 1.  Structurally, the Triton X-detergents contain an 8 carbon hydrophobic portion 
and varying sizes of polyethylene oxide repeats. 
 
 
Determination of Optimal Detergent Concentration 
 The minimum concentration at which maximum β-hematin formation is observed 
was determined using a range from 1-400 μM for each of the detergents, as well as the 
blend of neutral lipids (Figure 12).  This concentration is referred to as the ‘optimal’ 
detergent concentration.  Within this concentration range, all detergents except SDS and 
CHAPS produced 80-90% formation of β-hematin.  SDS and CHAPS are ionic and 
zwitterionic, respectively, while all other detergents (including the lipid blend) are 
neutral.  As micelles or vesicles, the ionic surfaces of SDS and CHAPS are exposed to 
water.  This observation suggests that the presence of a neutral surface facilitates more 
efficient β-hematin formation, in agreement with previously published reports exploring 
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the role of charge on lipid surfaces.
51,60
  A closer examination of the Triton X-detergents 
(Figure 12C) reveals the optimal concentration of detergent varies based on the size of 
the polyethylene oxide (PEO) chain length.  Specifically, as the PEO chain length 
increases, the optimal concentration of detergent necessary for β-hematin formation 
decreases  
 
 
 
 
Figure 12.  (A) The minimum concentration of Triton X-100 detergent was found to be 
30 µM. (B) The minimum concentration of mediator necessary to promote maximal 
formation of β-hematin (the ‘optimal’ concentration) was determined for each detergent. 
(C) The optimal concentration of Triton X-detergent as a function of increasing PEO 
chain length reveals a trend. 
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Characterization of β-Hematin Product 
 Morphological and structural analysis of the product obtained upon incubation of 
free heme with the optimal concentration of each detergent confirmed the presence of β-
hematin for all detergents except SDS and CHAPS.  Infrared spectra of the products of 
neutral detergents displayed prominent IR peaks at 1662 cm
-1
 and 1210 cm
-1
, indicating 
the formation of the C=O stretching vibration and the C-O stretching vibration of hematin 
linked dimers.  In the case of SDS and CHAPS, the product was heavily degraded as a 
result of the 5% pyridine washes.  This would suggest that the majority of the product 
obtained is likely comprised primarily of heme aggregates rather than β-hematin.   
 SEM and TEM imaging were used to examine the morphology of the β-hematin 
crystals produced by different detergents.   Well-formed crystals resembling hemozoin 
were observed in the presence of all detergents except SDS (Figure 13).   
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Figure 13.  SEM and TEM of the β-hematin product obtained using the indicated 
detergent mediator.  Scale bar = 500 nm, CL = PEO chain length 
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Characterization of Detergent Nanostructures 
 SNLDs have been shown to serve as a lipophilic reservoir for free heme and 
support the rapid formation of β-hematin, likely occurring at the lipid/aqueous interface.51  
Similar to lipids, most detergents will spontaneously form organized particles above a 
certain concentration known as the CMC (specific to each detergent).  These 
nanostructures are generally spherical in shape with the CMC being influenced by the 
temperature, pressure and the presence of other substances in solution (such as 
electrolytes).  Since these nanostructures are similar in shape and composition to the 
SNLDs that support β-hematin formation, we wanted to determine if they are present for 
the detergent mediators examined in this study under assay conditions.   DLS studies 
have previously shown that under assay conditions, SNLDs exist in two size populations 
- the largest population of SNLDs was ~50-200 nm in diameter, with a smaller 
population of ~1-10 µm in diameter.
46
  The size and stability of the nanostructures was 
determined for Tween-20, Tween-80, SDS, CHAPS and NP-40 using the optimal 
detergent concentration.  For the Triton X-detergents, a concentration of 50 µM was 
used.  The particle diameter observed within this set of detergents under assay conditions 
ranged from ~100 – 300 nm (Figure 14).  As micelles are typically 5-10 nm in diameter, 
it is likely that the detergent exists as vesicles under assay conditions.           
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Figure 14.  Average size of vesicles measured at the optimal concentration of detergent 
under assay conditions.  
 
  
Kinetics of Detergent-Mediated β-Hematin Formation 
The kinetics of β-hematin formation was determined in the presence of each of 
the detergents.  CHAPS, Tween-20, Tween-80 and NP-40 were each examined at the 
optimal detergent concentration (Table 2).  Tween-20 and Tween-80 both facilitated 
rapid formation of β-hematin with half-lives of 5 and 7 min, respectively.  The half-life of 
CHAPS was 630 min, though the product produced was not stable and easily degraded 
when washed with 5% pyridine.  The product obtained from the SDS detergent was very 
unstable and a half-life could not be determined.  The half-life of β-hematin formation in 
the presence of NP-40 exhibited a half-life of 53 min.  All detergents exhibited sigmoidal 
growth profiles. 
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Table 2.  The half-life of β-hematin formation was determined in the presence of each of 
the detergent mediators. 
 
 
 
The kinetics of β-hematin formation in the presence of each of the Triton X-
detergents was determined using a concentration of 50 µM (Table 2) detergent.  This 
analysis reveals that the half-life of β-hematin formation is influenced by the PEO chain 
length.  Specifically, the longer the PEO chain length, the more rapid β-hematin 
formation is observed (Figure 15).  Additionally, Triton X-mediated β-hematin formation 
exhibits a sigmoidal shaped growth curve, consistent with previous reports of solvent-
mediated β-hematin formation.57,58   
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Figure 15.  The kinetics of detergent-mediated β-hematin formation were monitored over 
the course of 24 hours.  Shown here are the Triton X-detergents, identified based on the 
number of repeating polyethylene oxide units.  BH = β-hematin    
 
 
 The sigmoidal growth profile observed for detergent-mediated β-hematin 
formation is typical of a crystallization process.  Specifically, this type of curve is 
reflective of a nucleation and growth phase where an initial induction phase of ~20 
minutes is observed followed by rapid product formation.  The Avrami equation is 
frequently used to model this nucleation and growth process (see methods).
59
  In this 
equation, the Avrami constant, n, represents the type of nucleation and dimensionality of 
the growth process and typically takes an integer value where n = 1, 2, 3 or 4.  The 
kinetics data were fitted to the Avrami equation and constrained to each of the four 
integer values of n.  Table 3 lists the best fit value of n obtained from each of the 
detergent mediators.   
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Detergent n r
2
 z (min
-n
)
a 
Triton X-45 4 0.989 7.52 ± 0.57 x 10
-12
 
Triton X-114
*
 4 0.973 2.68 ± 0.34 x 10
-10
 
Triton X-100 4 0.989 9.65 ± 0.77 x 10
-10
 
Triton X-102 4 0.991 1.87 ± 0.13 x 10
-9
 
Triton X-165 4 0.982 4.92 ± 0.52 x 10
-9
 
Triton X-305 4 0.985 9.11 ± 0.95 x 10
-9
 
NP-40
*
 4 0.973 7.26 ± 1.34 x 10
-8
 
Tween-80 1 0.958 0.11 ± 0.01 
Tween-20 1 0.936 0.12 ± 0.02 
CHAPS* 4 0.973 6.30 ± 0.87 x 10
-12
 
 
Table 3.  The best-fit value of the Avrami equation was determined for each of the 
detergents.  *These detergents had slightly better fits for n = 3.  
a
The rate constant 
calculated based on the indicated Avrami constant, n. 
 
 
Tween-20 and Tween-80 had excellent fits for n = 1 but deviated significantly for 
all other values of n. This fit indicates that crystal growth follows instantaneous 
nucleation and rod-like growth in one dimension.  All other detergents conform to n = 3 
and 4.  Figure 16 represents the fit for the Avrami constants to the kinetics data obtained 
from Triton X-45 and 305.  Since there is almost no difference in fit, we chose to use the 
value of n = 4 to describe the kinetics of these detergents since this is consistent with 
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other systems that have been described previously.
57,58,61
  Specifically, an Avrami 
constant of n = 4 describes a system where nucleation is sporadic and spherical growth 
occurs in three dimensions.    
 
       
 
Figure 16.  The kinetics data was fit to the Avrami equation.  β-hematin formation 
mediated by (A)Triton X-45 and (B) Triton X-305 exhibit best fits to n = 4. 
 
 
Solubility of Heme in the Presence of Triton X-Detergents 
 There is clearly a correlation between PEO chain length and the half-life of β-
hematin formation mediated by the Triton X-detergents (Figure 15).  In an effort to 
explain this correlation, we examined the solubility of heme in the presence of each of the 
Triton X-detergents since this is the rate-limiting step in β-hematin.48,58 Solubilized heme 
was measured at 105 minutes under assay conditions at 50 μM of each of the Triton X-
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detergents.  Figure 17 reveals as the PEO chain length size increases, more efficient 
solubilization of heme is achieved.      
 
 
 
Figure 17.  The solubility of heme increases as a function of increasing PEO chain 
length. 
 
 
Discussion 
 
Though the precise mechanism of hemozoin formation is not yet fully understood, 
current evidence indicates that neutral lipid droplets located in the digestive food vacuole 
of the parasite play an important role in hemozoin formation.  Previous investigations 
have demonstrated that SNLDs serve as a reservoir for free heme and are a kinetically 
competent site for β-hematin formation.46,51  Here, our aim was to determine whether 
detergents could serve as surrogates for SNLDs in the process of β-hematin formation.  
Since detergents are similar to lipids in molecular structure (hydrophilic head groups and 
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hydrophobic tails) and in the spontaneous organization into spherical structures when 
present at concentrations above the detergent-specific CMC values, we hypothesized that 
detergent vesicles would support the formation of β-hematin.   
Each of the nine neutral detergents examined in this study were efficient 
mediators of β-hematin formation.  On the other hand, the ionic and zwitterionic 
detergents SDS and CHAPS produced material that was unstable and likely consists 
primarily of heme aggregates rather than β-hematin.  This observation substantiates the 
importance of utilizing a neutral mediator for β-hematin formation.   
The optimal concentration which promoted maximal β-hematin formation was 
determined for each detergent.  For all detergents except SDS and CHAPS, the product 
obtained at this concentration of mediator was confirmed to be β-hematin.  Further, DLS 
confirmed that detergent vesicles are present for each of the detergents under these 
conditions ranging in size from ~100-300 nm.  This size distribution is consistent with 
SNLDs examined under assay conditions (the largest population of SNLDs was ~50-200 
nm).  Current evidence indicates that β-hematin formation readily occurs at interfacial 
regions of lipids or solvents.
58,60
  Based on this data, it is reasonable to hypothesize that 
detergent-mediated β-hematin formation would occur at the surface of vesicle particles 
present in solution. 
The kinetics of detergent-mediated β-hematin formation was shown to follow a 
sigmoidal growth profile typical of a crystallization process that involves an initial 
nucleation phase followed by a rapid growth phase.  The Avrami equation was used to 
determine the type of nucleation and dimensionality of the growth.  Tween-20 and 
Tween-80 had excellent fits for n =1, indicating that crystal formation occurs as a result 
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of instantaneous nucleation and rod-like growth in one dimension.  The remaining 
detergents conformed to n = 3 and 4 but since there was almost no difference in fit, we 
chose the value of n = 4 to describe the kinetics of these detergents since this is consistent 
with other systems that have been described previously.
57,58,61
  Therefore, the 
crystallization process for these detergents occurs as a result of sporadic nucleation and 
spherical growth occurs in three dimensions. 
Though the neutral detergent mediators efficiently support the formation of β-
hematin, there are clear differences in half-lives.  Derivatives of NP-40, the Triton X-
detergents, were analyzed to facilitate a direct comparison of the PEO chain length in the 
process of β-hematin formation.  We observed a clear correlation where the longer the 
PEO chain length, the more rapid β-hematin formation was observed.  In an effort to 
understand this relationship, the solubility of heme in the presence of each detergent was 
analyzed since this is the rate-limiting step in β-hematin formation.  At 105 min, a linear 
relationship was revealed between PEO chain length and the amount of free heme that 
was solubilized (r
2
 = 0.99).  This relationship clearly indicates that the longer PEO chain 
length facilitates quicker formation of β-hematin as a result of more rapid solubilization 
of free heme.   
Here, we have demonstrated that neutral detergent vesicles can serve as surrogates 
for SNLDs in β-hematin formation.  This observation allows the digestive food vacuole 
conditions where hemozoin formation occurs to be recapitulated without the need of 
obtaining expensive neutral lipids.  Consequently, one of the neutral detergents discussed 
here, NP-40, has been utilized as a β-hematin mediator in a high-throughput screening 
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assay.  In the next chapter, the optimization, validation and use of the NP-40 β-hematin 
formation assay will be described.  
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Chapter IV 
 
β-HEMATIN AS A TARGET FOR HIGH-THROUGHPUT SCREENING54 
 
Background 
 
 With antimalarial drug resistance on the rise, there is a pressing need for the 
discovery of novel chemical scaffolds that are active against Plasmodium spp.  One 
discovery technique is high-throughput screening (HTS), where thousands to millions of 
small molecules are rapidly tested for activity in assay.  An HTS suitable assay is 
generally formatted for use in 384- or 1536-well microtiter plates in order to test a large 
number of compounds in a short amount of time.  Furthermore, an HTS amenable assay 
must involve minimal processing steps, be highly robust and should be comprised of 
easily accessible reagents at a minimal cost.  Assays can be either phenotypic or target-
based in nature.  In antimalarial HTS, phenotypic assays are those that seek to identify 
small molecules that are capable of killing the parasite itself in P.falciparum infected 
erythrocytes.  The disadvantage to this approach is that the mechanism of action of 
inhibitors is unknown, and can be quite difficult to elucidate.  In target-based assays, a 
specific cellular process, such as hemozoin formation, is used to identify potential 
antimalarials.  Inhibitor/target interactions can be studied immediately after identifying 
hits, an advantage over phenotypic screening.  An additional advantage is the option to 
select pathways that are specific to the parasite.  The disadvantage to target-based 
screening is that activity does not necessarily confer to the whole-cell assay.     
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The use of HTS in antimalarial drug discovery has been utilized in recent years 
for both target-based and phenotypic assays.
50,54,62-68
  Of the target based assays, several 
have been developed for the purpose of identifying inhibitors of β-hematin 
formation.
50,54,69,70
  One of the first successful assays developed for use in HTS utilized 
radioactive 
14
C-labeled hematin to quantitate β-hematin formation using scintillation 
counting.
65
  Crystallization was mediated by the addition of lipid-rich extracts from 
parasite lysates.  The semi-automated assay tested over 100,000 compounds in 96-well 
plates and identified 45 nonquinoline hits.  Of these 45 compounds, the structural classes 
of compounds identified included triarylcarbinols, piperazines, benzophenones, imides, 
hydrazides, indoles and isoxazoles.  The non-quinoline hits were then tested in a 
secondary whole-cell assay consisting of cultures of CQ-sensitive and CQ-resistant P. 
falciparum.  Four compounds were identified to have activity in both strains at 
concentrations of <5 µM (the IC50 of CQ in sensitive strains of P. falciparum is ~25 nM).  
Though few of the compounds identified in the β-hematin inhibition screen were active 
against parasite cultures, the ability of HTS to identify novel pharmacophores supported 
the utility of this approach.  However, this assay was not utilized to its full potential due 
to deficiencies in design.  The semi-automated use of 96-well plates would be considered 
a medium-throughput method compared to the more often used 384- and 1536- well 
plates.  Further, the need for trophozoite lysates and radioactive hematin limits the use of 
this assay to laboratories capable of maintaining parasite cultures and open to the 
restrictions imposed by utilizing radioactive substrates.  Superior β-hematin formation 
assays should boast increased throughput of compound screening, incorporating more 
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readily available substrates, and using improved methods of quantification that do not 
require the use of radio-labeled heme.       
 
 
Part I.  Validation of the NP-40 β-Hematin Formation Assay and Results of a High-
Throughput Screening Campaign
54 
 
Introduction 
 
 Plasmodium falciparum, the most virulent species of the malaria parasite, is 
responsible for nearly one million deaths each year.
71
  The overwhelming majority of 
these deaths occur among young children residing in sub-Saharan Africa.  Alarmingly, 
the parasite has developed resistance mechanisms to nearly all affordable, widely-
available antimalarials.
72,73
  It is therefore critical to enrich the antimalarial drug 
discovery pipeline with lead probe candidates.  Fortunately, several unique pathways 
have been identified that serve as drug targets including inhibition of DNA synthesis, de 
novo heme biosynthesis, glycolysis and hemozoin inhibition. 
 During the intraerythrocytic stages of infection, the malaria parasite consumes 
upwards of 80% of the infected red blood cells hemoglobin content to serve as a source 
of amino acids.
7
  This process of hemoglobin degradation occurs within the parasite’s 
digestive food vacuole, an acidic organelle (pH ~4.8-5.2).  As a consequence of 
hemoglobin degradation, toxic free heme is liberated.  Lacking an enzymatic method of 
heme detoxification, the malaria parasite has evolved a method by which it converts 
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soluble free heme into an insoluble, nontoxic biomineral called hemozoin, the malarial 
pigment.
48
  Though hemozoin has been studied since the 18
th
 century, it was not until 
1999 that XRD revealed hemozoin consists of a centrosymmetric triclinic unit cell 
comprised of reciprocal head-to-tail dimeric units of heme bound through propionate O-
Fe(III).
27
  The propionic acid groups of the heme dimer then hydrogen bond with other 
dimers to form the extended crystal.  The in vivo mechanism of hemozoin formation has 
been contested for many years, though emerging evidence concerning the mechanism of 
hemozoin formation implicates the involvement of neutral lipids present within the 
digestive food vacuole as the site of crystal nucleation and growth (Chapter II).
45,52,53
 
Analysis of the digestive food vacuole concentrated neutral lipid particles by mass 
spectrometry identified a specific blend of neutral lipids in a 4:2:1:1:1 ratio of 
monostearic, monopalmitic, dipalmitic, dioleic and dilinoleic glycerols.
43,44
  Synthetic 
neutral lipid droplets (SNLDs) that consist of this biologically relevant blend of neutral 
lipids successfully promote the rapid formation of β-hematin (half-life of 1.9 ± 0.01 min) 
under physiologically realistic pH and temperature conditions (Chapter II).  Further, 
soluble free heme was shown to rapidly partition in the SNLDs in a pH-dependent 
manner.  The pH profile of heme partitioning resembles that of β-hematin formation. 
46,51,60
  Collectively, this evidence substantiates a role for neutral lipid particles in the 
process of hemozoin formation. 
 As perturbations to hemozoin formation lead to parasite death, understanding the 
mechanism of hemozoin formation is useful.  Chloroquine (CQ), one of the most 
successful antimalarials ever developed, owes its activity to inhibition of hemozoin 
formation.
19,74
  Unfortunately, the parasite has developed resistance to the use of this 
 59 
quinoline-based antimalarial.  However, this resistance is not due to changes in the 
hemozoin formation pathway, but rather arises from mutations in PfCRT, a membrane 
protein localized to the digestive food vacuole.
22,24,37
  Mutations are thought to be 
responsible for reduced accumulation of CQ within the digestive food vacuole, thereby 
preventing CQ-heme interactions from occurring.  This efflux mechanism is seemingly 
specific for quinoline-based antimalarials.  In the case of CQ, resistance can be overcome 
by synthetically altering the side chain, as derivatives of this quinoline scaffold retain 
activity against resistant strains.
75,76
  Consequently, hemozoin formation remains an 
important drug target for the development of new antimalarials.      
 Recently, the NP-40 β-hematin formation assay was validated for use in 
screening.
77
  This assay utilizes the lipophilic detergent, NP-40, to serve as a surrogate 
for in vitro β-hematin formation under physiologically relevant assay conditions (Chapter 
III).  This detergent mediator is low cost and requires no special handling steps in assay 
setup.
54
  Here, the β-hematin formation assay has been utilized to screen a library of 
144,330 commercially available compounds in the Vanderbilt University High-
Throughput Screening Facility.  Each of the target-specific hits was analyzed for in vitro 
antimalarial activity in in vitro cultures of P. falciparum.  Follow-up dose-response data 
was collected for each in vitro antimalarial compound.  Those that exhibited nanomolar 
activity against the parasite were further examined in a multi-drug resistant strain of P. 
falciparum.  
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Experimental Methods 
 
Materials 
 Nonidet P-40 (NP-40) was purchased from Pierce Biotechnology, Rockford, Il.  
Flat bottom, 384-well plates (3680, Corning) and optical bottom plates (142761, Nunc) 
were purchcased from Fisher.  Minimum Essential Medium (MEM) and 3-(4,5-
dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) were purchased through 
Fisher.   Hemin (≥98%, Fluka), amodiaquine, sodium acetate trihydrate, and pyridine 
were obtained from Sigma-Aldrich, St. Louis, MO.  SYBR Green I nucleic acid gel stain 
(10,000X) was supplied by Invitrogen.  The screening library consisted of compounds 
originating from ChemBridge and ChemDiv.   
 
Detergent-mediated NP-40 β-hematin formation assay 
 The β-hematin formation assay was adapted for use in a 384-well microtiter plate 
as previously described.
54
  Solutions were added to the microtiter plate in the order of 
water (20 μL), NP-40 stock solution (5 μL), acetone (7 μL) and heme suspension (25 μL).  
The NP-40 stock solution (348 μM) was prepared in water.  It is important to note that 
there are two different detergents, both called NP-40.  A 25 mM stock solution of 
hematin was prepared by dissolving hemin chloride in DMSO followed by one minute of 
sonication.  The heme solution was then filtered through a 0.22 µm PVDF membrane 
filter unit.  From this solution, the heme suspension (228 μM) was added to a 2 M acetate 
buffer at pH 4.9 and vortexed for ~ 5 sec.  The plate was then incubated for four hours in 
a shaking water bath at 45 rpm and 37°C.  Following incubation, the microtiter plate was 
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removed from the water bath and the assay was analyzed using the pyridine-ferrochrome 
method developed by Egan and coworkers.
50
  Following the addition of 15 μL of acetone 
to each well of the plate, 8 μL of pyridine solution was added (50% pyridine, 20% 
acetone, water and 200 mM HEPES, pH 7.4) so that the final concentration of pyridine 
was 5% (v/v).  Following a 30 minute interval of shaking to facilitate the solubilization of 
free heme, the absorbance of the resulting complex was measured at 405 nm on a 
SpectraMax M5 plate reader. 
 
Identification of β-hematin Inhibitors 
 Test compounds in the Vanderbilt University High-Throughput Screening Facility 
originated from ChemBridge and ChemDiv. A Labcyte Echo 550 non- contact acoustic 
liquid delivery system was used to deliver all control and test compounds to the 384-well 
assay plate.  Positive controls consisted of a 100 μM final concentration of amodiaquine 
(dissolved in DMSO) and negative controls consisted of DMSO only.  Controls were 
added to the first and last two columns of each plate in an alternating, checkerboard 
pattern.  All test compounds (10 mM in DMSO) were added so that the final test 
concentration was 19.3 μM (320 total compounds tested per plate).  Following addition 
of controls and test compounds, the reagents of the β-hematin formation assay described 
above were added using a Thermo Scientific Multidrop Combi Bulk Reagent Dispenser.  
Inhibition of β-hematin was assessed relative to the positive and negative controls on 
each plate.  Compounds inhibiting >80% β-hematin formation were considered hits.  This 
stringent threshold for identifying β-hematin inhibitors facilitated the identification of a 
set of potent inhibitors of crystallization.  Each hit was then tested in duplicate in a dose-
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response assay to identify false-positives and establish IC50 values using a range of 
concentrations of test compound from 0.5 – 110 μM.  Sigmoidal dose-response curves 
were generated using GraphPad Prism v5.0 (March 7, 2007).   
  
Determination of Drift, Z’ and Edge Effects 
 For the purpose of assay validation, positive controls of the IC100 of AQ, and 
negative controls with no drug were added to the plate in an alternating, ‘checkerboard’ 
pattern.  The quality of the assay was measured by the Z’ statistical test proposed by 
Zhang.
78
 The assay was analyzed for drift and edge effects using established guidelines of 
the NCGC (Assay Guidance Manual Version 5.0, 2008, Eli Lilly and Company and NIH 
Chemical Genomics Center.  Available online at: 
http://www.ncgc.nih.gov/guidance/manual_toc.html (last accessed [October 26, 2010])). 
 
Cytotoxicity Test Using the RAW 264.7 Murine Cell Line 
 The murine macrophage-like cell line RAW 264.7 (American Type Culture 
Collection TIB-71, Monassas, VA) was used for testing the cytotoxicity of select 
compounds confirmed active in the parasite assay.
79
  A concentration range from 0-20 
µM was tested in a 96-well flat bottom tissue culture treated assay plate.  Cells were 
delivered at a concentration of 2 X10
4 
cells/well in a solution of minimum essential 
medium (MEM) supplemented with 10% fetal bovine serum and incubated overnight at 
37°C and 5% CO2.  The following morning, drugs (diluted using MEM) were added to 
the culture plates.  After 30 hours, media was replaced in each well.  The cells were 
returned to incubation and allowed to recover overnight.   The following day, a solution 
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of MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide) was prepared at 
1.5 mg MTT/1 mL of MEM.  The wells were then emptied and 180 µL of MEM and 30 
µL of MTT solution were added and incubated for one hour.  The wells were emptied and 
the purple precipitate was allowed to dry completely.  A 200 µL solution of acidified 
isopropanol was added and mixed then analyzed at 590 nm on the SpectraMax M5 plate 
reader. 
 
P. Falciparum Culture Conditions 
 P. falciparum strains D6 and C235 were maintained using a modification of 
methods described by Trager and Jensen.
80
  RPMI 1640 medium supplemented with 25 
mM HEPES, 11 mM glucose, 0.24% sodium bicarbonate, 10% human A(+) plasma 
(heat-inactivated) and 29 uM hypoxanthine was prepared weekly.  Cultures were 
maintained at 5% hematocrit in A(+) blood (washed two times with RPMI medium and 
used no longer than one week).  Culture medium was routinely exchanged and 
subcultured upon reaching 5% parasitemia (every 3-4 days).  Cultures were incubated at 
37⁰C in a gas mixture of 5% O2, 5% CO2 and nitrogen. 
 
Malaria SYBR Green I Fluorescence Assay 
 Inhibitors of β-hematin formation were tested in the CQ-sensitive, D6 strain of P. 
falciparum using a modification of literature methods.
81
  Briefly, test compounds were 
prescreened at a concentration of 23 μM at 0.3% starting parasitemia (2% hematocrit) in 
duplicate in 384-well optical bottom microtiter plates.  Positive and negative controls 
consisted of a kill concentration of CQ (400 nM in water) and water, respectively. Dose-
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response curves were established for each active compound from a concentration of 0-23 
μM.  Sigmoidal dose-response curves were generated using GraphPad Prism v5.0 (March 
7, 2007)  
 
Clustering Analysis (kindly provided by Mariusz Butkiewicz) 
 β-hematin active compounds were analyzed by means of hierarchical clustering 
with Average Linkage as cluster distance measure.
82
  The similarity calculation among all 
compound pairs was based on common occurring molecule fragments. The fragment 
library was established by determining the largest common substructure between pairs of 
molecules keeping ring systems intact.  Each fragment had a minimum of four atoms. 
The resulting library contained 165 unique molecule fragments. Pairwise distances were 
calculated based on molecule fragment overlap using tanimoto coefficients between 
molecular fragment sets.
83
  All atoms were considered equivalent.  Bonds were compared 
by order, ring membership, and aromaticity. A cluster linkage cutoff of 0.65 was chosen 
to find a balance between number of clusters and the scaffold purity in each cluster. 
 The analysis yielded at total of 47 clusters including 17 singletons (clusters 
containing 3 or fewer compounds).   A careful analysis of each of the clusters resulted in 
the identification of 13 primary scaffolds that represent 51% of the entire set of β-hematin 
inhibitors.  Some of the scaffolds are found within more than one cluster, reflecting the 
structural diversity associated with that particular scaffold. 
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Results 
 
Primary NP-40 Detergent Mediated β-Hematin Formation Screen 
 The NP-40 detergent mediated β-hematin formation assay originally reported for 
use in 96-well plates was modified and validated for suitability in high-throughput 384-
well plate screening (Scheme 2).
77
  While the chemistry of the assay remained 
unchanged, the processing of the assay was deemed unsuitable for HTS.   In the original 
protocol, after incubation, the plate was centrifuged for one hour and the supernatant 
removed.  The differential solubility of non-aggregated heme and β-hematin in sodium 
bicarbonate was used to isolate product by centrifugation.  Subsequently, treatment with 
sodium hydroxide allowed quantification of β-hematin formation.  The original method 
required over two hours of centrifugation, and multiple manual solution removal and 
additions to achieve a readable sample.  The assay was simplified by implementing  the 
colorimetric pyridine ferrochrome method described by Egan and coworkers.
84
  A 50% 
pyridine solution in 20% acetone/water was added to each well, resulting in a final 
concentration of 5% v/v pyridine.  The pyridine complexes free heme (absorbance at 405 
nm), but not β-hematin, allowing for the rapid quantification of hemozoin formation. To 
ensure that the drug-response of this assay was preserved in this modified 384-well 
format, the IC50’s of AQ and CQ were determined for comparison to the neutral lipid 
mediated assay.  The IC50 using the NP-40 assay was 21.0 µM for AQ and 53.0 µM for 
CQ.  This compares nicely to the assay mediated by the biological neutral lipid 
composition present within the parasite’s digestive food vacuole where the IC50’s of AQ 
and CQ were 23.1 µM and 85.3 µM.  To further assess the drug response of the NP-40 
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assay, a series of known drugs were evaluated for β-hematin inhibition at a 100 µM 
concentration (Table 4).  Positive controls consisted of the antimalarials CQ, AQ and 
quinacrine, all known inhibitors of hemozoin formation.  Negative controls were 
compounds that do not inhibit formation of hemozoin including pyrimethamine 
(antimalarial), indomethacin (antipyretic) and 8-hydroxyquinoline (a non-antimalarial 
quinoline).  The results in Table 4 indicate the successful inhibition of β-hematin 
formation in the presence of positive controls, while only negligible crystal inhibition is 
observed in the presence of negative control drugs. 
 
 
 
Drug 
Known 
β-Hematin 
Activity 
% 
Inhibition 
Pyrimethamine - 1 
Indomethacin - 4 
8-
Hydroxyquinoline 
- 5 
Chloroquine + 98 
Amodiaquine + 100 
Quinacrine + 100 
 
 
Table 4.  A panel of known inhibitors of β-hematin formation were tested in the NP-40 
assay at a concentration of 100 µM.  The known inhibitors of β-hematin formation 
(indicated by a (+)) successfully prevented crystallization.  The (-) drugs which are 
known as non-inhibitors of β-hematin formation were inactive in this assay.54  
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 The quality of the assay was assessed by determining Z’ using a 384-well plate of 
positive and negative controls consisting of wells with the IC100 of AQ and wells with an 
equal volume of DMSO distributed across the plate in an alternating, ‘checkerboard’ 
pattern (Figure 18).
78
  Here, a favorable Z’ of 0.82 is observed, well above the often 
reported 0.5 threshold value.  The assay was also analyzed for drift and edge effects using 
the methods suggested by the NCGC. The maximal drift of the positive control was <2%, 
while the maximal drift of the negative control was <4% (maximal drift was observed 
when plotting well number by column, then by row).  The assay was repeated on 
different days using freshly prepared solutions to ensure reproducibility of these results. 
 
 
 
 
Figure 18.  A ‘checkerboard’ pattern of positive and negative controls was utilized to 
analyze the Z’, drift and edge effects of the NP-40 detergent mediated assay prior to 
screening.
54
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Scheme 2. Steps in the NP-40 β-hematin formation assay in HTS.54 
 
 
Identification of β-Hematin Inhibitors 
 A total of 144,330 compounds from the Vanderbilt University HTS library were 
tested in the NP-40 β-hematin formation assay (Scheme 2). This screening effort resulted 
in the identification of 729 compounds exhibiting >80% inhibitory activity relative to 
controls (0.5% hit rate).  This threshold for identifying hits ensured that only potent β-
hematin inhibitors were identified in addition to providing a manageable number of 
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compounds for follow-up dose response testing.  Each preliminary hit was cherry-picked 
and tested in a dose-response assay (0.5 – 110 uM) to identify false-positives and to 
establish the potency of each hit against β-hematin formation.  Compounds exhibiting 
IC50 values < 27 μM were confirmed as hits.   Using this approach, a total of 530 hits was 
confirmed (0.14% false-positive hit rate, see Appendix D for full hit list).  Of these, all 
had more potent IC50 values than CQ (53.0 µM) and 457 were more potent than AQ (21.0 
μM) in this assay.  The top ten most potent β-hematin inhibitors identified in this screen 
are shown in Table 5 to demonstrate the level of structural diversity resulting from this 
screening effort. 
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Table 5. The top ten most potent β-hematin inhibitors identified in the screening effort.  
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Activity of β-hematin inhibitors in cultures of P. falciparum 
 While the β-hematin formation assay successfully identified over 500 highly 
potent inhibitors of heme crystallization, it was vital to establish whether or not these 
compounds retained activity in in vitro cultures of P. falciparum.  As such, the malaria 
SYBR green I-based fluorescence assay described by Johnson and coworkers was used to 
establish the activity of each of the 530 β-hematin inhibitors against parasitized red blood 
cells.
81
  Each β-hematin inhibitor was prescreened at a concentration of 23 µM.  Percent 
inhibition was determined relative to positive (kill concentration of CQ) and negative 
(DMSO only) controls.  Test compounds that exhibited >90% inhibition of parasitemia 
were considered hits.  Using these criteria to identify hits, 171 of the β-hematin inhibitors 
identified in the primary screen were also active against the parasite cultures.  This high 
hit rate (32%) was quite surprising, as previous analysis of HTS libraries against cultures 
of parasitized red blood cells have resulted in hit rates of ~1% when compounds were 
tested at a similar concentration and similar activity thresholds were considered.
68
  The 
considerable increase in in vitro antimalarial activity observed within the β-hematin 
inhibitors would suggest that many of these compounds are indeed reaching their 
proposed target, hemozoin.   
 Follow-up dose-response analysis of the 171 β-hematin inhibiting in vitro 
antimalarial compounds revealed that many highly potent compounds were present 
within this subset of the screening library.  Specifically, 73 compounds exhibited < 5 μM 
activity against P. falciparum, including 25 compounds with nanomolar activity.  The ten 
most potent in vitro antimalarial β-hematin inhibitors identified in this screen are shown 
in Table 6. Furthermore, each compound exhibiting nanomolar activity against the D6 
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strain was also tested against the multidrug-resistant C235 strain of P. falciparum to 
determine the resistance index associated with each of the most potent in vitro 
antimalarial β-hematin inhibitors.  For 21 of the 25 nanomolar potent in vitro 
antimalarials identified, the resistance indices were between 0.2 - 3, suggesting that the 
majority of these compounds may serve as valuable starting points for lead probe 
optimization.       
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Table 6.  The top ten most potent in vitro antimalarial β-hematin inhibitors identified in 
the HTS effort. 
 
 
Structural characterization of hits 
 In an effort to assess the chemical diversity of compounds exhibiting activity 
against β-hematin formation, a clustering analysis was performed using hierarchical 
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clustering with Average Linkage as a cluster distance measure.  This analysis yielded a 
total of 47 clusters including 17 singletons (a cluster containing three or fewer 
compounds).  The resultant clusters were then carefully scrutinized to identify scaffolds 
present within the data set of β-hematin inhibitors.  Figure 19 shows the 13 predominant 
scaffolds identified in this analysis.  The number of β-hematin inhibitors associated with 
each scaffold (as well as the number of those β-hematin inhibitors that also showed in 
vitro antimalarial activity) is shown above each scaffold.  These 13 scaffolds represent 
51% of the total number of β-hematin inhibitors identified. 
 
 
 
Figure 19.  The 13 scaffolds that represent 52% of the β-hematin inhibitors identified in 
the screening effort. 
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Quinoline-Based (scaffolds A, G, J and K) 
 Quinoline-based compounds are among the most successful and widely used 
antimalarials developed to date.  Though most strains of the parasite have developed 
resistance to CQ, several classes of quinoline derivatives that evade the mechanism of 
resistance have been developed including ferroquine which is currently in clinical 
development.
75,76
  The ability to overcome quinoline resistance suggests that creative 
medicinal chemistry could perpetuate quinolines as a valid scaffold.  Of the 530 β-
hematin inhibitors identified, several quinoline-based scaffolds were noted.  Scaffolds A, 
B, J and K represented 12, 12, 19 and 98 of the total number of β-hematin inhibitors 
identified, respectively.  Further, approximately one-third of these quinoline-based β-
hematin inhibitors were also active against the parasite.  While scaffold A was previously 
reported in the results of the pilot screen (38,000 compounds were screened), scaffolds G, 
J and K were only identified after completion of screening the entire HTS library of 
144,330 compounds.
54
  Derivatives of both scaffold G and J have previously been 
reported in the PubChem database (http://pubchem.ncbi.nlm.nih.gov/)  as having activity 
against P. falciparum targets M18 aspartyl aminopeptidase (AID 1822), plastid activity 
(AID 504834) and glucose-6-phosphate dehydrogenase activity (AID 504690).  No 
previously reported activity for scaffold K was found.   
 
Phenyl benzamides (scaffolds B, D and E) 
 Several phenyl benzamides were also identified from the clustering analysis. 
Benzamides have previously been investigated for their activity against P. falciparum 
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(AID 2306) and have also been identified as inhibitors of the P. falciparum pyrimidine 
biosynthetic enzyme dihydroorotate dehydrogenase PfDHODH.
54,64,85,86
  Scaffolds B, D 
and E contained 12, 16 and 11 β-hematin inhibitors, respectively.  Surprisingly, nearly 
half (46%) of these phenyl benzamide β-hematin inhibitors were also active in parasite 
cultures.   
 
Benzylethene (scaffolds A and I) 
 Scaffolds A and I contain an ethene-bridged phenyl group to either a quinoline or 
benzimidazole.  Though A is an 8-hydroxyquinoline (and by structural definition is a 
quinoline), the quinoline portion of this scaffold does not explain its activity.  Previous 
analysis of 8-hydroxyquinoline has demonstrated that this compound is not active against 
β-hematin formation.  Therefore, the activity of scaffold A must be related to the addition 
of the ethane-bridged phenyl group.  As such, it is more accurate to group scaffold A with 
scaffold I than to associate it strictly as a quionoline.  The two scaffolds, A and I, 
containing this structural motif have previously been reported to have in vitro 
antimalarial activity (AID 2306).
64
   Scaffolds A and I contained 12 and 14 compounds, 
respectively. 58% of scaffold A β-hematin inhibitors were active against the parasite 
while 14% of the β-hematin inhibitors from cluster I were active against the parasite.   
 
Miscellaneous Compounds: 
 In addition to the 13 scaffolds identified in this effort, a large number of 
interesting compounds were not associated with a specific scaffold type, or only 
accounted for a very small percentage of the overall hit rate.  Specifically, 261 β-hematin 
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inhibitors that did not fall into a specific scaffold were identified including 90 in vitro 
antimalarial compounds.  The structural diversity of these compounds include pyridines, 
amides, indoles, acridinediones, amides, ethers and thiols, among others. 
Discussion 
 Utilizing the biologically relevant conditions under which hemozoin formation 
occurs within the digestive food vacuole of the parasite, 144,330 compounds were 
screened to identify those that inhibit β-hematin formation.  As a result of this effort, 530 
potent β-hematin inhibitors were identified, 32% of these hits were further shown to have 
in vitro antimalarial activity.  Previous successful attempts to identify in vitro 
antimalarial compounds in HTS libraries have resulted in hit rates of ~1% when 
compounds were tested at a similar concentration and similar activity thresholds were 
considered.
68
 Therefore, by utilizing an assay that successfully recapitulates biological 
conditions within the digestive food vacuole of the parasite, a higher percentage of 
compounds retained activity against in vitro cultures of P. falciparum.  Further, this 
strong correlation between target-specific and in vitro antimalarial activity suggests that 
many of these compounds are indeed acting on their proposed target, hemozoin.   
 Examination of the structures that were identified as having activity against β-
hematin formation screen reveals 13 distinct scaffolds that represent 269 of the total 
number of compounds identified in this screen (Figure 19).  The remaining 261 
compounds that were not associated with one of the 13 scaffolds encompass a wide range 
of structural diversity.  It is important to note that the overwhelming majority of these 
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compounds have not previously been reported as having activity against β-hematin 
formation. 
 HTS has become a valuable technique to rapidly identify in vitro antimalarial 
compounds.  Notably, GlaxoSmithKline (GSK), St. Jude Children’s Research Hospital 
and Novartis have screened millions of compounds against P. falciparum.
62-64
  Though 
these efforts have resulted in the identification of thousands of chemical starting points, 
the optimization of the lead compounds into useful drugs may prove challenging since 
the targets of these in vitro antimalarial compounds are unknown.  The reductionist 
approach reported herein facilitates the prioritization of HTS in vitro antimalarial 
compounds based on their activity against a specific antimalarial target, hemozoin 
formation. The next stage of this work will be to validate hemozoin as the in vivo target 
for each of the compounds exhibiting nanomolar activity against P. falciparum.
74
  
Compounds that are confirmed to inhibit hemozoin formation in parasite cultures will 
then be tested further in terms of solubility, permeability and metabolic stability.  With 
such a diverse library of compounds, the probability of identifying multiple lead 
candidates for further development is likely. 
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Part II. Preliminary SAR Evaluation of Four Scaffolds Identified in the HTS 
Campaign 
 
Introduction 
 
 The NP-40 β-hematin formation assay was successfully utilized to screen a library 
of 144,330 compounds (Part I).  The screening campaign resulted in the identification of 
530 inhibitors of β-hematin formation (see Appendix D for complete list of active 
compounds and their respective activities activity).  With hundreds of chemical starting 
points available, four scaffolds (Figure 20, triarylimidazole, benz-azole, pyridyl- and 
phenyl- amide, and hydroxyquinoline) were selected for a preliminary structure-activity 
analysis (SAR).  The goal of this effort was to obtain a more detailed understanding of 
the activity of each scaffold in order to determine if a more rigorous and expensive SAR 
analysis is warranted.  These four scaffolds were selected based on 1) the chemical 
tractability for synthetic chemistry 2) commercial availability and 3) in vitro antimalarial 
activity.  
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Figure 20.  Preliminary SAR analysis of four scaffolds was explored. (I) triarylimidazole 
(II) benzimidazole and benzoxazole (III) phenylbenzamide and pyridylbenzamide (IV) 
hydroxyquinoline 
 
 
Results 
 
I.  Triarylimidazole 
 The triarylimidazole scaffold exhibits a wide range of biological activity 
including antibacterial and analgesic activity  and has previously been shown to inhibit β-
hematin formation.
54,87
   Though potent in vitro antimalarial compounds containing this 
core scaffold have been identified, the mechanism of interaction with the putative target, 
heme, has not previously been explored.   The NP-40 β-hematin formation assay 
 
 
I 
 
II 
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IV 
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identified a particularly potent compound that is also a potent in vitro antimalarial (IC50 = 
310 nM, Figure 21).  A literature review revealed that this scaffold has not previously 
been explored for use as an antimalarial.  A set of eleven derivatives were therefore 
selected with the guidance of the Chemical Synthesis Core at Vanderbilt.  The derivatives 
were selected in order to examine the significance of three structural components of the 
original hit (Figure 22):  
1) determine the importance of O-rich substituents on the phenyl ring (red)  
2) determine if the phenyl ring can be replaced with a pyridine ring
36
 (blue)  
3) determine the consequences of substitution on the phenyl rings (green) 
 
 
 
Figure 21.  The original hit identified in the HTS screen exhibited an IC50’s of 12.6µM in 
the β-hematin formation assay and 310 nM in the MSF assay. 
 
 
 Of the eleven derivatives obtained, ten retained activity in the β-hematin 
formation assay.  The compound that lost activity is the triarylimidazole that contains no 
substituents on the phenyl rings.  Concentration-response data reveals IC50 potencies for 
the ten actives ranging from 3.49 – 218 μM.  When tested against in culture of P. 
falciparum, nine compounds exhibited activity with IC50 values ranging from 201 nM – 
20.7 μM.  A careful structural examination reveals that the compounds in the second row 
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(Figure 22) are the most active against the malaria parasite.  The common feature in this 
subset of compounds is the presence of oxygen-containing functional groups at the 2-
phenyl position.  Though the precise molecular interactions that are responsible for this 
increased activity are not yet understood, two hypotheses are considered:  
1) The oxygen atoms, as electron donating groups, could increase the electronegativity of 
the phenyl ring.  The increased negative charge on the phenyl ring could then facilitate 
pi-cation interactions between the phenyl ring and the Fe(III) center of heme.   
2) As is observed for the antimalarial halofantrine, an oxygen atom could coordinate 
directly to the Fe(III) center of heme, thereby preventing the formation of the reciprocal 
heme-propionate dimeric species that is incorporated into the hemozoin crystal.
88
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Figure 22.  A set of eleven triarylimidazoles were obtained/synthesized in order to 
further explore the activity of this scaffold. Parenthesis denote: (IC50 β-hematin inhibitory 
activity, IC50 μM in vitro antimalarial activity) 
 
 
 
 84 
II.  Benz-azole 
 The benzimidazole scaffold is an important pharmacophore and privileged 
structure exhibiting a broad range of biological activity.  Benzimidazoles have been 
widely used in both humans and livestock as broad spectrum anthelminthics (i.e. 
albendazole, mebendazole).
89
  The benzimidazole and benzoxazole scaffolds have 
previously been identified as antimalarial inhibitors of β-hematin formation.54,64,90    A 
literature evaluation reveals a range of benz-azoles have inhibitory activity against β-
hematin formation; however this scaffold has not previously been optimized for use as an 
antimalarial.  In the HTS analysis (Part I), 49 benz-azoles were identified that exhibited 
potent β-hematin inhibitory activity.  A careful examination of these hits prompted a 
further investigation based around two specific benz-azole scaffolds (Figure 23).  
 
 
 
Figure 23.  Analysis of the hits identified in the HTS effort revealed several interesting 
benz-azole scaffolds including a benzimidazole (VU0002101) and a benzoxazole 
(VU00090092).  Both compounds contain a 2-phenyl benz-azole scaffold (blue).  The 
green highlighted portion indicates the region of the molecule that was altered in the 
derivatives obtained. 
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 The common feature of both benz-azole scaffolds is the presence of the phenyl 
substituent in the 2 position.  Furthermore, each scaffold also contains an amide group, 
though the location of this group differs for each of the scaffolds.  For the benzimidazole, 
VU0002101, the focus was to obtain derivatives that preserved the core scaffold (blue) 
while altering the pyridyl amide (green) portion of the molecule.  For the benzoxazole 
(VU0090092), the derivatives obtained preserved the core scaffold (blue) while 
substituting the phenoxyacetamide portion of the molecule (green).  A total of 13 benz-
azole derivatives were obtained.  Six derivatives of the benzoxazole scaffold 
(VU0090092) were obtained but none of these retained β-hematin inhibitory or in vitro 
antimalarial activity, suggesting that modifications to the 5 position are not trivial.  For 
the benzimidazole scaffold (VU0002101), seven derivatives were selected, with five 
exhibiting activity against β-hematin formation and four with in vitro antimalarial activity 
(Figure 24).   
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Figure 24.  A set of 13 benz-azoles were obtained in order to further explore the activity 
of this scaffold. The two original compounds that prompted exploration of these scaffolds 
are shown at the top of the figure.  Parenthesis denote: (IC50 β-hematin inhibitory 
activity, IC50 μM in vitro antimalarial activity)   
 
 
 
 There are three mechanisms by which β-hematin inhibitory activity can be 
observed (Figure 25).  First, the inhibitor can bind directly to the β-hematin crystal.  As a 
result of this capping mechanism, heme cannot be incorporated into the growing β-
hematin crystal.
41
  Alternatively, β-hematin inhibition can be the result of interactions 
between the inhibitor and free heme, as is thought to be the case for many antimalarial 
hemozoin inhibitors.
41,91
  In this assay β-hematin inhibition can also be the result of 
interactions between the inhibitor and NP-40 detergent, compromising the ability of the 
NP-40 detergent to mediate crystallization. 
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Figure 25.  There are multiple modes by which a compound could potentially inhibit β-
formation in the assay.  (I)  Interaction with the β-hematin crystal  (II) Interaction with 
free heme  (III)  Interaction with mediator 
 
  
 
 
  Here, we wanted to determine if the benzimidazole scaffold interacts with free 
heme.  This interaction can be observed by monitoring the heme Soret band using UV-
Vis spectrophotometry.
88
   Figure 26A reveals that upon titration of the heme solution 
with benzimidazole β-hematin inhibitor, a hypochromic shift occurs in the Soret band.  
This type of shift has been observed with other β-hematin inhibitors such as chloroquine 
and halofantrine and is indicative of π-π interactions with heme.88   Therefore, this 
evidence clearly demonstrates that the benzimidazole does indeed interact directly with 
heme, leading to inhibition of β-hematin formation.  As a control, one of the 
benzimidazole derivatives that did not exhibit β-hematin inhibitory activity was analyzed 
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under the same conditions.  No significant change in the heme Soret band was observed 
(Figure 26B).   
 
 
 
 
Figure 26.  Solutions of free heme were titrated with (A) a benzimidazole β-hematin 
inhibitor and (B) a control benzimidazole that does not inhibit β-hematin formation.  This 
analysis confirms that the benzimidazole β-hematin inhibitor directly interacts with free 
heme, leading to the inhibitory activity observed for this compound. 
 
 
 
 
III.  Pyridylbenzamides 
 Benzamides have previously been investigated for their activity against P. 
falciparum and have been shown to inhibit both β-hematin formation and PfDHODH (an 
enzyme in the de novo pyrimidine biosynthetic).
54,85,86
  In the HTS effort, several 
benzamides and pyridylbenzamides were identified which prompted further examination 
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of this scaffold.  VU0003659 is both a pyridylbenzamide and phenylbenzamide and 
exhibits potent β-hematin inhibitory and in vitro antimalarial activity (Figure 27).   
 
 
 
Figure 27.  VU0003659 was selected from the HTS results for further evaluation.  The 
derivatives obtained preserved the pyridyl portion of the scaffold (black) while 
substituting the benzamide portion (blue).       
 
 
 
 For this scaffold, the focus was to obtain derivatives that preserve the 
pyridylbenzamide moiety and focus on substituting the benzamide portion of the scaffold 
(blue, Figure 27).  Consequently, a total of eleven derivatives were (Figure 28) obtained.  
Five of the compounds exhibited β-hematin inhibitory activity with IC50 values ranging 
from 50.0 – 171 µM.  Four of the five β-hematin inhibitors retained activity against 
cultures of P. falciparum with IC50 values ranging from 1.9 – 9.64 µM. 
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Figure 28.  A set of eleven pyridylbenzamides were. Parenthesis denote: (IC50 β-hematin 
inhibitory activity, IC50 μM in vitro antimalarial activity)   
 
 
IV.  Hydroxyquinoline 
 The HTS screening efforts revealed several hydroxyquinolines that were active 
against β-hematin formation and toxic to the parasite (Figure 29).  This scaffold contains 
an ethene-bridged phenyl group to a quinoline, though the HTS screen revealed that a 
benzimidazole can substitute the quinoline ring as a scaffold.  It is interesting that 8-
hydroxyquinoline itself (the core scaffold) is not active against β-hematin formation.  
This suggests that the ethene-bridged phenyl ring plays a role in the activity of this 
scaffold.  
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Figure 29.  A set of six hydroxyquinolines were obtained in an effort to establish the 
effects of substitution at the hydroxyl (red) position or substitution of the phenyl ring 
(blue). 
 
 
 
A moderate amount of structural diversity was observed for this scaffold in the 
HTS screen (Figure 30A).  We therefore expected that manipulation of this scaffold 
would lead to derivatives where activity is retained.  A set of six derivatives were 
obtained based on this scaffold.  The primary focus was to establish the effects of 1) 
adding bulk to the 8-position of the quinoline ring and 2) substitutions at the ethene-
bridged phenyl ring (Figure 30B).  Three of the compounds exhibited β-hematin 
inhibitory activity with IC50 values ranging from 42.3 – 442 µM.  Interestingly, five of 
derivatives exhibited in vitro antimalarial activity with IC50 values ranging from 1.9 – 12 
µM.  Since several of the compounds had no activity in the β-hematin formation assay, 
while maintaining activity against the malaria parasite suggests that this in vitro 
antimalarial activity is either the result of interaction with two distinct targets (one of 
which is possibly hemozoin formation) in P. falciparum or activity is due to another 
pathway altogether.  Two independent targets could explain why three of the compounds 
with diminished activity against β-hematin formation is still toxic to the parasite.  Indeed, 
a review of the literature reveals that in vitro antimalarial compounds containing this core 
scaffold also exhibits activity against multiple aminopeptidases that are present in the 
 92 
digestive food vacuole of the parasite and play key roles in the process of hemoglobin 
digestion.     
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Figure 30.  (A) Hydroxyquinolines identified in the HTS screen and (B) the set of 6 
hydroxyquinolines that were obtained.  Parenthesis denote: (IC50 β-hematin inhibitory 
activity, IC50 μM in vitro antimalarial activity)   
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 A common feature of the hydroxyquinoline compounds exhibiting diminished 
activity in the β-hematin formation assay is the absence of O-containing functional 
groups on the ethene-bridged phenyl ring.  There is potential that oxygen rich functional 
groups on this phenyl ring increase electron density and promote higher affinity 
interactions with free heme.  Alternatively,  the O atom itself could perhaps interact with 
the Fe(III) center of free heme, as is the case for the antimalarial halofantrine.
88
    This 
hypothesis was examined by exploiting the sensitivity of heme to its environmental 
conditions (Figure 31).
92
   
 
 
Figure 31.  The speciation of free heme can be readily manipulated. (I) The µ-oxo 
dimeric species of heme and (II) the π-π dimeric species of heme can be controlled by the 
identity of the solvent. 
 
 
 Specifically, the μ-oxo dimeric species of free heme was promoted by 
solubilization in 40% DMSO, pH 7.4.  Under these conditions, the heme Soret band 
exhibits a characteristic shoulder peak (~370 nm) that is not observed in monomeric free 
heme or pi-pi dimeric free heme when observed with UV-Vis spectrophotometry.
92
   As a 
II
I 
I 
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five coordinate species, if a molecule binds to the Fe(III) center of free heme, the μ-oxo 
dimeric linkage will be broken and the shoulder peak will no longer be observed.  If a β-
hematin inhibitor owes its activity to direct coordination to the Fe(III) center, the Fe-O-Fe 
linkage will be broken and the shape of the Soret band will change.  As such, a 
representative hydroxyquinoline was analyzed using this approach.  Figure 32 
demonstrates that the shoulder peak of the heme Soret band decreases upon titration with 
the hydroxyquinoline β-hematin inhibitor.  In fact, at 58 μM concentration of the 
inhibitor, the Soret band now exhibits the characteristic shape of a pi-pi dimeric species.  
This is supportive of direct coordination of the hydroxyquinoline to the Fe(III) center of 
heme.    
 
 
 
Figure 32.  The hydroxyquinoline compound was titrated into a solution of μ-oxo 
dimeric free heme.  The shoulder-shift in Soret band as a function of increasing 
concentration of hydroxyquinoline suggests that this compound is outcompeting the μ-
oxo dimer linkage.  This is indicative of coordination of the hydroxyquinoline to the 
Fe(III) center of heme, thereby inhibiting β-hematin formation.  
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Conclusions and Future Directions 
 
The HTS efforts discussed in Part I resulted in the identification of multiple 
scaffolds that have not previously been acknowledged as inhibitors of β-hematin 
formation and/or in vitro antimalarial compounds.  The majority of these scaffolds have 
also never been evaluated for use as potential lead probe candidates.  Therefore, four of 
these scaffolds were selected for a preliminary SAR analysis to determine the usefulness 
of each scaffold for optimization.   The primary goal of this analysis was to determine if 
derivatives of each scaffold would retain β-hematin inhibitory and in vitro antimalarial 
activity.  The four scaffolds were selected based upon the chemical tractability for 
synthetic chemistry, commercial availability and/or potency of in vitro antimalarial 
activity.   
The triarylimidazole compound originally identified in the HTS effort exhibited 
more potent β-hematin inhibitory activity than either amodiaquine or CQ in this assay.  
This compound was also potent against both CQ-sensitive and multi-drug resistant strains 
of P. falciparum with IC50 values of 310 nM and 942 nM, respectively.  Analysis of the 
eleven derivatives obtained for further study suggest that the presence of –OH or –OMe 
substituents on the phenyl ring contribute to the potency of this scaffold.  This 
observation was also made for the hydroxyquinoline scaffold.  Though the precise 
molecular interactions that are responsible for this activity are not yet known, two 
hypotheses are considered regarding the importance of oxygen substituents in the 
triarylimidazole and the hydroxyquinoline scaffold.   1) The oxygen atoms donate 
electron density to the phenyl ring.  Since electron donating groups strengthen the cation-
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π interactions, we could expect the affinity between the –OH or –OMe substituted phenyl 
ring of the triarylimidazole or hydroxyquinoline with the Fe(III) center of heme to be 
increased.
93
  2) Alternatively, an oxygen atom could be coordinating directly to the 
Fe(III) center of heme as is the case of the antimalarial halofantrine.
88
  For the 
hydroxyquinoline scaffold, spectrophotometric data was obtained in order to investigate 
hypothesis ‘2’.  The results of this analysis demonstrate that the µ-oxo dimeric species of 
heme is reduced upon titration with a hydroxyquinoline compound containing an –OH 
substituent on the phenyl ring.  This is indicative of direct coordination to the Fe(III) 
center of heme.  Future efforts will be necessary to validate that this interaction leads to 
the activity of the hydroxyquinoline.  This analysis will also be necessary for the 
triarylimidazole.  
  Fewer than 50% of the pyridylbenzamide and benz-azole derivatives obtained 
retained β-hematin inhibitory or in vitro antimalarial activity.  Since a small number of 
derivatives were obtained for these scaffolds, further investigation will be necessary 
before any conclusions regarding the usefulness of either scaffold for optimization can be 
made. 
Our investigation has resulted in meaningful preliminary information regarding 
the triarylimidazole and hydroxyquinoline scaffolds.  We will now focus on elucidating 
the specific molecular interactions that lead to β-hematin inhibitory activity.  Specifically, 
the role of the –OH and –OMe substituents will be determined.  If the oxygen containing 
substituents are verified to play a primary role in the observed activity, our focus can shift 
to optimizing the pharmacokinetic properties of the scaffolds while preserving the portion 
of the scaffold that leads to inhibitory activity.  For the pyridylbenzamide and benz-azole 
 98 
scaffolds, additional derivatives must be analyzed before any conclusions regarding the 
value of these two scaffolds as potential lead probe candidates can be made.  Compounds 
that inhibit β-hematin formation from all four of the scaffolds will also be analyzed in 
cultures of P. falciparum in order to validate that hemozoin is the biological target 
leading to in vitro antimalarial activity.
74
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Part III:  Identification of β-Hematin Inhibitors from In vitro antimalarial 
Compounds Identified in Phenotypic Screens 
 
Introduction 
 
 In antimalarial HTS, phenotypic assays are those that seek to identify small 
molecules that are capable of killing P.falciparum.   Recently, phenotypic screens have 
been completed by GSK and Novartis against millions of compounds in their respective 
HTS collections.
62,63
  These results were released to the public and identified thousands 
of chemical starting points for lead compound development.  Importantly, these 
compounds are highly potent with IC50 values of < 2 µM in cultures of P. falciparum.  
The scientific community now has access to an arsenal of thousands of compounds that 
are highly toxic to the parasite, but the process of developing these hits into robust lead 
compounds will be challenging.  It is reasonable to assume that identification of the 
molecular targets could aid in prioritization of these hits, while optimization steps could 
also potentially be decreased since the hit-target interactions could be directly studied, 
saving time, and money.   
Recently, the Medicines for Malaria Venture (MMV) initiated a collaborative 
effort with GSK to identify the targets of the 13,231 in vitro antimalarial compounds 
reported as hits in the phenotypic screening effort.  Here, we report the evaluation of the 
GSK compounds in the β-hematin formation assay.   
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Experimental Methods 
 
NP-40 β-Hematin Formation Assay 
 The NP-40 β-hematin formation assay protocol was modified from previously 
reported method.
54
  Solutions were added to the microtiter plate in the order of water (20 
μL), NP-40 stock solution (5 μL), acetone (7 μL) and heme suspension (25 μL).  
Following the addition of water, the plate was shaken for 30 minutes to ensure 
solubilization of the test compound.  The absorbance of each plate was then measured at 
405 nm on a BioTek plate reader (pre-read, this ensures that background signal can be 
removed from the final plate reading upon completion of the assay).  The NP-40 stock 
solution (348 μM) was prepared in water.  A 25 mM stock solution of hematin was 
prepared by dissolving hemin chloride in DMSO followed by one minute of sonication.  
The heme solution was then filtered through a 0.22 µm PVDF membrane filter unit.  
From this solution, the heme suspension (228 μM) was added to a 2 M acetate buffer at 
pH 4.9 and vortexed for ~ 5 sec.  The plate was then incubated for six hours in a shaking 
water bath at 90 rpm and 37°C.  Following incubation, the microtiter plate was removed 
from the water bath and the assay was analyzed using the pyridine-ferrochrome method.  
Following the addition of 15 μL of acetone to each well of the plate, 8 μL of pyridine 
solution was added (50% pyridine, 20% acetone, water and 200 mM HEPES, pH 7.4) so 
that the final concentration of pyridine was 5% (v/v).  Following a 30 minute interval of 
shaking to facilitate the solubilization of free heme, the absorbance of the resulting 
complex was measured at 405 nm and the background signal from the pre-read 
absorbance was removed for each well. 
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GSK Compound Analysis 
 Over 13,000 unique compounds were received from GSK in duplicate (125 nL 
volumes).  Each compound was tested for inhibitory activity against β-hematin 
formation.  Positive controls consisted of a 100 μM final concentration of amodiaquine 
(dissolved in DMSO) and negative controls consisted of DMSO only.  Controls were 
added to columns 6 (DMSO, added by GSK) and 18 (amodiaquine, added by Vanderbilt).  
Following addition of controls, the reagents of the β-hematin formation assay described 
above were added to the plate.  Percent inhibitory activity of each test compound was 
calculated relative to positive and negative control wells added to each plate.  The 
standard deviation of each plate was calculated relative to the negative controls where the 
highest deviation was observed.     
 
Target Confirmation in P. falciparum 
 In order to confirm hemozoin as the in vivo target of in vitro antimalarial activity, 
a heme speciation assay was used to measure the ratio of free heme:hemozoin present in 
the parasite.  In this assay, tightly synchronized ring-stage parasite cultures (50 mL 
culture volume, 2% hematocrit, 5% parasitemia) are treated with a test compound and 
incubated for approximately 30 hours, allowing the rings to mature into schizonts where 
hemozoin formation is expected to be maximal.  Following incubation at 37⁰C, the 
culture is transferred to 50 mL tubes and centrifuged at 1500 rpm for ten min.  The 
culture media is removed and erythrocytes are lysed with a 0.05% solution of saponin, 
leaving trophozoites in the culture.  Pyridine is then used to examine the concentration of 
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heme available as free heme.  Sodium hydroxide is then used to solubilize and quantitate 
hemozoin.  
 
Results 
 
The 13,231 in vitro antimalarial compounds were tested in duplicate in the β-
hematin formation assay.  Excellent Z’ values were obtained with an average of 0.85.  
The average standard deviation of the negative controls was ~10%.  Percent inhibitory 
activity was measured for each compound relative to positive and negative controls.  The 
hits were prioritized into three sets: 
1) >90% inhibitory activity, potent hits 
2) 80% - 90% inhibitory activity, compounds with moderate activity 
3) 50%-70% inhibitory activity, compounds with minimal activity  
 
Inhibitory Activity Number of compounds 
50 – 70% 276 
80 – 90% 293 
>90% 250 
 
Table 7. β-hematin inhibitors were prioritized based on % inhibitory activity. 
 
 
In the original HTS screen discussed in Part I, compounds that inhibited >80% of 
β-hematin formation were considered hits.  Using this definition of a hit, a hit-rate of 
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0.37% was obtained.  In comparison, the GSK library contained a significantly higher 
number of active compounds.   To maintain a reasonable hit-rate, the threshold that 
defines a hit was moved up to compounds exhibiting >90% inhibitory activity.  This 
threshold resulted in a 1.9% hit-rate (250 hits).  The enrichment in activity was not 
unexpected since the GSK library compounds are predetermined to have affinity toward 
targets present in P. falciparum.   
The compounds in the GSK library were also prioritized based on cluster identity.  
We chose to perform this structural analysis for all compounds that exhibited >50% 
inhibitory activity.  The threshold was lowered for this analysis so that the scaffolds that 
have enriched β-hematin inhibitory activity could be elucidated.  The GSK library is 
comprised of 416 clusters.  Ten of these clusters were identified where at least 50% of the 
members exhibited at >50% inhibitory activity (Table 8).  Figure 33 identifies a 
representative compound from each of the ten clusters.  It is clear that the 2-biphenyl 
benzimidazole represents the majority of active clusters.  
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Cluster # hits 
% of 
compounds in 
this cluster that 
are hits 
23 25 76 
80 7 70 
69 8 67 
39 13 65 
35 14 64 
10 37 61 
221 6 60 
27 15 56 
29 14 54 
15 21 51 
 
Table 8.  Ten clusters were identified where more than half of the members exhibited 
>50% inhibitory activity. 
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Figure 33.  Representative compounds from each cluster where >50% of members 
inhibit β-hematin formation. 
 
 
 
 As evident in the screening results, many of the in vitro antimalarial compounds 
identified by GSK were also active in the β-hematin formation assay, suggesting 
hemozoin as the target.  In order to demonstrate that hemozoin is indeed the in vivo target 
of in vitro antimalarial activity, a heme speciation assay can be utilized which determines 
the ratio of free heme:hemozoin present in the parasite.
 74
  If a test compound truly targets 
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the hemozoin formation pathway, then the ratio of free heme should increase as a 
function of increasing drug concentration.   In this assay, tightly synchronized ring-stage 
parasite cultures (50 mL culture volume, 1% hematocrit, 5% parasitemia) are treated with 
a β-hematin inhibitor and incubated for approximately 30 hours, allowing the rings to 
mature into schizonts where hemozoin formation is expected to be maximal.  The ratio of 
free heme:hemozoin present in the parasite is then measured.  Figure 34A shows the 
treatment of parasite cultures with CQ.  From this plot, as the parasite dies (from 
increasing CQ concentration), there is an increase in the percentage of heme that is 
available as free heme.  Therefore, as higher concentrations of CQ are added to the 
parasite culture, hemozoin formation is inhibited and there is a measurable increase in the 
percentage of heme that is available as “free heme”, thus implicating hemozoin as the 
primary molecular pathway responsible for parasite death.  Using this assay, we have 
begun to evaluate each of the top 250 commercially available β-hematin inhibitors to 
validate hemozoin as the molecular pathway responsible for parasite death.  For the β-
hematin inhibitor identified in Figure 34, it is clear that the percentage of free heme 
increases as a function of increased inhibitor concentration. 
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Figure 34. Examination of the effects of β-hematin inhibitor on the heme:hemozoin ratio 
in P. falciparum. (A) Parasite culture treated with CQ.  The β-hematin inhibitor identified 
in B was used to treat cultures of the parasite.  (B)* % of heme that is available as free 
heme and (C)* % of heme that is incorporated into the hemozoin (Hz) crystal  *Data 
obtained by Jill Combrinck. 
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Conclusions and Future Directions 
 
 Potent inhibitors of β-hematin formation have successfully been identified from 
the GSK library of in vitro antimalarial compounds.  We will next analyze the top 250 β-
hematin inhibitors in a dose-response format.  Using this information, a preliminary SAR 
analysis in collaboration with University of Cape Town (Cape Town, South Africa) will 
be performed in order to identify compounds that are worthy of lead optimization.  SAR 
analysis will also be completed for the 2-biphenyl benzimidazole scaffold with enriched 
β-hematin inhibitory.  Target validation of the top 250 commercially available β-hematin 
inhibitors is currently underway to determine if the molecular pathway responsible for 
parasite death is hemozoin inhibition.   
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Chapter V 
 
APPLICATION OF MACHINE LEARNING TECHNIQUES REVEALS PATHWAY 
SPECIFIC INHIBITORS FOR β-HEMATIN CRYSTALLIZATION IN PLASMODIUM 
FALCIPARUM
124 
 
Introduction 
 
 The malaria eradication campaigns of the mid 1900’s dramatically lowered 
infections worldwide through a combination of vector control methods and drug 
treatment using the antimalarial chloroquine (CQ).
3
  After two decades the focus of these 
efforts shifted to a less ambitious goal of malaria control due in part to resistance and 
safety concerns.  Recently, resurgence in malaria cases have been observed, primarily in 
underdeveloped countries and due in large part to the development of resistance 
mechanisms to nearly all affordable antimalarial drugs and insecticides.
4,5
  Though it has 
been over 50 years since resistance to CQ was first reported, no affordable replacement 
has been developed.
94,95
  Perhaps the primary reason that progress has been slow is 
because malaria is a disease of poverty.
96
  With no market incentive, pharmaceutical 
companies have historically shown little interest in antimalarial drug development since 
R&D investments would not be recouped.  There has also been a lack of public funding 
for tropical diseases, referred to as the ‘90/10 split’, where 90% of the US health-related 
funding goes to research for only 10% of the worldwide disease burden.
97
  Fortunately, 
interest in malaria control has increased in recent years, including an initiative announced 
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in 2007 by the Bill & Melinda Gates Foundation to eradicate malaria worldwide.  
Furthermore, through the advent of public-private partnerships (PPP’s), pharmaceutical 
companies are now collaborating with non-profit organizations to develop new 
antimalarial drugs.
98
   
 Although malaria has historically been a neglected disease, there is reason to be 
optimistic.  Several significant advances have been made in antimalarial drug discovery, 
particularly in the past ten years.  Perhaps one of the most exciting advancements has 
been the full genomic sequencing of P. falciparum and P. vivax which allows for the 
identification of new druggable targets.
99,100
  Additionally, a more in-depth understanding 
of parasite biochemistry has allowed the introduction of high-throughput screening (HTS) 
techniques for both target-based and phenotypic assays.  Successful target-based assays 
have been developed including those that target inhibitors of β-hematin formation, 
aminopeptidase activity, the mitochondrial electron transport chain, and pyrimidine 
biosynthesis.  Phenotypic assays have also been developed to identify molecules that are 
toxic to parasite cultures.  Recently, phenotypic  screens have been completed by GSK 
and Novartis against millions of compounds in their respective HTS collections.
62
  The 
results were released to the public and identified thousands of potent chemical starting 
points for lead compound development.   
 The scientific community now has access to an arsenal of thousands of 
compounds that are highly toxic to the parasite, but the process of developing these hits 
into robust lead compounds will be challenging.  It is reasonable to assume that 
identification of the molecular targets could aid in prioritization of these hits, while 
optimization steps could also potentially be decreased since the hit-target interactions 
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could be directly studied, saving time, and money.  While the experimental determination 
of targets is possible in some cases, it is time-consuming and expensive to develop and 
apply target-specific high-throughput screening (HTS) to large numbers of compounds. 
 Here we propose a more affordable in silico pre-screening of compounds to sort 
and prioritize according to their likelihood to interact with a specific target. The 
development of quantitative structure activity relationship (QSAR) models has shown 
practical value for in silico screening of potential hit compounds to identify novel 
chemical entities with a desired biological activity 
101-103
. Hence, application of QSAR 
models to in silico screen drug-like small molecules enables the prioritization of focused 
libraries for acquisition and experimental verification. Further, such models can be 
applied in biomedical research for hit-to-lead or hit-to-probe optimization.  
We test if ligand-based virtual screening approaches are able to streamline 
antimalarial drug discovery focusing on inhibition of β-hematin formation as target 
pathway. An in-house diverse small molecule library (144,330 total compounds) with an 
initial hit rate of 0.4% (530/144,330) was used as a knowledge-base to establish QSAR 
models.  A theoretical enrichment of ~37 was established using an independent data set.  
These models were applied to virtually screen the publically available databases of in 
vitro antimalarial compounds.  Experimentally, enrichment of ~44 fold was achieved for 
the GSK data set using a threshold cutoff of 70µM. 
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Experimental Methods 
 
β-Hematin Formation HTS Assay 
The β-hematin formation assay has been described previously for use in HTS (Chapter 
IV, Part I).  Briefly, over 140,000 10 mM library compounds originating from 
ChemBridge and ChemDiv were tested at 19.3 μM, A bulk liquid dispenser was used to 
add water, NP-40 (30.55 μM) and heme (100 μM) suspended in a pH 4.9 acetate buffer (1 
mM).The plates were incubated for five hours in a shaking water bath at 37°C.  The 
pyridine-ferrochrome method of quantification was used to analyze the inhibitory activity 
of compounds by adding a solution containing 50% pyridine, 20% acetone, and water 
solution buffered with a 200 mM pH 7.4 HEPES buffer such that the final concentration 
in each well was 5% pyridine (vol/vol).  From this method, we identified hits as those 
compounds exhibiting greater than 50% inhibitory activity.  Follow-up dose-response 
curves were generated for all hits in order to eliminate false-positives and determine the 
potency of each hit. 
 
QSAR model training (This section was kindly provided by Mariusz Butkiewicz)  
Quantitative structure activity relationships seek to correlate the often complex 
non-linear relations between chemical structure and biological activity for a specific 
protein target
101,103
. Modern QSAR techniques employ advanced 2D molecular 
fingerprints and 3D molecular descriptors coupled with machine learning 
104,105
. The 
descriptors employed in this study (scalar, 2D/3D auto-correlation, radial distribution 
functions) are fragment-independent and translation/rotation invariant. Thus, the resultant 
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fingerprints are constant in length and independent from molecule orientation in space. A 
total of 1,284 numerical descriptors in 60 categories were implemented in this. 3D 
conformations were calculated for all molecules with CORINA 
106
. A set of five machine 
learning algorithms was implemented in this study including Artificial Neural Networks 
107-109
, Support Vector Machines 
110,111
, kappa – Nearest Neighbors 112,113, Kohonen 
networks 
114,115
, and Decision Trees 
116,117
. Machine learning models can adapt to 
complex interrelations and are capable of detecting even small signals at high noise 
levels. Hence, each of these methods is applied when no simple mathematical model can 
be assumed, many influencing factors interact, and the experimental uncertainty is high. 
The training data set had 80% of the data points employed in the actual training process. 
The number of training iterations was limited through early termination to counter 
“overfitting” of the machine learning model to the training data. A monitoring data set 
consisting of 10% of the data points was used to optimize all training parameters of the 
machine learning methods and to invoke early termination. The final 10% of the data 
points are set aside as an independent data set. It is not used in the training process, but 
used to evaluate the final model. There was no overlap of compounds between training, 
monitoring, and independent data sets. Sequential Forward Feature selection
118,119
 was 
chosen to determine an optimized descriptor set for every combination of machine 
learning technique. Systematically, each data partition is chosen once as an independent 
dataset and cross–validated through machine learning model training 120. The overall 
accuracy of all cross - validated QSAR models was evaluated by calculating a jury 
consensus of all predicted pIC50 values for each independent data set iteration.  
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Results 
 
Training Set 
 The heme detoxification biomineral, hemozoin, is the target of quinoline 
antimalarials.  Resistance to these drugs is the result of efflux mechanisms developed by 
the parasite rather than changes to the pathway itself.  For this reason, hemozoin remains 
a valid drug target for the development of new antimalarial probes.  Recently, a β-
hematin (synthetic hemozoin) formation assay was designed to mimic conditions present 
in the digestive food vacuole of the malaria parasite where hemozoin formation occurs.  
This assay was adapted for use in HTS and utilized to screen a library of over 144,000 
compounds.  The screening effort resulted in the identification of inhibitors of β-hematin 
formation (see Chapter IV).  A follow-up dose-response assay was used to establish the 
potency of each hit, with all of the compounds having more potent activity in this assay 
than chloroquine. While the hits identified in this screening effort will be utilized for the 
identification of lead probe candidates, what can be learned from the set of over 142,000 
compounds that are not active in this assay? 
 
QSAR model   
Here, the results of the entire screening effort, both positives and negatives have 
been utilized to provide the knowledge-base for a target specific QSAR model by 
bcl::ChemInfo. Briefly: this in silico ligand based virtual screening suite applied a diverse 
set of orthogonal machine learning techniques to model nonlinear relations between the 
chemical structure of the ligand and its associated inhibitory concentration. It determines 
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an optimal set of numerical descriptors of chemical structure through feature forward 
selection (FFS) or feature backward elimination (FBE). The predictive power of the 
models was assessed determining for an independent dataset a variety of measures such 
as positive predictive value (PPV) and area under the curve (AUC) in receiver operator 
characteristics (ROCs). The best performing model was chosen by maximizing the PPV 
in the range critical for in silico screening and prioritization, here when selecting 0.1%-
1.0% of compounds from a library. The final model achieved a PPV value of 0.69 for the 
top 0.1% to 1% of positive predicted compounds, i.e. 70% of the predicted active 
compounds are true actives. This corresponds to an enrichment of ~37 and was achieved 
using a cutoff of 1% false positive rate (see Figure ). 
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Figure 35*: The final QSAR model is quantified by ROC curve analysis. The left graph 
shows a plot of false positive rate (FPR) compared to the true positive rate (TPR) 
achieving an area under the curve of 0.88. At an FPR cutoff of 5% an enrichment of 17 
was achieved.  The sub-graph shows the same roc curve on a logarithmic scale. On the 
right hand site, a plot of precision in respect to the fraction of positive predicted 
compounds is plotted on a logarithmic scale. The ideal precision trajectory is represented 
by the black dotted line. To recover all active compounds contained in the in–house 
screened library, the range from 0.0001 to 0.01 was evaluated with a precision integral of 
0.58 in comparison to the ideal precision curve. To recover the top 100, 200, 300, and 
400 compounds precision integral of 0.66, 0.69, 0.63, and 0.60 was achieved, 
respectively. *Figure was kindly provided by Mariusz Butkiewicz 
  
 
QSAR model prioritizes GlaxoSmithKline and Novartis compounds for inhibition of β-
hematin pathway 
 GlaxoSmithKline (GSK) and Novartis have screened their corporate libraries and 
identified hit compounds acting against in vitro culture of the malaria parasite, P. 
falciparum. The targets of these potent in vitro antimalarial compounds are unknown and 
it would be far too expensive to order all of the commercially available compounds from 
these hits to test for activity against the β-hematin formation.   In an effort to prioritize 
compounds most likely to have activity against this pathway, the QSAR model was 
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applied to virtually screen the active compounds published by GSK and Novartis.  The 
output of the QSAR model is a predicted half maximal inhibition concentration (IC50) for 
β-hematin inhibition.  Overlapping compounds between the training data and the 
GSK/Novartis data sets were taken out of the screened libraries to avoid re-identification 
of known actives.  The remaining compounds were grouped into seven ‘Bins’ based on 
the potency of the predicted IC50 values (0-70 µM, 71 - 140 µM, etc). The GSK library 
contained a total of 13,533 compounds of which 249 compounds (below 70 µM) were 
predicted to express inhibitory effects in silico (see Table 9). The Novartis library 
contained 5,697 compounds and the computational model predicted 37 compounds as 
inhibitors with an IC50 of below 70 µM. This results yields an in silico hit rate of 1.8% 
and 0.6% for the GSK and Novartis compounds. 
 
 
 
Table 9.  Prioritization of the GSK and Novartis compounds based on predicted activity 
against β-hematin formation. 
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Experimental analysis of enrichment by predicted activity binning and structural 
similarity 
 The accuracy of the QSAR model to predict inhibitors of beta-hematin formation 
was experimentally validated using the GSK in vitro antimalarial data sets.  Compounds 
were first pre-screened in the NP-40 detergent mediated β-hematin formation assay.  
Compounds inhibiting >80% of crystallization were considered hits, and were 
subsequently tested in a dose-response manner to establish potency.  As evidenced in 
Error! Reference source not found., the GSK data sets show a substantial increase in 
enrichment in Bin 1, where the hit-rate for the GSK set was 16%.  Bin 2 also showed an 
increased degree of enrichment where 10% of the GSK compounds tested were active.  
The percentage of actives continues to decrease as a function of increasing Bin number, 
such that the largest ratio of active:inactive is observed in Bin 1, the bin predicted to 
contain the highest percentage of actives according to the QSAR model. 
 It is also worth noting that a small degree of enrichment is observed in bins 5-7.  
This is almost certainly due to the fact that the GSK and Novartis compounds are biased 
as they are known to inhibit some pathway within the parasite.  As such, a higher hit-rate 
would be expected than that observed when screening a non-biased library, leading to 
some degree of enrichment. 
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Figure 36.  Experimental evaluation of the GSK compounds reveals enrichment of 
activity in Bin 1. 
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Discussion 
 
 The GSK and Novartis screening efforts have resulted in the identification of 
thousands of chemical starting points for lead probe identification, but the molecular 
targets of these active compounds are unknown. Leveraging this rich data source for the 
development of lead and probe compounds hinges on identification of pathway and 
target, a time-consuming and resource-intense process.  Hemozoin, a validated target 
specific to the parasite, has been studied in great detail and serves as an important 
pathway for future antimalarial development.  One has to expect hemozoin inhibitors 
present in the data collected by GSK and Novartis.  Therefore, one approach to select 
these compounds would be high-throughput screening the GSK and Novartis compounds 
for compounds that perturb the hemozoin formation pathway.  To avoid testing all 20,000 
active compounds, the challenge is to prioritize those that are most likely to inhibit 
hemozoin formation.  This has been addressed by using a QSAR model to virtually 
screen the 20,000 compounds to prioritize those that are most likely to inhibit β-hematin 
formation – a process that also eliminates the need to have access to all 20,000 
compounds.   
The training set was provided by an HTS campaign that screened over 140,000 
compounds to identify inhibitors of β-hematin formation (0.4% hit-rate).  This method of 
developing a QSAR model takes advantage of the chemical space provided by both, 
active and inactive compounds.  The resulting model was used to virtually screen the 
GSK and Novartis hits and prioritize the compounds based on predicted IC50.  When 
testing a subset of compounds predicted to inhibit of β-hematin formation with IC50 
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values better than 70 µM, ~80% turned out to be active (PPV) representing an enrichment 
of >80 fold.  We further demonstrate that PPV correlates tightly with predicted activity.  
Compounds with a low pIC50 value are predicted with a high confidence yielding a 
decrease of enrichment with increasing Bin number. Therefore, this method confidently 
filters for inhibitors of β-hematin formation.  An analysis of the compounds in Bin 1 
reveals that many diverse structural scaffolds are predicted to have activity against β-
hematin formation.  Among these actives are several quinoline, quinazoline, 
benzimidazole and carbazole scaffolds.      
 While the approach taken here has successfully filtered compounds to predict 
inhibitors of β-hematin formation, it is important to note that this approach for identifying 
target-specific activity is not limited to β-hematin, and can be applied to any pathway 
within the parasite given access to HTS data.  In fact, multiple parasite-specific pathways 
have been the focus of target-based screening efforts in recent years.  One such effort 
screened a 220,000 compounds library to identify inhibitors of P. falciparum pyrimidine 
biosynthetic enzyme dihydroorotate dehydrogenase (PfDHODH), resulting in the 
identification of 1249 hits.  Perhaps a QSAR model for the results of the PfDHODH 
screening results would allow the delineation of pathway specific inhibitors of β-hematin 
formation and PfDHODH inhibitors.  Alternatively, the model could be quite useful in 
identifying in vitro antimalarial compounds that have dual-targeting activity.          
The QSAR approach developed here is not specific to the malaria parasite, and 
can be used for target-elucidation in other diseases as well.  This is particularly applicable 
for use in neglected diseases where limited funding restricts the expensive and time-
consuming process of target-elucidation.  A further application of this model would be to 
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guide the selection of second generation compounds in the process of lead development.  
By creating a large list of possible second generation compounds, the model can 
prioritize a subset of compounds predicted to have more potent activity against the target. 
 
Acknowledgments 
 
This work was a collaborative effort with the Meiler lab.  Mariusz Butkiewicz 
was responsible for the computational portion of the QSAR model and will be co-author 
on the manuscript that results from this work.  Kim Fong is currently working on 
pathway validation of the validated β-hematin inhibitors (from Bin1) in P. falciparum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 124 
CHAPTER VI 
 
FUTURE DIRECTIONS AND FINAL THOUGHTS 
 
 Herein, I have presented evidence that solidifies neutral lipid droplets as the site 
of hemozoin formation within the parasite, and identified the lipophilic detergent, NP-40, 
as a surrogate for these lipids.  The NP-40 detergent-mediated assay has been utilized in 
HTS where 144,330 compounds were analyzed for β-hematin inhibitory activity.  As a 
result, 530 β-hematin inhibitors were identified, 171 of which exhibit in vitro antimalarial 
activity.  With the HTS campaign complete, it is now time to begin the arduous process 
of lead identification and optimization. 
 
Lead Identification 
 
 In order to identify robust, quality leads from the HTS results, the 171 in vitro 
antimalarial compounds must be effectively prioritized.  We will prioritize compounds 
based on validation of hemozoin as the target, synthetic feasibility, preliminary SAR 
analysis, compound chemistry, PK properties, susceptibility for resistance to develop in 
P. falciparum, and activity against multiple stages of the parasite life cycle.  Taken 
together, these experiments will guide the selection of a small number of hits to advance 
to the expensive and time-consuming process of lead optimization. 
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Validation of Hemozoin Inhibition 
 The lipophilic detergent, NP-40, was selected as a surrogate for the biologically 
relevant neutral lipid droplets based on its similarity in assay performance.  By utilizing 
an assay that successfully recapitulates the biological conditions within the digestive food 
vacuole of the parasite, 32% of the β-hematin inhibitors retained activity against cultures 
of P. falciparum, suggesting hemozoin formation as the pathway.  Efforts are now 
underway to substantiate hemozoin inhibition as the molecular pathway responsible for 
parasite death.  A powerful technique for quantitating heme accumulation and consequent 
parasite death as a function of drug dosing was recently reported (called the heme 
speciation assay).
74
  This technique involves strenuous assay conditions that severely 
limit the number of compounds that can be analyzed in a reasonable amount of time 
(each compound currently takes 1-2 weeks to examine).  To facilitate a more rapid 
analysis of hemozoin inhibition, the throughput of this assay are must be increased. 
 In its current format, the heme speciation assay requires 10 mL of packed, 
parasitized erythrocytes containing highly synchronized rings.  This large volume of 
culture is necessary for the quantitation of free heme and hemozoin using UV-Vis 
spectroscopy.  An approach to reducing the volume of culture necessary is to utilize more 
sensitive spectroscopic techniques to detect heme.  To address this, the Wright lab is 
currently validating the assay using inductively coupled plasma optical emission 
spectroscopy (ICP-OES) for heme quantification.  With this approach, the heme 
speciation assay could be adapted for use in a 6-well plate, as opposed to a 50 mL flask, 
resulting in a significant increase in throughput. 
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 If we cannot successfully increase the throughput of the heme speciation assay, 
we must have an approach to down-select the number of compounds that need to be 
validated using the current assay format.  This will be necessary since testing all 171 in 
vitro antimalarials in the current format of the heme speciation assay would take 
approximately 6 years to complete (assuming one researcher is responsible for all 
experiments).  One approach to identify off-target antimalarials is to monitor hemozoin 
formation using fluorescence microscopy.  Specifically, the fluorescent properties of 
hemozoin can be exploited to monitor crystal formation in parasite cultures treated with 
the in vitro antimalarial β-hematin inhibitors identified in the screen.  Hemozoin 
formation would be monitored (relative to drug-free controls) in 384-well plates to 
determine whether the test compound affects the crystallization process.  A deviation in 
hemozoin formation would suggest crystallization as the target.  If hemozoin formation 
occurs normally, then parasite death would be due to some other pathway.  Using this 
approach to rapidly filter out compounds that do not interfere with hemozoin formation, 
fewer compounds would need to be validated in the heme speciation assay in its current, 
low-throughput format.   
 
Synthetic Amenability and SAR 
 The synthetic amenability of validated hemozoin inhibitors will be analyzed to 
determine if a preliminary SAR analysis can be readily completed in a cost-effective 
manner.   Primarily, we are interested to determine if the activity of the compound can be 
maintained following modifications to the core scaffold.  If the compound loses activity 
following minor structural modifications, then the process of lead optimization would be 
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quite challenging.  We previously completed this analysis based on the results of the pilot 
screen and selected several compounds for an SAR analysis (see Chapter IV, Part II).  
The full results of the screening effort will now be reviewed in a similar manner. 
 For compounds selected as synthetically amenable, a collection of ~5-20 
derivatives of each compound will be obtained from commercial resources or synthesized 
for a preliminary SAR analysis.  This will not be necessary for all validated hemozoin 
inhibitors since 61% of these compounds share a substructure with at least four other 
compounds in the screening results.  From this analysis, we aim to determine which 
molecular features give rise to β-hematin inhibitory and in vitro antimalarial activity.  
Since the presumptive target, heme, is well studied, this SAR analysis will designed so 
that the interactions between target/inhibitor can be thoroughly analyzed.     
 
Antimalarial Properties 
 Validated hemozoin inhibitors will be further prioritized based on their selectivity 
for the parasite, activity against multiple strains of P. falciparum, rapid development of 
resistance, and activity against other stages of the parasite lifecycle.  The first step will be 
to analyze the selectivity of each hemozoin inhibitor for the parasite.  This will be 
accomplished by determining the toxicity in mammalian cell culture (HEP2).  
Compounds should exhibit >ten-fold selectivity for the parasite toxicity versus 
mammalian cultures.  Compounds showing selectivity for the parasite will then be tested 
in multiple multidrug-resistant strain of the parasite.  By establishing the inhibitor dose-
response in resistant strains, the resistance index (RI = IC50 multidrug-resistant strain / 
IC50 drug sensitive strain) can be calculated for each compound to identify those that are 
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predisposed for resistance.  We have completed this stage of the process for the 25 
nanomolar potent hits identified in the screen.  For 21 of the nanomolar-potent in vitro 
antimalarials identified, the calculated RI was < 3, indicating that these 21 compounds 
are approximately as effective against drug-resistant strains as they are against sensitive 
strains (Table 10).  
 
 
        
Table 10. The RI values were calculated for each of the in vitro antimalarials that 
exhibited nanomolar potency. 
 
VU identifier
BH formation 
IC50 (µM)
D6 IC50 
(uM)
C235 IC50 
(uM)
Resistance 
Index
VU0098755 12.6 0.106 0.127 1.2
VU0073687 6.3 0.185 0.551 3.0
VU0001281 5.9 0.194 0.174 0.9
VU0065708 16.2 0.198 0.184 0.9
VU0096505 8.8 0.238 0.217 0.9
VU0107282 17.0 0.290 0.540 1.9
VU0114785 13.4 0.346 4.8 13.9
VU0002101 14.3 0.348 0.412 1.2
VU0028177 13.3 0.350 0.465 1.3
VU0063971 8.9 0.384 0.833 2.2
VU0129813 26.8 0.396 0.294 0.7
VU0114734 22.1 0.461 1.1 2.5
VU0122653 24.5 0.550 0.900 1.6
VU0000264 2.0 0.593 0.248 0.4
VU0065892 6.2 0.611 0.693 1.1
VU0010690 25.0 0.673 1.5 2.3
VU0094619 2.4 0.700 0.284 0.4
VU0012464 7.3 0.708 0.923 1.3
VU0008057 9.6 0.730 1.5 2.1
VU0358149 8.3 0.778 19.1 24.5
VU0015078 1.1 0.810 5.7 7.1
VU0119324 21.5 0.845 0.186 0.2
VU0078364 5.3 0.922 2.0 2.1
VU0107278 11.8 0.951 3.9 4.1
VU0064165 15.4 0.993 1.0 1.0
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 Each compound with an RI of <3 will be further tested to identify those 
compounds that are susceptible to accelerated resistance by the parasite.  This will be 
accomplished by co-incubating validated hemozoin inhibitors at sub-lethal concentrations 
(5-20% of the IC50 concentration) in cultures of the D6 strain of the parasite.  In one-week 
intervals, the IC50 of the hemozoin inhibitor will be established to determine if there is 
any increase in the concentration of test compound necessary to clear the parasite.  
Development of an antimalarial possessing activity against multiple stages of the parasite 
lifecycle is highly desirable.  This includes activity against the liver stage and 
gametocytes (to block transmission).        
 Further considerations for hemozoin inhibitors that perform optimally in the 
above described assays will be taken into account for the selection of lead drug 
candidates including performance in typical PK assays.  The chemistry of the subset of 
compounds must also be taken into account including properties such as solubility, 
stability and synthetic feasibility.  According to the compound progression criteria used 
by the Medicines for Malaria Venture (MMV, a nonprofit organization focusing on the 
development of antimalarials), compounds should be soluble in PBS at >20 μg/ml and 
stable in solid form.  Synthesis should be straightforward and cost-effective.    
 Superior compounds selected based on the criteria described above will be tested 
in the P. berghei mouse model of malaria in the 4 day suppressive Peters test (10mg/kg 
bodyweight).  If parasite clearance is successful in the mouse model, further tests in the 
monkey model of human malaria will be performed.  Compounds that meet the majority 
of the criteria discussed above and effectively clear the parasite from the mouse and 
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monkey model can then be submitted for lead optimization where the potency and drug 
properties of each hit will be improved.    
 
Lead Optimization 
 
 Several strategies for streamlining the process of lead optimization can be 
imagined based on our knowledge of the biology of the malaria parasite and the target, 
hemozoin.  We can begin by considering the in vivo site of hemozoin formation, the 
neutral lipid body located within the digestive food vacuole.  This localization of the 
target within a malaria-specific organelle presents an opportunity for increasing the 
potency of lead compounds.  Specifically, leads can be modified to increase accumulation 
within the neutral lipid droplets that reside within the digestive food vacuole.  
Chloroquine serves as an excellent example of increased potency based on drug 
accumulation.  At cytosol pH, chloroquine exists in its neutral form and passes through 
lipid membranes, ultimately penetrating the parasitic digestive food vacuole.  Upon 
entering this acidic (pH ~4.8) compartment, the weakly basic amine groups become 
protonated.  In its protonated form, chloroquine becomes trapped, resulting in high local 
concentrations of the drug.  This property of vacuolar concentration has been exploited in 
the development of the acridone antimalarials where the addition of weakly basic amine 
groups facilitated accumulation and increased potency.
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 Increasing digestive food 
vacuole accumulation is a clear strategy for the development of potent derivatives of the 
lead compounds.  A second level of hemozoin targeting is possible by increasing the 
compound accumulation within neutral lipid droplets where free heme rapidly 
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accumulates and consequent hemozoin formation occurs.  This level of optimization 
could be completed by analyzing the preferential partitioning of lead compounds into 
physiologically relevant neutral lipids (see Chapter II).  Slight increases in the 
lipophilicity of leads could result in increased accumulation within the neutral lipid 
bodies.  This accumulation of inhibitor at the site of hemozoin formation could result in 
increased potency of the lead compound.       
 
Target/Inhibitor Molecular Interactions 
 Hemozoin inhibition occurs either by 1) interactions with free heme or 2) capping 
of the hemozoin crystal.  Either mode of interaction will ultimately result in parasite 
death due to heme-associated toxicity.  However, by understanding the precise molecular 
interactions that occur, we can more effectively optimize leads that have increased 
affinity towards heme or hemozoin.  Methods for determining the mode of interaction 
responsible for parasite death were presented in Chapter IV, Part II. 
 After establishing the mode of hemozoin inhibition, target/inhibitor interactions 
can be analyzed in detail using ITC, paramagnetic NMR and XRD.  These tools will 
allow us to definitively identify the molecular interactions that occur between the 
inhibitor and target.  This information facilitates the optimization of a lead compounds 
drug-like properties that maintain the features of the molecule that give rise to hemozoin 
inhibition. 
 An additional strategy for streamlining the lead optimization process utilizes the 
QSAR model presented in Chapter V.  This model was shown to be a valid tool for 
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predicting β-hematin inhibitory activity.  This model could also be used to guide the 
selection second generation derivatives of lead compounds.     
 
FINAL THOUGHTS 
 
 Since I began researching malaria in 2008, many significant advances have been 
made in the field of antimalarial drug discovery, including the identification of over 
13,000 potent in vitro antimalarials by GSK.
62
  There have been setbacks, as well.  
Foremost, artemisinin resistance was confirmed in Western Cambodia in 2009, and later 
in Thailand.
73
  Alarmingly, these resistance mechanisms appear to have arisen 
independently, and artemisinin is the last line of defense we have against malaria.  If 
artemisinin resistance spreads to or develops in endemic African countries, the 
consequences will be devastating.  It is a critical time to prime the antimalarial pipeline 
with potential replacement drugs, and much of this work will be the responsibility of the 
academic community. 
 Drug discovery has long been the responsibility of the pharmaceutical industry, 
but times are changing.  In the past ten years, academia has established an important role 
in drug discovery – particularly regarding neglected and tropical diseases.  These 
diseases, including malaria, represent huge financial investments that will have zero 
return.  Therefore, it has been the responsibility of academia to tackle malaria, 
particularly in unraveling the biology of P. falciparum which can then be exploited for 
the development of new drugs.  Chapter II of this thesis, regarding the mechanism of 
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hemozoin formation, is a prime example of the role of academia in the drug discovery 
process.   
Inhibition of hemozoin formation may not be a newly identified drug target, but it 
remains invaluable nonetheless.  It is specific to the malaria parasite, essential for parasite 
survival, and we have a clear strategy for targeting the organelle in which hemozoin 
formation occurs.  It is also a validated target.  Chloroquine, which is perhaps the most 
successful antimalarial drug ever developed, targets the hemozoin formation pathway.
74
  
With the acknowledgment of hemozoin as such a valuable drug target, why are there no 
new drugs that exploit this pathway?  A primary reason is that the biology of this target 
was, until recently, poorly understood.  This changed in 2010, when we published data 
that reveals neutral lipid droplets (NLDs) as the location of free heme accumulation and a 
kinetically competent site for hemozoin formation.
51
  This represents the first time that 
heme has been shown to rapidly accumulate throughout the NLDs prior to hemozoin 
formation.  This small piece of knowledge represents an exciting opportunity for drug 
discovery.  We can optimize hemozoin inhibitors to concentrate within the NLDs located 
in the digestive food vacuole by manipulating the lipophilicity of inhibitors.  Drugs that 
more effectively target the site of hemozoin formation would be more potent and 
potentially have fewer side effects.  In addition, by identifying NLDs as the site of 
hemozoin formation, we can mimic this process in assay format for the identification of 
novel hemozoin inhibitors.
54
    
 While it is true that the pharmaceutical industry has made outstanding efforts to 
identify in vitro antimalarial compounds in the past few years, the amount of time and 
money devoted to malaria compared to the profitable diseases of affluence is small.  
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Furthermore, the screens utilized by pharma were not novel, but had been previously 
developed by academia.  This meant that the assay could be readily adapted and required 
minor assay validation and optimization steps.  Pharma has never developed an assay for 
malaria, and is unlikely to in the future due to the enormous time and financial 
investment that is necessary.  Fortunately, academia’s newly established role in drug 
discovery has prompted the development of a number of assays that can be used in an 
HTS effort. 
 HTS in the academic setting has only recently been implemented at a few 
institutions, though this technique for drug discovery has been utilized by pharma for 
over 25 years.  Though pharma has focused its use of HTS to financially rewarding 
diseases, many within the academic community have utilized HTS for tropical and 
neglected diseases.
54,81,85
  Our lab has been fortunate enough to unite our advances in the 
understanding of hemozoin formation with the Vanderbilt HTS facility.  Upon identifying 
the role of NLDs in hemozoin formation, we successfully developed an HTS assay to 
mimic this crystallization process (Chapter IV).  Not only did we identify over 500 potent 
inhibitors, but the majority of these compounds have never been associated with activity 
against β-hematin formation.  Upon testing these compounds against P. falciparum, we 
found that over 33% kill the parasite.  While many of these in vitro antimalarials have 
previously been identified as toxic to the parasite, they have never been associated with 
β-hematin formation.  Therefore, the results of our screen not only represent the 
discovery of novel β-hematin inhibitors, but give us the opportunity to utilize the 
structural data to more effectively analyze large phenotypic screens for compounds that 
are likely to be targeting hemozoin formation (Chapter V).  This is a significant 
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advancement, since a limiting factor in the prioritization of large phenotypic screens is 
the identification of targets. 
 Our screening efforts represent the importance of developing an assay that is 
biologically relevant.  Previous efforts by other groups to screen for hemozoin inhibitors 
have been abandoned, since so few (~1-2%) of their β-hematin inhibitors killed the 
parasite during the pilot screen.
70
  Why did we succeed where others failed?  Perhaps this 
success is due to the fact that we have more accurately recapitulated biological conditions 
where hemozoin formation occurs.  Understanding the biological formation of hemozoin 
was time-consuming.  We were not the first to develop a screen for β-hematin inhibitors, 
but we are the most successful.  This is an important message for those hoping to develop 
target-based screens.            
 Here we have taken a systematic approach to exploit hemozoin formation as a 
pathway for drug discovery, accomplishing what the pharmaceutical industry would not 
and what most academic labs could not.  The results of these efforts offer many novel 
chemical starting points for drug discovery.  We are currently working to identify lead 
compounds to submit to the drug discovery pipeline.  This is a critical time to enrich the 
antimalarial pipeline, since we are now on a race against time to develop a replacement 
for artemisinin before resistance is realized worldwide.     
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Appendix A 
 
Identification of Natural Product Extracts that Inhibit β-Hematin Formation 
 
While pharmaceutical companies primarily rely on the promise offered by 
screening small molecule libraries, natural products are now quite underutilized in this 
industry.  Throughout history, natural resources have been used for their antimalarial 
effectiveness.   In particular, the bark from the Cinchona tree was successfully used in the 
treatment of malaria, and later extracts identified the presence of quinine as the active 
drug component.  Artemisinin, another effective antimalarial, is a natural product of the 
Wormwood shrub.  Here, an underutilized resource, cave microorganisms, were analyzed 
in an attempt to identify new inhibitors of β-hematin formation.  The state of Tennessee 
contains over 7,000 cave systems, six of which have been selected for the isolation of 
bacteria cultures by Brian Bachmann and coworkers.  Cave microorganisms exist in a 
hypercompetive environment where nutrient resources are limited, requiring organisms to 
evolve at a rapid rate, resulting in a rich resource for secondary metabolites.  These 
metabolites can then be exploited by extraction methods followed by their incorporation 
into the detergent based β-hematin inhibition assay. 
 
Proof of Concept:  Analysis of Cinchona Bark 
A real-world application was tested in attempt to rediscover the antimalarial β-
hematin inhibitor, quinine.  An ethanol extraction of Cinchona bark powdered 
supplement was fractioned onto a 96-well plate and separated by an acetonitrile:water 
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gradient using reverse phase liquid chromatography tandem mass spectrometry (RP-LC-
MS/MS). One milliliter fractions of each sample were collected per minute in 96-deep 
well source plates and transferred to 96-well destination plates for screening, ensuring 
synchronization with the LC-MS/MS data to facilitate spectral identification of each 
well’s compound(s).  A compound capable of inhibiting 50% of β-hematin formation was 
identified and LC/MS data confirmed the presence of quinine in well 19 (Figure 37). 
 
 
Figure 37: The extraction of quinine from cinchona bark. 
 
Extraction of Metabolites from Cave Microorganisms 
The NP-40 HTS assay was successfully adapted for use in screening natural 
product extracts from cave microorganisms. The substrate concentrations remain as 
previously reported, with the addition of acetonitrile (7.5% v/v) to suspend the fractioned 
extracts in a 96-well plate. The assay was completely validated and utilized to test the 
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bioactivity of a diverse library of bacterial extracts. The samples tested consisted of 
bacterial strains isolated from soil samples that were collected from three different caves. 
In order to further diversify the library of compounds, each purified strain was grown 
under six different media conditions to elicit a unique set of secondary metabolites from 
each bacterial strain. Isolated actinomycete strains were cultured under six unique media 
conditions followed by a series of extraction procedures. Metabolites were extracted from 
the mycelium using 100% methanol (h1) and 100% acetone (h2), resulting in two unique 
extracts from the cell mass. Activated HP-20 resin was then added to the supernatant of 
the fermentation broth and stirred for thirty minutes followed by three extractions using 
20%, 60%, and 100% methanol (fractions h3-h5, respectively). For the extraction of 
nonpolar metabolites such as polyketides and oligosaccharides, ethyl acetate was added 
to a separate supernatant, shaken, then decanted and dried (e1). This resulted in two 
extracts taken directly from the cell mass, and four extracts taken from the supernatant. 
Extracts were then fractioned onto a 96-well plate and stored dry at -20 °C.    
Plates containing fractions of the bacterial culture extracts were tested in a 
preliminary screen depicted in Figure 37.  The 2σ and 3σ values are established based on 
a control plate containing the ICmax of amodiaquine (100 uM).  A value above 3σ 
indicates an inhibitor that is within three standard deviations of the amodiaquine control 
and should be further analyzed for bioactivity.  It should be noted that during the 
fractioning process, each well is characterized based on UV-Vis data, mass spectrometry 
analysis, and LC data such that each well is thoroughly analyzed during the fractioning 
process.  In the plate at hand, there are three fractions that are within three standard 
deviations of the amodiaquine control 
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Full Screening Results 
The goal of screening 8,640 fractions was achieved with 199 active wells 
resulting in a hit rate of ~2.2% of screened fractions (Table 11). Figure 38 is a typical 
screen where green dots represent test compounds. The solid lines represent the average 
value of control wells, where the dashed lines include the absorbance values that are 
within three standard deviations of the corresponding control. Test compounds that are at 
least three standard deviations above the negative control are considered to have  
statistically significant activity. Test compounds that fall within the red lines are 
considered to be particularly potent, capable of inhibiting β-hematin formation to the 
same extent as the IC100 amodiaquine control. Figure 38 represents a single actinomycete 
strain grown under two different media conditions and extracted using 100% methanol. 
The result is a clustering of compounds at elution times between 9-15 minutes. This was 
visualized in the natural products software developed by CFD Research Corporation, 
indicated by the red bars (Figure 39). This overlapping activity is common in the active 
strains tested thus far and is the result of either high concentrations of active compound 
that is carried into multiple wells, or a class of closely related compounds that display 
similar degrees of activity in the β-hematin formation assay. 
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Figure 38.  A single actinomycete strain grown under two different media conditions and 
extracted using 100% methanol. The result is a clustering of compounds at elution times 
between 9-15 minutes. 
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 When viewing the positive ion MS data for the active fractions, the mass 
correlation feature of the software identified a common mass of 347.0 m/z in the active 
region of each plate. Though a promising correlation between mass and activity is 
observed, further analysis is required to determine if this common mass is in fact 
responsible for the β-hematin formation inhibition.  
With the screening goals accomplished, activity guided fractionation will be used 
to positively identify active compounds. Briefly, a large scale culture (10 L) of the active 
actinomycete strain will be grown to ensure sufficient metabolite production. The extract 
will be fractioned on a Sephadex LH-20 column and tested for activity in the β-hematin 
formation assay. Active fractions will, then, be further purified using a C18 column and 
again tested for activity. If active fractions are sufficiently pure, then NMR will be used 
to positively identify the active compound(s) in each extract. This approach will be used 
to characterize those active compounds identified during screening. 
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Figure 39.  This activity of actinomycete extracts presented in Figure 38 were visualized 
in the natural products software developed by CFD Research Corporation.  Activity is 
indicated by the red bars. 
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Table 11. Extracts screened. Highlighted extracts are active in the β-hematin formation 
assay. 
Strain 
Identifier 
Growth 
Media 
Extraction Protocol 
Strain 
Identifier 
Growth 
Media 
Extraction Protocol 
  H1 H2 H3 H4 H5 E1 H7   H1 H2 H3 H4 H5 E1 H7 
1 OA      X  13 BA X  X X X X  
1 KE      X  13 KE X   X    
1 KA      X  13 EA X X X X X   
2 KE      X  13 QB X X   X   
2 ET      X  13 KA X X X X  X  
2 BA      X  14 EA      X  
2 EA      X  14 KA      X  
3 OA      X  14 BA      X  
4 OA       X 15 BA  X X X X X  
4 KA       X 15 QB  X X X X   
4 BA       X 15 OA  X X X X   
4 QB       X 15 EA  X X X X   
5 OA      X  15 KE  X X X X   
5 KA       X 15 KA  X X X X   
5 KE       X 16 QB      X  
6 KE      X  17 QB X X X X X X  
6 KA      X  17 KE X X   X X  
7 EA  X X X X   17 BA X X X X X   
7 OA  X X X X   17 KA X X   X   
7 KA X X      17 OA X X X X X X  
8 EA X X X X X   17 EA X X X X X   
8 QB X X X X    18 BA      X  
8 KE X  X X X   19 OA      X  
8 KA X X X  X   19 KA      X  
8 OA X X X X X   19 BA      X  
8 BA X  X X X   20 ET      X  
9 OA      X  21 QB      X  
10 BA      X  21 EA      X  
10 KA      X  21 KA      X  
10 OA      X  22 EA      X  
10 QB      X  22 KE      X  
11 QB      X  22 QB      X  
11 KE      X  23 KA X X X X X   
11 EA      X  23 OA   X  X   
11 KA      X  23 BA X X X X X   
11 BA      X  23 EA X X X X X   
12 KA      X  23 QB X X  X X   
13 OA X X  X X X  23 KE X X  X X   
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Appendix B 
 
Parasite Culturing Protocol 
 
Schedule for one week culturing period: 
Day 1: Off 
Day 2: Change media 
Day 3: Subculture (split) parasite 
Day 4: Off 
Day 5: Change media, Add blood 
Day 6: Change media 
Day 7: Subculture (split) parasite 
 
 The schedule is critical to the survival of the parasite, as the parasite is very 
sensitive to media conditions.   Ideally, parasite work should be done at roughly the same 
time each day.  However, if you are occasionally a few hours early or late from the time 
you normally care for the parasite, it is ok.   
I. Reagent Preparation 
Preparation of RPMI basic medium (500 mL) 
- Take one container of RPMI medium.  
- Add 1 g glucose.  
- Add 3 g HEPES.  
- Gently shake contents in bottle until dissolved, then filter sterilize with filter. 
Store in refrigerator.  
 
1. Preparation of 1.45 mM hypoxanthine stock (200 ml) 
- Dissolve 10.0 mg hypoxanthine in 50 ml distilled H2O.  
- Heat for 10 min (until dissolved)  
- Filter sterilize and store 4 ºC. 
 
2. Preparation of TCM complete medium (100 mL) 
- Take two sterile 50 mL tubes. To each, add the following: 
- 42.5 mL RPMI.  
- 5.25 mL plasma.  
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- 1.6 mL sodium bicarbonate. 
- 1.0 mL hypoxanthine stock. 
- Keep complete medium no longer than one week. 
 
II Washing 50% HCT Blood    
- Place (15 mL) blood into 50 mL sterile conical tube. 
- Place (15 mL) of RPMI in each tube containing the blood 
- Spin at 3000 RPM for 8 minutes.  Turn brake to ‘1’ position to avoid 
resuspending the blood.     
- Remove RPMI and buffy coat (a thick white coat on top of the blood layer) 
- Repeat Steps 4-6  
- After repeating step 6 add TCM to the blood so that you have a 50% Hct 
solution 
- Use blood no longer than one week 
 
III Parasite Care Routine 
For 25 mL flask culture: 
- Carefully remove flasks from incubator.  Let sit for 10  minutes to allow 
disturbed RBC’s to settle to bottom of flask. 
- Remove ~4mL of the media without removing RBCs 
- Replace with 4 mL of TCM, if adding blood use 0.1 mL of 50% HCT Blood 
- Gas culture with blood gas (90% N2, 5% O2, 5% CO2 for 30 sec 
- Place in 37°C Incubator 
 
IV Subculture/Splitting Parasite 
Using a 25 mL flask: 
-    4.5 mL of TCM  
-    0.5 mL of 50% HCT Blood 
-    Depending on the split from previous cultures, do a 1/50 (if parasitemia is 
>5%) or 1/100 (if parasitemia is <5%) split: 1/50 split means adding 0.1 mL of 
old culture 1/100 split 0.05 mL of old culture 
- Gas with Mixed Gas for 30 sec 
 -     Place in 37°C Incubator 
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Appendix C 
 
 
Malaria SYBR Green-I Assay 
 
 The malaria SYBR Green-I assay (MSF) is used to identify in vitro antimalarial 
compounds in 384-well plate format.  This assay was adapted from Johnson et al.
81
  This 
assay is performed on a ‘split’ day of the parasite culturing schedule (Appendix B).   
 
Optimal Parasite Culture: 
 In order for the assay to perform optimally, the cultures should be healthy.  In this 
instance healthy is defined as a culture that is growing as expected (5-8% parasitemia on 
a ‘split’ day) and shows no signs of being ‘stressed’ when viewed under the light 
microscope.   
 
Plate Preparation: 
 Because the reagents used in this assay are sensitive to high O2 concentrations, the 
assay should be setup quickly.   
1. Prepare the drug plate 
a. Add compound to be tested to the plate (384-well black, clear-bottom 
microtiter plate). 
b. Add vehicle controls if necessary. 
c. Add kill concentration of chloroquine (500 nM) 
d. Add IC50 concentrations for chloroquine.  This is performed to ensure that 
parasite is healthy and responding to drug treatment as expected (~20 nM 
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for D6 strain and ~200 nM for C235 strain).  While b-c need to be added 
to each plate, this step (d), can be added to a separate plate.   
2. Prepare culture stock 
Each well should contain 0.3 % parasitemia (from healthy culture), 2% 
Hct of fresh blood, 38 µL of TCM and 4.25 μL of RPMI.  If test 
compounds are added using the ECHO delivery system (such that low 
volumes of test compound are present) then parasite, TCM, blood and 
RPMI can be premixed to facilitate quick and easy delivery of assay 
components.  Alternatively, the test compound can be solubilized in RPMI 
and 4.25 µL of this solution can be added to the plate.  In this instance, the 
TCM, blood and parasite culture will be premixed and added to the plate 
(38 µL). 
 
3.  Assay incubation  
a. The plate should be quickly transferred to a humidified incubator with a 
blood gas atmosphere (90% nitrogen, 5% oxygen and 5% carbon dioxide).   
b. Incubate plate for 72 hours.  Do not disturb plate during this time. 
c. Remove plate from incubator 
4  Addition of SYBR Green-I stock 
a) Prepare a stock solution of SYBR Green-I using Lysis Buffer (100 mM 
Tris HCl pH 7.5, 10 mM EDTA, 0.16% Saponin (w/v), 1.6% Triton X 
(v/v)) 
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b) Add 0.2 μL SYBR Green-I (stock from Invitrogen, 10,000X) to 1 mL of 
lysis buffer or equivalent ratio.  Note:  SYBR Green-I was does not 
respond well to freeze-thaw cycles so these should be avoided by freezing 
down small aliquots (~30 μL/tube). 
c) Add 38 µL of this solution to each test well of the assay plate. 
d) Leave in dark drawer overnight. 
e) Read plate (BOTTOM READ only) at an excitation/emission wavelength 
of 488/522. 
f) Calculate inhibitory activity relative to the positive and negative control 
wells. 
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Appendix D 
 
Full Results of Hits Identified in the HTS Screen 
 
 In the following pages, each of the compounds identified as a hit in the HTS 
screen (Chapter IV) is listed by the VU identifier.  In addition to the VU number for each 
hit, the IC50 values for β-hematin inhibition (BH), drug sensitive P. falciparum (D6) and 
the multi-drug resistant strain of P. falciparum (C235) are included where appropriate.  
ND = not determined. Inactive indicates that inhibitory activity >90% was not observed 
and therefore an IC50 value was not determined. 
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VU identifier Structure
BH  IC50 
(µM)
 D6 IC50 
(uM)
C235 IC50 
(uM)
VU identifier Structure
BH  IC50 
(µM)
 D6 IC50 
(uM)
C235 IC50 
(uM)
VU0098755[n+]1(c2c(cc(cc2)C)ccc1\C=C\c1c[nH]c2c1cccc2)CC12.6 0.106 0.127 VU0065892S1(c2c(c3c1cccc3)ccc(c1nc([nH]c1c1ccccc1)c1cc(c(c(c1)OC)O)OC)c2)(=O)=O6. 0.611 0.693
VU0073687n1(c(c(c2c1ccc(C(Nc1cc3c(nc(cc3C)N(CC)CC)cc1)=O)c2)C)C)C6.3 0.185 0.551 VU0010690 C(Nc1cc(ccc1)C)(=S)N\N=C\c1c(ccc(c1)Br)O 25.0 0.673 1.5
VU0001281[N+](c1cc(C(Nc2ccncc2)=O)cc(C(Nc2ccncc2)=O)c1)([O-])=O5.9 0.194 0.174 VU0094619n1c([nH]c(c1c1ccccc1)c1ccc(cc1)O)c1cc(c(c(c1)OC)O)OC2.4 0.700 0.284
VU0065708n1(c2c(c3c1cccc3)cccc2)CC(C[n+]1c2c(O)cccc2ccc1)O16.2 0.198 0.184 VU0012464[N+](c1ccc(N\N=C\c2cc(c(c(c2)Br)O)Br)cc1)([O-])=O 7.3 0.708 0.923
VU0096505n1c(nc2c(c1NCc1occc1)cccc2)Nc1ccc(Br)cc18.8 0.238 0.217 VU0008057 [n+]1(c2c(c(cc1)N/N=C/c1ccc(F)cc1)cccc2)[O-] 9.6 0.730 1.5
VU0107282[N+](c1cc(C(Nc2cc3c(nc(N4CCC(CC4)C)cc3C)cc2)=O)ccc1Cl)([O-])=O17.0 0.290 0.540 VU0358149C([n+]1ccc(\C=C\c2ccc(Cl)cc2)cc1)(N1CCOCC1)=O 8.3 0.778 19.1
VU0114785S(c1c([N+]([O-])=O)cc(C(Nc2cc(c(cc2)C)Cl)=O)cc1)(c1c(Cl)cccc1)(=O)=O13.4 0.346 4.8 VU0015078 c12[nH]c3c(c1CCNC2CCc1ccccc1)ccc(c3)OC 1.1 0.810 5.7
VU0002101c1(nc2c([nH]1)cccc2)c1ccc(NC(c2cc(Br)cnc2)=O)cc114.3 0.348 0.412 VU0119324c12c(Nc3ccc(C(N(CC)CC)=O)cc3)ccnc1cc1c(c2)cccc121.5 0.845 0.186
VU0028177C12(\C(=C(/C(O1)c1cc(c(cc1)C)Cl)\C(=O)OC)\C(=O)OC)C(c1c(C2=O)cccc1)=O13.3 0.350 0.465 VU0078364c12c(n(nc1c1cc(OC)ccc1)C)sc(c2)C(Nc1cc(C(F)(F)F)ccc1)=O5.3 0.922 2.0
VU0063971c12c(oc3c1ccc1c3CN(CO1)CC\C\1=C\CCCC1)C(c1c(C2=O)cccc1)=O8.9 0.384 0.833 VU0107278c1(C(Nc2cc3c(nc(cc3C)N(CC)CC)cc2)=O)cc(nc2c1cccc2)c1occc111.8 0.951 3.9
VU0129813n c(nc2c(c1NCc1occc1)cccc2)Nc1ccc(cc1)OCC26.8 0.396 0.294 VU0064165c 2c(Nc3ccc(N4CCN(CC4)CCC#N)cc3)ccnc1cc1c(c2)cccc115.4 0.993 1.0
VU0114734c1([N+]([O-])=O)c(Sc2ccc(cc2)OC)ccc(C(NC2CCN(Cc3ccccc3)CC2)=O)c122.1 0.461 1.1 VU0068266C/1\ =C(/c3c(NC1c1c(ccs1)C)ccc1c3cccn1)\CC(CC2=O)c1ccccc118.3 1.0 ND
VU0122653C\1(=C(\N\C\2=C(/C1c1ccncc1)\C(CC(C2)c1ccc(cc1)OC)=O)/C)/C(OC1CCCCC1)=O24.5 0.550 0.900 VU0359100 c1(C(Nc2cc(Cl)ccc2)=O)c(nc2c(c1)cccc2)N 10.9 1.1 7.916
VU0000264 n1c2c(cc(c1)O)cc(cc2)C 2.0 0.593 0.248 VU0013883c1([N+]([O-])=O)c(N2CCN(CC2)C)cccc1/C=N/Nc1ccc(Br)cc119.5 1.4 ND
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VU0065413c (c(nc2c(n1)cccc2)Nc1ccc(F)cc1)Nc1ccc(F)cc116.5 1.4 ND VU0043533c1(oc(C(NC(Nc2ccc(CN3CCOCC3)cc2)=S)=O)cc1)c1c(ccc(c1)Cl)Cl2.0 2.7 ND
VU0118945n1c(N(c2nc3c(O)cccc3cc2)C)ccc2c1c(O)ccc222.5 1.5 ND VU0033980 c1(n[nH]c(c1)c1cc(F)ccc1)c1c(ccc(c1)Cl)O 21.7 2.7 ND
VU0060841C\1(=C(\C(c2c(O1)c(CN1CCN(CC1)C)c(cc2)O)=O)/Oc1ccc(c2ccccc2)cc1)/C(F)(F)F17.3 1.5 ND VU0133680S(/N=C\1/C=C(\C(c2c1cccc2)=O)/Nc1ccc(C(=O)O)cc1)(c1c(cc(cc1C)C)C)(=O)=O14.8 2.8 ND
VU0358549C/1\2=C(/C(N\3/C(=N1)/C=C\C=C3)=O)\C=C(/C(N2CCc1ccccc1)=N)\C(NC(c1ccccc1)C)=O7.2 1.6 ND VU0073686n1c(cc(c2c1ccc(NC(c1cc(c(c(c1)OC)OC)OC)=O)c2)C)N(CC)CC13.5 3.0 ND
VU0117011c1(nc2c([nH]1)cc(NC(c1ccc(cc1)OC)=O)cc2)c1ccc(NC(c2ccc(cc2)OC)=O)cc110.4 1.7 ND VU0064114C/1\2=C(/c3c(NC1c1cc(c(OCc4ccccc4)cc1)OC)ccc1c3cccn1)\CCCC2=O16.5 3.0 ND
VU0358176n1c(nc2c(c1NCc1c(OC)cccc1)cccc2)c1cc(c(cc1)OC)OC2.4 1.7 ND VU0077964S(c1cc2C(\C(\C(NC3CCCCC3)=O)=C/Nc2cc1)=O)(Nc1ccc(cc1)CC)(=O)=O10.3 3.1 ND
VU0117080c1(nc2c([nH]1)cc(NC(c1oc(cc1)Br)=O)cc2)c1ccc(NC(c2oc(cc2)Br)=O)cc111.4 1.7 ND VU0106972C1(N(C(Nc2c1cc(cc2)Br)=O)c1ccc(cc1)Cl)(C(NC(c1ccccc1)C)=O)O21.4 3.2 ND
VU0015069N1C(C(C(C(C1c1ccc(cc1)O)C)=O)C)c1ccc(cc1)O10.4 1.9 ND VU0000641n1c2c(c(\C=C/c3ccc(N(C)C)cc3)cc1/C=C/c1ccc(N(C)C)cc1)cccc24.6 3.5 ND
VU0125795c1(c(n(c2c1cc(c(c2)Br)O)c1ccccc1)CN(C)C)C(=O)OCC16.2 2.0 ND VU0054768[N+](c1cc(C(Nc2cc(NC(c3cc(Cl)ccc3)=O)ccc2)=O)ccc1OCC)([O-])=O22.6 3.5 ND
VU0077944S(c1cc2C(\C(\C(NC3C(C)CCCC3)=O)=C/Nc2cc1)=O)(Nc1ccc(cc1)CC)(=O)=O25.6 2.2 ND VU0042031 n12c(cc(c1C)c1cc(c(cc1)OC)OC)c(ccc2)C 1.7 3.5 ND
VU0123773c1(c2c3c([nH]c2)ccc(c3)Br)nc(c([nH]1)c1ccccc1)c1ccccc112.7 2.2 ND VU0066706c12c(c3c4c1cccc4ccc3)nc(nn2)SCC(Nc1cc(C(=O)O)c(cc1)Cl)=O16.3 3.6 ND
VU0007713c1(nc(nc(n1)N\N=C\c1ccc(cc1)O)Nc1ccc(F)cc1)N(C)C10.3 2.3 ND VU0021012 c12[nH]c3c(c1CCCC2(CN)[H])cc(cc3)C 19.3 3.7 ND
VU0055392[N+](c1cc(c2oc(C(Nc3ccc(NC(c4occc4)=O)cc3)=O)cc2)ccc1)([O-])=O13.7 2.3 ND VU0123046C=1(\C(\C\ =C(/N/C1/C)\CC(CC2=O)c1ccc(cc1)Cl)c1cc(O)ccc1)/C(OC1CCCCC1)=O22.6 3.9 ND
VU0129734n1c(c([nH]c1c1cc(c(cc1)O)OCC)c1ccc(cc1)F)c1ccc(cc1)F18.7 2.4 ND VU0077557N1\2\C(=N/C(C1=O)CC(=O)NCCCC)\c1c(\N=C2\SCC(Nc2cc(ccc2OC)Cl)=O)cccc110.5 3.9 ND
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VU0002229n1c2c(O)cccc2ccc1\C=C\c1cc(c(OCc2ccccc2)cc1)OC16.5 2.4 ND VU0127450n1c(nc2c(c1NCc1ccc(Cl)cc1)cccc2)c1cc(c(c(c1)OC)OC)OC17.3 4.7 ND
VU0060490 11.0 4.1 ND VU0358764[N+](c1cc([N+]([O-])=O)cc(C(Nc2ccncc2)=O)c1)([O-])=O9.0 4.8 ND
VU0068286C/1\2=C(/c3c(NC1c1c(cc(cc1)OC)OC)ccc1c3cccn1)\CC(CC2=O)c1ccccc119.1 4.1 ND VU0121735N (C(NC(CC1(c1c(cc(cc1)O)O)C)(C)C)=S)c1cc(C(F)(F)F)ccc111.0 5.0 ND
VU0066798n1c2c(cc(NCc3c(c(CC=C)ccc3)O)c1)cccc2 21.5 4.2 ND VU0081577S(N1c2c(CC1)cccc2)(c1cc(C(Nc2ccc(Oc3ccccc3)cc2)=O)ccc1F)(=O)=O24.4 5.1 ND
VU0116830S(c1cc2C(\C(\C(NC(c3cc4c(OCCO4)cc3)C)=O)=C/Nc2cc1)=O)(Nc1ccc(cc1)C(C)C)(=O)=O11.9 4.2 ND VU0015041c12c([N+]([O-])=O)ccc(c1non2)Nc1cc(C(F)(F)F)c(cc1)Cl19.9 5.1 ND
VU0358505n1c2c(OCc3ccccc3)cccc2ccc1/C=C/c1c(c(OC)ccc1)O18.1 4.2 ND VU0095273c1(oc(cc1)c1ccc(cc1)Cl)C(Nc1ccc(Cc2ccncc2)cc1)=O21.7 5.1 ND
VU0073736n1c(cc(c2c1ccc(NC(c1ccc(cc1)OCC)=O)c2)C)N(CC)CC10.2 4.2 ND VU0068227C/1\2=C(/c3c(NC1c1ccc(cc1)OCC)ccc1c3cccn1)\CC(CC2=O)c1ccccc123.7 5.1 ND
VU0359436c12/C(=N/NC(Nc3ccc(cc3)CC)=S)/CC3(Oc1ccc(c2)O)CCN(C(=O)C)CC35.0 4.3 ND VU0132168 c1(C(c2oc(cc2)C)c2c(ccc(c2)Br)O)oc(cc1)C 13.8 5.2 ND
VU0060770c12c(c(sc1ncnc2N1CCN(c2ccc(cc2)OC)CC1)C(Nc1cc(c(c(c1)OC)OC)OC)=O)C24.8 4.3 ND VU0111491S(c1cc2C(\C(\C(NC3CCCC3)=O)=C/Nc2cc1)=O)(Nc1ccc(cc1)CC)(=O)=O16.5 5.3 ND
VU0073706[N+](c1c(cc(C(Nc2cc3c(nc(cc3C)N(CC)CC)cc2)=O)cc1)C)([O-])=O2.9 4.3 ND VU0105653N1(C(Nc2c(C1=O)ccc(C(Nc1cc(c(cc1)OC)OC)=O)c2)=S)c1cc(C(F)(F)F)ccc1Cl20.0 5.3 ND
VU0122425c1(nc2c([nH]1)cccc2)c1c(ccc(NC(c2cc(c(cc2)OC)Cl)=O)c1)Cl21.5 4.3 ND VU0098496n1c2c(OCc3ccccc3)cccc2ccc1/C=C/c1c(cc(c(c1)OC)OC)OC19.3 5.5 ND
VU0358181n c(nc2c(c1NCc1ccccc1)cccc2)c1cc(c(cc1)OC)OC15.7 4.4 ND VU0128298
c1(c2nc(sc2)Nc2ccc(NC(=O)C)cc2)sc(nc1C)NC(=O)c1ccccc1
11.5 5.5 ND
VU0116790S(Nc1c(C)cccc1)(c1cc2C(\C(\C(NC3C(C(CCC3)C)C)=O)=C/Nc2cc1)=O)(=O)=O10.6 4.5 ND VU0057475 N1C(Nc2c3c1cccc3ccc2)c1cc(c(cc1)O)OCC 18.6 5.5 ND
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VU0054902n1c(oc2c1cc(NC(c1cc(c(c(c1)OC)OC)OC)=O)cc2)c1ccc(C(C)(C)C)cc117.9 4.6 ND VU0081575S(c1cc(C(Nc2cc(c(cc2)C)F)=O)ccc1F)(NC(c1ccccc1)c1ccccc1)(=O)=O21.3 5.6 ND
VU0124893c1(nc c(s1)cccc2)c1c(ccc(\N=C\c2oc(N3CC(OC(C3)C)C)cc2)c1)O25.8 4.6 ND VU0033455C(c1c2c(ccc1O)cccc2)(NC(=O)c1ccccc1)c1ccc(cc1)C26.8 5.9 ND
VU0057426N1C(Nc2c3c1cccc3ccc2)(c1cc(c(cc1)O)O)[H]21.2 5.9 ND VU0106991C1(N(C(Nc2c1cc(cc2)Br)=O)c1ccc(cc1)OCC)(C(NC1CCCCCCC1)=O)O18.2 6.2 ND
VU0124098C1(Nc2c3c(N1)cccc3ccc2)(c1cc(c(c(c1)OC)O)OC)[H]7.6 5.9 ND VU0115413S(N(c1ccc(cc1)F)CC)(c1cc2C(\C(\C(NC(C)(C)C)=O)=C/Nc2cc1)=O)(=O)=O15.8 6.3 ND
VU0077973S(Nc1c(CC)cccc1)(c1cc2C(\C(\C(NC(CC)C)=O)=C/Nc2cc1)=O)(=O)=O3.7 6.0 ND VU0107331[N+](c1c(cc(C(Nc2cc3c(nc(N4CCC(CC4)C)cc3C)cc2)=O)cc1)C)([O-])=O21.9 6.3 ND
VU0056498c1(nc2c(s1)cccc2)c1c(ccc(NC(c2cnccc2)=O)c1)O16.6 6.0 ND VU0099400n1nc(c2c(c1c1ccc(cc1)O)cccc2)Nc1ccc(C(=O)OC)cc115.4 6.4 ND
VU0068256C/1\2=C(/c3c(NC1c1ccc(cc1)OCCC)ccc1c3cccn1)\CC(CC2=O)c1ccccc11.6 6.0 ND VU0073509C1(N(C(Nc2c1cc(cc2)Br)=O)c1ccc(cc1)Cl)(C(NC1CCCCC1)=O)O6.9 6.5 ND
VU0116780S(Nc1c(C)cccc1)(c1cc2C(\C(\C(NC3CCCC3)=O)=C/Nc2cc1)=O)(=O)=O1.4 6.1 ND VU0073498C1(N(C(Nc2c1cc(cc2)Br)=O)c1cc(OC)ccc1)(C(NC1CCCCCCC1)=O)O10.1 6.6 ND
VU0066820[N+](c1cc(N2Cc3c(OC2)ccc(c3)Cl)ccc1)([O-])=O19.8 6.1 ND VU0071259C/1(=C/c2c(NC1CC=C)ccc(c2)C)\c1nc2c(cc(cc2)C)cc1 7.9 6.7 ND
VU0066885S(c1sccc1)(Nc1cc(c(c2c1cccc2)O)Cl)(=O)=O13.9 6.1 ND VU0077935S(Nc1c(F)cccc1)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCN1CCOCC1)=O)(=O)=O23.6 6.8 ND
VU0194156Cc1ccc2[nH]c(nc2c1)/C(=C/c1c[nH]nc1c1ccc(F)cc1)/C#N10.5 6.2 ND VU0119224[N+](c1cc2nc([nH]c2cc1)/C=C/c1ccc(Cl)cc1)([O-])=O21.5 6.8 12.38
VU0068276C/1\2=C(/c3c(NC1c1c(Br)cccc1)ccc1c3cccn1)\CC(CC2=O)(C)C1.3 6.2 ND VU0012237 c1(sc2c(c1N)ccc(n2)c1cnccc1)C(=O)OCC 13.6 6.9 ND
VU0081548S(N1c2c(CC1)cccc2)(c1cc(C(Nc2ccc(Br)cc2)=O)ccc1F)(=O)=O22.3 6.2 ND VU0007007N1(C(c2c(C1=O)cccc2)(c1ccc(cc1)O)c1ccc(cc1)O)c1ccccc117.7 6.9 ND
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VU0112087c12n(c(c(s1)C(Nc1ccncc1)=O)C)cc(n2)c1ccccc120.2 7.0 ND VU0129181C1(C(C(C(OC1=O)c1c(ccc(c1)Br)O)(C)C)=O)(C)C 16.1 9.0 ND
VU0094315c1(nc2c(n1C)cccc2)NCc1c2c(ccc1O)cccc2 17.6 7.1 ND VU0099289n1c(c([nH]c1c1ccc(cc1)O)c1ccc(cc1)Br)c1ccccc1 5.7 9.1 ND
VU0007691c1(nc(nc(n1)N\N=C\c1c(ccc(c1)Br)OC)NCc1ccccc1)N1CCOCC19.7 7.2 ND VU0054351[N+](c1cc(C(Nc2cc(NC(c3cc(Cl)ccc3)=O)ccc2)=O)ccc1OC)([O-])=O17.0 9.1 ND
VU0358440c1(c(C(=O)OCC)cnc2c1cc(C(=O)OC)cc2)Nc1cc(O)ccc115.4 7.3 ND VU0140514c1(nc2c(c(c1)C)cc(NC(c1cc(cc(c1)OC)OC)=O)cc2)N1CCC(CC1)C22.6 9.1 ND
VU0131684n1c2c(O)cccc2ccc1\C=C\c1cc(c(cc1)O)Br 15.0 7.6 ND VU0116989S(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCC\C\1=C\CCCC1)=O)(Nc1cc2c(OCCO2)cc1)(=O)=O14.4 9.3 ND
VU0117249S(N1C(c2cnccc2)CCCC1)(c1cc2C(/C(=C\Nc2cc1)/C(=O)NCCc1ccccc1)=O)(=O)=O7.9 7.7 ND VU0002784C(c1cc(NC(c2cnccc2)=O)c(Oc2c(c3ccccc3)cccc2)cc1)(F)(F)F13.9 9.4 ND
VU0033649c1(n2c(nc1C)cc(cc2)C)c1nc(sc1)Nc1ccc(cc1)O21.5 7.7 ND VU0358468C12(N3/N=C(\CC3c3c(O1)ccc(c3)Br)/c1ccc(cc1)OC)C(Nc1c2cccc1)=O5.6 9.5 ND
VU0122447c1(nc2c([nH]1)cccc2)c1c(NC(c2c([N+]([O-])=O)ccc(c2)Cl)=O)cccc117.3 7.9 ND VU0069083C1([C@@]\2(N([C@@H]([C@H]1c1c(ccc(c1)OC)OC)C(=O)c1ccccc1)c1c(\C=C2)cccc1)[H])(C#N)C#N21.8 9.6 ND
VU0041098C/1(=C(/Oc2c(C1=O)ccc(c2C)OC(=O)C)\C(F)(F)F)\c1nc2c(s1)cccc27.8 7.9 ND VU0063940c1(c2c(c(c3c(c2oc1C)cccc3)O)C(N1CCOCC1)c1ccncc1)C(=O)OCC10.8 9.7 ND
VU0125966c1(nc2c([nH]1)cccc2)c1cc(NC(=O)COc2ccc(C(C)(C)C)cc2)ccc123.2 8.2 ND VU0358343c12c(\N=C(/N(C1=O)c1ccc(cc1)OC)\NN)sc1c2CCC1 3.7 9.7 ND
VU0077962S(c1cc2C(\C(\C(NC3CCCC3)=O)=C/Nc2cc1)=O)(Nc1cc(C(F)(F)F)ccc1)(=O)=O10.6 8.5 ND VU0060399C1(C(C(NC(C1[N+]([O-])=O)c1c(O)cccc1)c1c(O)cccc1)[N+]([O-])=O)(C)C11.0 9.8 ND
VU0116770S(Nc1c(C)cccc1)(c1cc2C(\C(\C(NC3CCCCC3)=O)=C/Nc2cc1)=O)(=O)=O13.6 8.5 ND VU0118993S(Nc1ccc(Br)cc1)(c1cc(C(Nc2ccc([N+]([O-])=O)cc2)=O)ccc1)(=O)=O15.9 9.9 ND
VU0007694c1(nc(nc(n1)N\N=C\c1c(Cl)cccc1)NCc1ccccc1)N1CCOCC110.0 8.7 ND VU0117177S(N(c ccccc1)CC=C)(c1cc2C(\C(=C/Nc2cc1)\C(NCc1cnccc1)=O)=O)(=O)=O7.6 9.9 ND
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VU0077946S(c1cc2C(\C(=C/Nc2cc1)\C(NCc1sccc1)=O)=O)(Nc1cc(cc(c1)C)C)(=O)=O10.3 9.9 ND VU0073716n1c(cc(c2c1ccc(NC(c1ccc(N(CC)CC)cc1)=O)c2)C)N(CC)CC9.3 11.9 ND
VU0131034c12c([N+]([O-])=O)c(cc(c1NC(C1C2\C=C/C1)c1ccc(cc1)Br)O)Cl4.5 10.4 ND VU0126165C= (/NC(/N=C(\C1)/C=C/c1cc(c(OCc2ccc(F)cc2)cc1)OCC)=O)\C(F)(F)F23.5 12.1 ND
VU0041052 3.4 10.4 ND VU0012258c1(c(c(cc(c1)Br)Br)O)C(N\N=C\c1c(ccc(c1)Br)O)=O 17.9 12.4 ND
VU0015715N1(/C(=N\C(=C/C1=O)\O)/SCC(Nc1ccc(Cl)cc1)=O)c1c(OC)cccc121.9 10.4 ND VU0114305S(N1CC(N(CC1)c1ccc(cc1)C)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)O)=O)(=O)=O5.7 12.4 ND
VU0093477c1(nc(nc2c1cccc2)c1cc(c(cc1)OC)OC)Nc1cc(cc(c1)OC)OC10.3 10.4 ND VU0059997S(c1c2c3c(N\C=N/c3ccc2)cc1)(c1ccc(cc1)C)(=O)=O 23.2 12.5 ND
VU0129123C1(N\C(=N/c2c1cccc2)\C=C\c1c([nH]c2c1cccc2)C)=O7.3 10.5 ND VU0081442N1(/C(=N\c2c(C1=N)c[nH]n2)/SCc1c(C)cccc1)c1ccc(cc1)Br17.4 12.7 ND
VU0358483c1(c(c2cc(C(=O)OCC)ccc2nc1)NCCc1cc(c(cc1)OC)OC)C(=O)OCC19.3 11.0 ND VU0005352 C(Nc1cc(c(cc1)Cl)Cl)(Nc1cnccc1)=O 16.8 12.9 ND
VU0116748S(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCc1ccccc1)=O)(Nc1cc(C(F)(F)F)ccc1)(=O)=O10.9 11.1 ND VU0077907S(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCCC)=O)(Nc1cc(SC)ccc1)(=O)=O11.2 13.5 ND
VU0093551c1(nc2c([nH]1)ccc(NC(c1ccc([N+]([O-])=O)cc1)=O)c2)c1cnccc11 .0 11.1 ND VU0066909c12[nH]c3c(c1CCCC2O)cc(C12CC4CC(C1)CC(C2)C4)cc315.4 14.0 ND
VU0111471S(c1cc2C(\C(\C(NC(c3ccccc3)C)=O)=C/Nc2cc1)=O)(Nc1cc(OC)ccc1)(=O)=O15.3 11.2 ND VU0004718 N(C(C(N1CCCCCC1)CC)=O)c1c(cc(cc1C)C)C 23.3 14.1 ND
VU0278601 Oc1ccc(\C=C\c2ccnc3ccccc23)cc1 12.5 11.3 ND VU0060787c1(nc2c([nH]1)cccc2)c1cc(NC(c2cc([N+]([O-])=O)ccc2Cl)=O)ccc117.1 14.2 ND
VU0099279c1(nc(c([nH]1)c1cscc1)c1ccccc1)c1c(cc(c(c1)OC)OC)OC10.0 11.7 ND VU0116728S(c1cc2C(\C(\C(NC(c3ccccc3)C)=O)=C/Nc2cc1)=O)(Nc1cc(C(F)(F)F)ccc1)(=O)=O10.2 15.7 ND
VU0077577N1\2\C(=N/C(C1=O)CC(N1CCN(CC1)c1ccccc1)=O)\c1c(\N=C2\SCc2ccc(Cl)cc2)cccc17. 11.9 ND VU0056416c1(nc2c([nH]1)cccc2)c1cc(NC(c2cc(c(cc2)OCC)Cl)=O)c(cc1)C21.2 16.1 ND
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VU0099202n1c(c2c(cc(cc2)O)O)csc1Nc1ccc(N(C)C)cc111.0 16.2 ND VU0112751 N/1(C(N/C(=C1)/c1ccc(cc1)C)=S)c1c(Cl)cccc1 3.0 NA NA
VU0065130n1c2c(O)cccc2ccc1/C=C/c1c(cc(c(c1)OC)O)Br9.4 16.3 ND VU0081492S(N1c2c(CC1)cccc2)(c1cc(C(Nc2cc(C(F)(F)F)ccc2)=O)ccc1F)(=O)=O11.0 NA NA
VU0133817S(N CC(CCC1)C)(c1ccc(NC(c2oc3c(c2C)cccc3)=O)cc1)(=O)=O21.2 16.3 ND VU0115401S(N(c1cc(c(cc1)C)C)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCCOC)=O)(=O)=O21.7 NA NA
VU0097482C/1\2=C(/c3c(NC1c1c4c(ccc1)cccc4)ccc1c3cccn1)\CCCC2=O11.0 16.5 ND VU0014981N1(c2nc(cc(n2)c2ccccc2)O)/N=C(\CC1=O)/c1ccccc1 0.4 NA NA
VU0126567C(c1cc(SCN2CCCCC2)c(cc1)O)(=O)OC 21.3 16.5 ND VU0114677S(N1Cc2c(CC1)cccc2)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCC)=O)(=O)=O8.3 NA NA
VU0120963C/1\2=C(/c3c(NC1c1c(c([N+]([O-])=O)cc(c1)Br)O)ccc1c3cccc1)\CC(CC2=O)(C)C14.9 16.8 ND VU0084736S(N(c1ccc(cc1)Br)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCOC)=O)(=O)=O9.0 NA NA
VU0115374S(N(c1c(cccc1C)C)C)(c1cc2C(\C(=C/Nc2cc1)\C(NCc1ncccc1)=O)=O)(=O)=O12.2 17.0 ND VU0130592c1(c2c(c(c3c(c2oc1C)cccc3)O)C(N1CCN(CC1)C)c1ccncc1)C(=O)OCC11.5 NA NA
VU0057485C1(Nc2c3c(N1)cccc3ccc2)(c1cc(c(c(c1)OC)O)Br)[H]17.2 17.3 ND VU0077974S(c1cc2C(\C(=C/Nc2cc1)\C(NCc1ccccc1)=O)=O)(Nc1ccc(cc1)CC)(=O)=O12.1 NA NA
VU0358463c1(nc(nc2c1cc(cc2)O)c1ccccc1)Nc1ccccc1 8.6 17.5 ND VU0000265[N+](c1ccc(\C=C\c2nc3c(c(c2)NC(CCCN(CC)CC)C)cc(cc3)OC)cc1)([O-])=O16.4 NA NA
VU0120913C/1\2=C(/c3c(NC1c1c(cc(c(c1)OC)O)Br)ccc1c3cccc1)\CC(CC2=O)(C)C7.9 17.6 ND VU0357676C12C(C(OC3C1OC1(O3)CCCCC1)C(Nc1c(O)cccc1)=O)OC1(O2)CCCCC117.3 NA NA
VU0357882n1c(oc2c1cc(cc2C)C)c1ccc(NC(c2cnccc2)=O)cc18.9 17.8 ND VU0012947 N1=NN1c1ccc(\C=C\C(c2ccc(cc2)O)=O)cc1 17.7 NA NA
VU0077975S(c1cc2C(\C(\C(NC(CC)C)=O)=C/Nc2cc1)=O)(Nc1ccc(cc1)OCC)(=O)=O8.5 NA NA VU0144619S(Nc1c(F)cccc1)(c1cc2C(\C(\C(NC3C(C(CCC3)C)C)=O)=C/Nc2cc1)=O)(=O)=O8.5 NA NA
VU0060352N1(C(/C(=C(\C1=O)/Cl)/Nc1c(O)cccc1)=O)c1c(c(ccc1)C)C4.8 NA NA VU0137617c1(c2nc(sc2)Nc2cc(C(=O)C)ccc2)sc(nc1C)NC(=O)C 22.5 NA NA
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VU0116811C=1(\C(N2c3c(CC2)cccc3)=O)/C(c2cc(S(Nc3c(C)cccc3)(=O)=O)ccc2N\C1)=O25.6 NA NA VU0358099c1(nc2c(n1C)cccc2)/C(=C/c1cc(c(c(c1)OC)O)Br)/C#N 3.4 NA NA
VU0032187N1C(C(Nc2c1cccc2)CC(Nc1cc(Cl)ccc1)=O)=O10.5 NA NA VU0357658C=1(/c2nc3c([nH]2)cccc3)\C(\Oc2c(/C1)ccc(c2)O)=N/NC(=S)N3.4 NA NA
VU0014379N1(c2nc(cs2)c2ccc(cc2)Br)N\C(=C/C1=O)\c1ccccc10.2 NA NA VU0012974 P(=O)(c1ccccc1)(O)CCCC 3.5 NA NA
VU0063871N1(c2nc3c(s2)cccc3)C(/C(=C(\C1c1ccc([N+]([O-])=O)cc1)/C(c1ccc(cc1)C)=O)/O)=O0.4 NA NA VU0000809 n1c(nc2c(c1NN)cccc2)c1cnccc1 3.6 NA NA
VU0020967c1(c(cc(cc1OC)NC1CCC(c2ccccc2)CC1)OC)OC1.5 NA NA VU0358204 c12n(c3c(c1CC(OC2=O)=O)cccc3)CC 4.1 NA NA
VU0099210N1C(C(Nc2c1cc(c(c2)C)C)CC(Nc1c(OC(F)F)cccc1)=O)=O2.2 NA NA VU0031736C\1(/C(N(NC1=O)c1cc(Br)ccc1)=O)=C/c1c(ccc([N+]([O-])=O)c1)N(C)C4.2 NA NA
VU0123869 2.4 NA NA VU0357755C/1(=C(/Oc2c(C1=O)ccc(c2C)O)\C(F)(F)F)\c1nc(cs1)C4.2 NA NA
VU0001216N12/C(=N\C(=C(/C1c1c(ccc(c1)OC)OC)\C(=O)OCC)\C)/S/C(/C2=O)=C\c1oc(c2c(C(=O)O)cccc2)cc12.6 NA NA VU0016715N (C(/C(=C\2/C(Nc3c2cccc3)=O)/SC1=S)=O)NC(c1c(O)cccc1)=O4.6 NA NA
VU0013068 P(=O)(c1ccccc1)(O)CCCCCC 2.9 NA NA VU0008926S(Nc1c(c(c(c(c1)Br)O)Br)Br)(c1ccc(cc1)C)(=O)=O 4.9 NA NA
VU0000817C12(c3c(Oc4c1cc(cc4)O)ccc(c3)O)c1c(c3c2cccc3)cccc13.1 NA NA VU0007239C(Nc1c(O)cccc1)(c1cc(C(Nc2c(O)cccc2)=O)ccc1)=O 5.0 NA NA
VU0357956c1(nc2c([nH]1)cccc2)/C(=C/c1oc(c2c(C(=O)O)cccc2)cc1)/C#N3.2 NA NA VU0081017n1c(oc2c1cc(NCc1c(c(cc(c1)I)C)O)cc2)c1cc(ccc1)C 5.1 NA NA
VU0009045 P1(c2c(Nc3c1cccc3)cccc2)(=O)O 3.2 NA NA VU0040337C1(c2c(NN1c1ccccc1)nc(C(F)(F)F)cc2c1sccc1)=O 5.3 NA NA
VU0073726[N+](c1cc(C(Nc2cc3c(nc(cc3C)N(CC)CC)cc2)=O)ccc1Cl)([O-])=O3.2 NA NA VU0101286C/1\2=C(/C(C3C(N(C(C3S1)=O)c1ccc(cc1)Br)=O)c1cc([N+]([O-])=O)ccc1O)\SC(N2)=O5.7 NA NA
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VU0129395N1(c2sc(nn2)C)C(/C(=C(\C1c1ccc(cc1)Cl)/C(c1ccc(cc1)C)=O)/O)=O5.8 NA NA VU0357745c1(nc2c([nH]1)cccc2)/C(=C/c1cc(c(c(c1)OCC)O)I)/C#N6.7 NA NA
VU0005674N1(C(S\C(\C1=O)=C\1/C(Nc2c1cccc2)=O)=S)C(C(=O)O)C(C)C5.8 NA NA VU0032616N1(c2nc(cs2)c2ccc(cc2)OC)/N=C(\C(C1=O)CC)/C 6.8 NA NA
VU0358326C=1(\c2nc c([nH]2)cccc3)/C(Oc2c(CN3CCN(CC3)C)c(ccc2\C1)O)=O5.9 NA NA VU0012564 n1(cnnc1)\N=C\c1cc(c(c(c1)Br)O)Br 7.0 NA NA
VU0358394C\1(/c2c(\C(=C1\C)\C#N)nc(c(c2C)C#N)N)=C/c1ccc(cc1)O5.9 NA NA VU0358180n1c(nc2c(c1NCc1ccc(F)cc1)cccc2)c1cc(c(cc1)OC)OC 7.0 NA NA
VU0004443c1(c(cc(c2cc(c(c(c2)Cl)O)Cl)cc1Cl)Cl)O 6.0 NA NA VU0006449 P(/C=C/c1ccccc1)(\C=C\c1ccccc1)(=O)O 7.0 NA NA
VU0357723c1(nc2c([nH]1)ccc(c2)C)/C(=C/c1c([N+]([O-])=O)c(c(cc1)O)OC)/C#N6.0 NA NA VU0111574N/1=C(/c2c(NC1=S)cc(c(c2)OC)OC)\Nc1cc(cc(c1)C)C 7.1 NA NA
VU0111544N/ =C(/c2c(NC1=S)cc(c(c2)OC)OC)\Nc1ccc(NC(=O)C)cc16.0 NA NA VU0005896N1(C(c2c(CC1=O)ccc(c2)OC)=O)c1c(cc(cc1)C)C 7.1 NA NA
VU0070839 N=1\N(C(C/C1/c1ccccc1)=O)c1ccccc1 6.3 NA NA VU0072331c1(c(C(=O)OCC)cnc2c1cc(c(c2)Cl)OC)Nc1cc(OC)ccc17.1 NA NA
VU0112741C (N(/C=C(\N1)/c1ccc(cc1)Br)c1ccc(cc1)C)=S6.3 NA NA VU0358036c1(nc2c([nH]1)cc(cc2)C)\C(=C\c1cc([N+]([O-])=O)c(cc1)O)\C#N7.3 NA NA
VU0078374c12c(n(nc1c1cc(OC)ccc1)C)sc(c2)C(Nc1cc(c(cc1)C)F)=O6.3 NA NA VU0117227S(N1c2c(CC1)cccc2)(c1cc2C(/C(=C\Nc2cc1)/C(NCc1c(OC)cccc1)=O)=O)(=O)=O7.3 NA NA
VU0098120c12[nH]c3c(c1CCCC2C(NCC(=O)OCC)=O)cc(cc3)Cl6.4 NA NA VU0069882N1(C(/C(=C(\C1c1cc([N+]([O-])=O)ccc1)/C(c1ccc(cc1)Cl)=O)/O)=O)c1nccs17.5 NA NA
VU0114299N1(C(SCN(C1)C(C)C)=S)Cc1ccc(cc1)OC 6.6 NA NA VU0002558c12c(c(c3c(n1)ccc(c3)Br)C(=O)O)CCc1c2ccc(c1)OC 7.8 NA NA
VU0127353N1C(C(Nc2c1cccc2)CC(Nc1c(OCC)cccc1)=O)=O6.7 NA NA VU0032566 N1(c2nc(cs2)c2ccc(cc2)Cl)/N=C(\C(C1=O)C)/C 7.9 NA NA
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VU0111505N/1=C(/c2c(NC1=S)cc(c(c2)OC)OC)\Nc1ccc(cc1)OC8.2 NA NA VU0122990n1(nc c(n1)ccc(c2)NC(c1oc(cc1)c1ccc([N+]([O-])=O)cc1)=O)c1cc(Cl)ccc18.9 NA NA
VU0111564N/1=C(/c2c(NC1=S)cc(c(c2)OC)OC)\Nc1ccncc18.2 NA NA VU0118615 C1(C(c2c(C1=O)cccc2)=O)(c1ccccc1)CO 8.9 NA NA
VU0002854c1([N+]([O-])=O)c(c(cc(c1)\C=C\c1nc2c(O)cccc2cc1)OC)O8.3 NA NA VU0017219 N1C(S\C(\C1=O)=C\c1c(cc(cc1)O)O)=S 9.0 NA NA
VU0114315S(N1c2c(CCC1)cccc2)(c1cc2C(\C(=C/Nc2cc1)\C(=O)O)=O)(=O)=O8.3 NA NA VU0112732 C1(N(/C=C(\N1)/C(C)(C)C)c1ccc(cc1)C)=S 9.1 NA NA
VU0358325C=1(\c2nc3c([nH]2)cccc3)/C(Oc2c(CN3CCOCC3)c(ccc2\C1)O)=O8.3 NA NA VU0049228 n12c(nnc1S)scc2c1ccccc1 9.2 NA NA
VU0032597N1(c2nc(cs2)c2ccc(cc2)C)/N=C(\C(C1=O)C)/C8.5 NA NA VU0077945S(Nc1c(F)cccc1)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCc1ccccc1)=O)(=O)=O9.2 NA NA
VU0117187S(N(c1ccccc )CC=C)(c1cc2C(\C(\C(NC3CCCCCC3)=O)=C/Nc2cc1)=O)(=O)=O8.5 NA NA VU0117246S(N(c1cc(ccc1)C)CC)(c1cc2C(\C(=C/Nc2cc1)\C(=O)O)=O)(=O)=O9.2 NA NA
VU0358119c1(nc2c([nH]1)cc(cn2)Br)\C(=C\c1oc(cc1)c1cc(C(=O)O)ccc1)\C#N8.6 NA NA VU0359431 n1c([nH]c2c1cccc2)/C=C/c1cc(Br)ccc1 9.3 NA NA
VU0114463n1c(noc1c cc(c(cc1)OC)OC)c1ccc(NC(c2cc([N+]([O-])=O)c(cc2)C)=O)cc18.7 NA NA VU0069737S(c1cc(C(Nc2c(c3c(s2)CCCC3)C#N)=O)ccc1Br)(N1CCOCC1)(=O)=O9.3 NA NA
VU0007463N1(\N=C(/CC1=O)\c1ccc(N)cc1)c1c(cc(cc1Cl)Cl)Cl8.8 NA NA VU0046416 n1c(n(c2c1cc(NC(Nc1ccc(I)cc1)=O)cc2)C)C 9.4 NA NA
VU0003854c1(C(Nc2ccncc2)=O)c(NC(c2c3c(ccc2)cccc3)=O)ccc(c1)I8.8 NA NA VU0014436 c1(c(cc(c(c1)O)Br)Br)/C=N/NC(=O)Cc1ccccc1 9.4 NA NA
VU0118075S(N(c1ccc(cc1)Br)C)(c1cc2C(\C(\C(NC3CCCCCC3)=O)=C/Nc2cc1)=O)(=O)=O8.8 NA NA VU0099166C/1\2=C(/c3c(NC1c1cc(c(cc1)O)OC)ccc1c3cccn1)\CC(CC2=O)(C)C9.7 NA NA
VU0014487c1(c(cc(cc1Br)\C=N\NC(c1cc(F)ccc1)=O)Br)O8.9 NA NA VU0130007S(N1CCCC1)(c1ccc(C(Nc2ccc(C34CC5(CC(C3)CC(C4)C5)O)cc2)=O)cc1)(=O)=O9.7 NA NA
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VU0003021c1(c(nc2c(n1)cc(NC(N1CCC(C(=O)OCC)CC1)=S)cc2)c1occc1)c1occc110.0 NA NA VU0130152N1(c2sc(S(c3ccc([N+]([O-])=O)cc3)(=O)=O)cn2)C(/C(=C(\C1c1ccc(cc1)F)/C(c1ccc(cc1)Cl)=O)/O)=O10.4 NA NA
VU0116758C=1(/C(c2cc(S(Nc3cc(C(F)(F)F)ccc3)(=O)=O)ccc2N\C1)=O)\C(N1CCN(c2c(OC)cccc2)CC1)=O10.1 NA NA VU0077972S(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCOC)=O)(Nc1cc(C(F)(F)F)ccc1)(=O)=O10.4 NA NA
VU0106077n1(c(c(c2c1cccc2)CC(=O)O)C(=O)O)CCC 10.1 NA NA VU0101451n1(c2c(c3c1cccc3)cc(CN1CCC(N3CCN(CC3)c3ccccc3)CC1)cc2)CC10.4 NA NA
VU0003541c1(c2c(ncn1)ccc(c2)I)Nc1ccc(NC(=O)C)cc1 10.1 NA NA VU0358575[N+](c1cc(\C=C\c2nc3c(O)cccc3cc2)c(cc1)OCC)([O-])=O10.4 NA NA
VU0071908c1(c(c2c(s1)CC(CC2)C)C#N)NC(c1cc(S(Nc2cc(C(=O)O)ccc2)(=O)=O)ccc1)=O10.1 NA NA VU0077917S(c1cc2C(\C(\C(NC3CCCC3)=O)=C/Nc2cc1)=O)(Nc1ccc(cc1)C(C)C)(=O)=O10.4 NA NA
VU0085247S(N1C(c2cnccc2)CCCC1)(c1cc2C(/C(=C\Nc2cc1)/C(=O)O)=O)(=O)=O10.1 NA NA VU0002405 C(c1cc(Br)cnc1)(Nc1cc(SC)ccc1)=O 10.5 NA NA
VU0084726S(N(c1ccc(cc1)Br)C)(c1cc2C(\C(=C/Nc2cc1)\C(NCc1ncccc1)=O)=O)(=O)=O10.2 NA NA VU0103650N1C(C2C(c3c1ccc(c3)C)\C=C/C2)c1ccc(\N=C\c2ccccc2)cc110.5 NA NA
VU0077914S(c1cc2C(\C(=C/Nc2cc1)\C(NCc1ncccc1)=O)=O)(Nc1ccc(cc1)CC)(=O)=O10.2 NA NA VU0111472S(c1cc2C(\C(=C/Nc2cc1)\C(NCc1cnccc1)=O)=O)(Nc1ccc(cc1)OCC)(=O)=O10.5 NA NA
VU0132027[N+](c1cc(C2Nc3c(C\4C2C\C=C4)cc(C(=O)O)cc3)ccc1O)([O-])=O10.2 NA NA VU0111935c1(n2c(nc1c1ccc(cc1)O)c(ccc2)C)Nc1cc2c(OCCO2)cc1 0.5 NA NA
VU0114374S(N1C(C)CCCC1)(c1cc2C(\C(=C/Nc2cc1)\C(=O)O)=O)(=O)=O10.2 NA NA VU0116831S(c1cc2C(\C(\C(NC(c3cc4c(OCCO4)cc3)C)=O)=C/Nc2cc1)=O)(Nc1cc(OC)ccc1)(=O)=O10.6 NA NA
VU0072160N1(C(Nc2c(C1=O)ccc(C(Nc1cc(C(=O)N)ccc1OC)=O)c2)=S)Cc1ccccc110.2 NA NA VU0116768S(c1cc2C(\C(=C/Nc2cc1)\C(NCc1c(Cl)cccc1)=O)=O)(Nc1ccc(cc1)C(C)C)(=O)=O10.6 NA NA
VU0054740N1(C(c2c(C1=O)cccc2)=O)c1cc(C(Nc2c(O)cccc2)=O)cc(C(Nc2c(O)cccc2)=O)c110.2 NA NA VU0115375S(N(c1ccc(cc1)F)C)(c1cc2C(\C(\C(NC(C)C)=O)=C/Nc2cc1)=O)(=O)=O10.6 NA NA
VU0359105C=1(\C(c2c3c(ccc2)cccc3)c2c(N/C1)cccc2)/c1nc2c(cc1)cccc210.3 NA NA VU0117236S(N(c1ccccc1)CC)(c1cc2C(\C(=C/Nc2cc1)\C(=O)O)=O)(=O)=O10.6 NA NA
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VU0040094N1(c2sc(c(n2)C)C(=O)OCC)C(/C(=C(\C1c1sccc1)/C(c1ccc(cc1)C)=O)/O)=O10.7 NA NA VU0066838N1(C(c2c(C1=O)ccc(\C\1=N\c3c(C(O1)=O)cccc3)c2)=O)c1c(c(C(=O)O)ccc1)C11.5 NA NA
VU0114047S(N1C(c2cnccc2)CCCC1)(c1ccc(NC(c2cc([N+]([O-])=O)c(cc2)Cl)=O)cc1)(=O)=O10.7 NA NA VU0116999S(c1cc2C(\C(=C/Nc2cc1)\C(NCc1ccccc1)=O)=O)(Nc1cc2c(OCCO2)cc1)(=O)=O11.5 NA NA
VU0077905C=1(/C(c2cc(S(Nc3ccc(cc3)CC)(=O)=O)ccc2N\C1)=O)\C(N(Cc1ccccc1)C)=O10.7 NA NA VU0027639C\1(/C(N(NC1=O)c1cc(c(cc1)Cl)Cl)=O)=C\c1cc(c(c(c1)OC)O)OC11.5 NA NA
VU0014485c1(c(c(cc(c1O)\C=N\NC(c1cc(F)ccc1)=O)Br)O)Br10.7 NA NA VU0002183n1c2c(OCc3c(Cl)cccc3)cccc2ccc1\C=C\c1ccc(cc1)O 11.5 NA NA
VU0127435 N1C(C(Nc2c1cccc2)CC(=O)NC)=O 10.8 NA NA VU0007003 c1(c(ccc(c1)Cc1cc(c(cc1)N)O)N)O 11.7 NA NA
VU0116930S(c1cc2C(\C(\C(NC3CCCCC3)=O)=C/Nc2cc1)=O)(Nc1cc2c(OCCO2)cc1)(=O)=O10.8 NA NA VU0118085S(N(c1ccc(cc1)Br)C)(c1cc2C(\C(\C(NC3CCCC3)=O)=C/Nc2cc1)=O)(=O)=O11.7 NA NA
VU0069898 c1(c2c(oc1NCC=C)c(cc(n2)O)O)C#N 11.1 NA NA VU0127434 N1C(C(Nc2c1cccc2)CC(Nc1ccc(cc1)O)=O)=O 11.8 NA NA
VU0003689c1(c(c2c(s1)CCCCCC2)C#N)NC(=O)CS\C\1=N\C(=C(/C(N1)=O)\Cc1ccccc1)\O11.1 NA NA VU0071475 11.8 NA NA
VU0278822COc1c(O)ccc(/C=C(\C#N)/c2nc3ccccc3[nH]2)c1[N+](=O)[O-]11.1 NA NA VU0108767S(c1cc2C(\C(=C/Nc2cc1)\C(=O)O)=O)(Nc1cc2c(OCCO2)cc1)(=O)=O11.9 NA NA
VU0121875c1(nc2c([nH]1)cccc2)c1ccc(NC(c2oc(cc2)c2ccc(cc2)Cl)=O)cc111.2 NA NA VU0124020N1(c2sc(S(c3ccc([N+]([O-])=O)cc3)(=O)=O)cn2)C(/C(=C(\C1c1cc(c(cc1)OC)O)/C(c1ccc(cc1)C)=O)/O)=O11.9 NA NA
VU0084725S(N(c1ccc(cc1)OCC)C)(c1cc2C(\C(\C(NC3CCCC3)=O)=C/Nc2cc1)=O)(=O)=O11.5 NA NA VU0032098N1(c2nc(cs2)c2ccc(cc2)Cl)/N=C(\CC1=O)/c1ccccc1 12.0 NA NA
VU0075742N1(c2nc3c(c(c2)C)cc(NC(=O)CCC(Nc2cc(c(cc2)C)F)=O)cc3)CC(CC(C1)C)C11.5 NA NA VU0081459S(NC1C(NCCCC1)=O)(c1cc2C(\C(=C/Nc2cc1)\C(NCc1c(OC)cccc1)=O)=O)(=O)=O12.1 NA NA
VU0121459n1c(oc2c1cc(NC(c1cc(c(c(c1)OC)OC)OC)=O)cc2)c1cc(c(cc1)C)Br11.5 NA NA VU0115384S(N(c c(cccc1C)C)C)(c1cc2C(\C(=C/Nc2cc1)\C(NCc1cnccc1)=O)=O)(=O)=O12.2 NA NA
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VU0012095c1(c(c(cc(c1)Br)Br)O)C(N\N=C\c1c(ccc(c1)Cl)O)=O12.2 NA NA VU0130575 c1(/C=2/OC(N\N2)=S)sc2c(c1Cl)cccc2 12.7 NA NA
VU0131032C12C(C(N(C1=O)c1ccc(cc1)OC)=O)C(N(O2)c1ccccc1)c1c(ccc(c1)Br)O12.3 NA NA VU0114899S(N1CCOCC1)(c1cc2C(\C(\C(NC(Cc3ccccc3)CC)=O)=C/Nc2cc1)=O)(=O)=O12.7 NA NA
VU0096684S(c1c2c3c(NC(c3ccc2)=O)cc1)(Nc1cc(C(C(OC(C)C)=O)C(C(F)(F)F)=O)c(c2c1cccc2)O)(=O)=O12.3 NA NA VU0116914S(c1cc2C(\C(\C(NC(c3ccccc3)C)=O)=C/Nc2cc1)=O)(Nc1ccc(cc1)OCC)(=O)=O13.0 NA NA
VU0001572S1(\N=C(/c2c1cccc2)\Nc1cc(C(=O)c2ccccc2)ccc1)(=O)=O12.4 NA NA VU0036008C=1(\c2nc3c([nH]2)cccc3)/C(Oc2c(c(ccc2\C1)O)CN(CC)CC)=O13.0 NA NA
VU0081154S(c1cc2C(\C(=C/Nc2cc1)\C(NCc1c(OC)cccc1)=O)=O)(N(Cc1ccccc1)C)(=O)=O12.4 NA NA VU0009704N1(C(\C(\C(NC1=O)=O)=C/c1[nH]c2c(c1)cccc2)=O)c1c2c(ccc1)cccc213.2 NA NA
VU0126984N1(c2nc3c(s )cccc3)C(/C(=C(\C1c1cc(c(cc1)OC)OC)/C(c1ccc(cc1)C)=O)/O)=O12.4 NA NA VU0093665N1(C(/C(=C(\C1=O)/Cl)/Nc1c(O)cccc1)=O)c1cc(ccc1OC)Cl13.3 NA NA
VU0081374S(N1CC(CCC1)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCCC)=O)(=O)=O12.4 NA NA VU0117238S(N1CCC(CC1)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCN1CCOCC1)=O)(=O)=O13.5 NA NA
VU0002339c1(nc2c(o1)ccc(c2)C(C)C)c1c(ccc(NC(c2cnccc2)=O)c1)Cl12.5 NA NA VU0043100 c1(c(c(cc(c1)Cl)Cl)O)CNc1cc2c(nc1)cccc2 13.8 NA NA
VU0107012C1(N(C(Nc2c1cc(cc2)Br)=O)c1ccc(cc1)OCC)(C(NC1C(C(CCC1)C)C)=O)O12.5 NA NA VU0117269S(c1cc C(/C(=C\Nc2cc1)/C(NCc1ccc(cc1)C)=O)=O)(N(CC)CC)(=O)=O13.9 NA NA
VU0044509N=1\C(\C\2=C(/O/C1/c1ccc(cc1)Br)\CCCC2)=S12.5 NA NA VU0096132N1(C(/C(=C(\C1c1cc(Cl)ccc1)/C(c1ccc(cc1)OCC)=O)/O)=O)c1nccs114.0 NA NA
VU0129453c1(nc2c(s1)cccc2)CC(c1c(cc(c(c1)CC)O)O)=O12.6 NA NA VU0129810N1(c2sc(c(n2)C)C(=O)OC)C(/C(=C(\C1c1ccc(cc1)C)/C(c1cc(c(cc1)OCC)C)=O)/O)=O14.1 NA NA
VU0033894 n1(c2cc(C(=O)O)ccc2O)c(ccc1C)C 12.6 NA NA VU0079933C\1/2=C(\C(N(\C(=N1)\SCC(Nc1nccs1)=O)c1c(cc(cc1)OC)OC)=O)/SC(N2c1ccccc1)=S14.3 NA NA
VU0085716[N+](c1cc2nc([nH]c2cc1)/C=C/c1ccc([N+]([O-])=O)cc1)([O-])=O12.6 NA NA VU0359073c1(nc2c([nH]1)ccc(c2)C)/C(=C\c1c2c(cc(c1)Cl)COCO2)/C#N14.4 NA NA
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VU0111889c 2c(n(nc1c1cc(OC)ccc1)C)sc(c2)C(Nc1cc(Cl)ccc1)=O4.4 NA NA VU0056471 n1(c(ccc1C)C)c1ccc(OCC(=O)O)cc1 15.4 NA NA
VU0081419S(N1c2c(CC1)cccc2)(c1cc2C(\C(\C(N(Cc3ccccc3)CC)=O)=C/Nc2cc1)=O)(=O)=O14.4 NA NA VU0144620S(Nc1c(c(Cl)ccc1)C)(c1cc2C(\C(\C(NC3CCCCC3)=O)=C/Nc2cc1)=O)(=O)=O15.4 NA NA
VU0129383N1(c2sc(c(n2)C)C(=O)OC)C(/C(=C(\C1c1cc(Br)ccc1)/C(c1ccc(cc1)Cl)=O)/O)=O14.6 NA NA VU0077916S(Nc1c(c(Cl)ccc1)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NC)=O)(=O)=O15.4 NA NA
VU0144628S(c1cc2C(\C(=C/Nc2cc1)\C(NCc1cnccc1)=O)=O)(Nc1cc(OC)ccc1)(=O)=O14.7 NA NA VU0107256[N+](c1cc(C(Nc2cc3c(nc(cc3C)N(CC)CC)cc2)=O)ccc1)([O-])=O15.5 NA NA
VU0085220S(N(c1ccc(cc1)F)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)O)=O)(=O)=O14.8 NA NA VU0041101C\1(=C(\C(c2c(O1)cc(cc2)O)=O)/Oc1c(Cl)cccc1F)/C(F)(F)F15.5 NA NA
VU0012439c1(sc2c(c1N)ccc(n2)c1cnccc1)C(=O)c1ccccc1 4.8 NA NA VU0117228S(N CCC(CC1)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCCOC)=O)(=O)=O15.5 NA NA
VU0059085S(c1cc([N+]([O-])=O)ccc1Cl)(Nc1cc(Sc2nc3c(s2)cccc3)c(cc1)O)(=O)=O14.9 NA NA VU0034663c1(c(n(c2c1cc(c(c2)Br)O)C)CNCc1ccccc1)C(=O)OCC15.6 NA NA
VU0111482S(c1cc2C(\C(\C(NC3CCCC3)=O)=C/Nc2cc1)=O)(Nc1ccc(cc1)OCC)(=O)=O5.0 NA NA VU0115410S(N(c cc(c(cc1)C)C)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCOC)=O)(=O)=O15.6 NA NA
VU0021348C\1(/C(N(\N=C1\C)c1ccccc1)=O)=C/c1cc(O)ccc115.1 NA NA VU0118489 c12C(c3c(C(c1ccc(c2)O)=O)cc(cc3)O)=O 15.7 NA NA
VU0020915c12c(c3c([nH]1)ccc(c3)C)CCC2C(=O)N 15.1 NA NA VU0011772N1(C(S/C(/C1=O)=C\c1ccc(cc1)O)=S)c1ccc(cc1)O 15.7 NA NA
VU0106675[N+](c1cc(C(Nc2cc3c(nc(N4CCOCC4)cc3C)cc2)=O)ccc1)([O-])=O5.1 NA NA VU0063881N1(c2nc3c(s2)cccc3)C(/C(=C(\C1c1c(cc(cc1)OC)OC)/C(c1ccc(cc1)C)=O)/O)=O15.7 NA NA
VU0002175n1c2c(O)cccc2ccc1\C=C\c1cc(c(cc1)O)OCC15.3 NA NA VU0056490 n1(c2c(C(=O)O)cc(cc2)Cl)c(ccc1C)C 15.7 NA NA
VU0115364S(N(c1c(cccc1C)C)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCC/C/1=C/CCCC1)=O)(=O)=O15.4 NA NA VU0107321[N+](c1cc(C(Nc2cc3c(nc(N4CCC(CC4)C)cc3C)cc2)=O)ccc1)([O-])=O15.7 NA NA
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VU0065728 c12n(nc(c1N)N)c(cc(n2)C)C 15.8 NA NA VU0126679n1c(scc1c1ccc(NC(=O)c2ccccc2)cc1)Nc1cc(O)ccc1 16.3 NA NA
VU0118468S(N(c c(CC)cccc1)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)O)=O)(=O)=O15.8 NA NA VU0130142N1(C(/C(=C(\C1c1cc(Br)ccc1)/C(c1ccc(cc1)Cl)=O)/O)=O)c1nccs116.3 NA NA
VU0065261n1(c2c(c3c1ccc(c3)I)cc(cc2)I)CC(CNC(C)(C)C)O15.9 NA NA VU0027357 N1C(C2C(c3c1ccc(c3)Cl)\C=C/C2)C(=O)O 16.3 NA NA
VU0068296C/1\2=C(/c3c(NC1c1cc(c(cc1)O)OCC)ccc1c3cccn1)\CC(CC2=O)c1ccccc116.0 NA NA VU0119378n1c([nH]c2c1c(ccc2)C)c1ccc(NC(c2ccc(N)cc2)=O)cc116.5 NA NA
VU0115403S(N(c1ccc(cc1)F)C)(c1cc2C(\C(\C(NC3CCCCCC3)=O)=C/Nc2cc1)=O)(=O)=O16.0 NA NA VU0064134C/1\2=C(/c3c(NC1c1cc(c(cc1)O)OCC)ccc1c3cccn1)\CC(CC2=O)(C)C16.5 NA NA
VU0038391N1(C(/C(=C(\C1=O)/Cl)/Nc1c(O)cccc1)=O)c1c(c(Cl)ccc1)Cl16.0 NA NA VU0121592n c(oc2c1cc(NC(c1cc(c(c(c1)OC)OC)OC)=O)cc2)c1ccc(cc1)C16.5 NA NA
VU0021346 c1(c(ccc(c1)Br)OC)/C=N/Nc1ncccc1 16.1 NA NA VU0144631S(c cc2C(\C(=C/Nc2cc1)\C(=O)NCCCC)=O)(Nc1ccc(cc1)C(C)C)(=O)=O16.5 NA NA
VU0113028 16.1 NA NA VU0124726c1(nc2c([nH]1)cccc2)c1ccc(NC(c2cc(Cl)ccc2)=O)cc116.6 NA NA
VU0126071c1(nc2c(s1)cc(cc2)OC)NC(c1cc(cc(c1)N)N)=O16.1 NA NA VU0122285 n1n(c(cc1c1ccc(cc1)OC)O)CCC#N 16.6 NA NA
VU0085686n1c([nH]c2c1cc([N+]([O-])=O)cc2)c1ccc(cc1)O16.1 NA NA VU0111422S(c cc2C(\C(=C/Nc2cc1)\C(=O)NCCOC)=O)(Nc1ccc(cc1)CC)(=O)=O16.7 NA NA
VU0013761 c1(C(=O)N)c(/N=C/c2ccc(cc2)O)cccc1 16.2 NA NA VU0012266c1(c(c(cc(c1)Br)Br)O)C(N\N=C\c1c[nH]c2c1cccc2)=O16.8 NA NA
VU0126098C\1(=C(\C(N(C1c1cc([N+]([O-])=O)ccc1)c1ccc(cc1)O)=O)/O)/C(c1ccc(cc1)C)=O16.2 NA NA VU0142474N1(c2nc3c(c(c2)C)cc(NC(=O)CCC(Nc2cc(ccc2OC)Cl)=O)cc3)CC(CC(C1)C)C16.8 NA NA
VU0039845c12c3c(CC4c1c(cc(c2OC)OC)CCN4)ccc(c3)O16.3 NA NA VU0094292c1(nc2c([nH]1)cc(C(=O)c1ccccc1)cc2)c1ccc(NC(c2c(OC)cccc2OC)=O)cc116.8 NA NA
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VU0119875S(c cc(C(Nc2cc(C(=O)O)ccc2)=O)ccc1C)(Nc1ccc(I)cc1)(=O)=O6.8 NA NA VU0114368 N1(C(SCN(C1)C(C)(C)C)=S)Cc1ccccc1 17.7 NA NA
VU0115363S(N(c1c(ccc(c1)C)C)C)(c1cc2C(\C(\C(NC(C)(C)C)=O)=C/Nc2cc1)=O)(=O)=O16.8 NA NA VU0073649C/1\2=C(/C(N/C(=N1)/SCc1ccc([N+]([O-])=O)cc1)=O)\C(/C/1=C(\N2)/CC(CC1=O)(C)C)c1ccncc117.7 NA NA
VU0066848N1(C(c2c(C1=O)ccc(C(Nc1cnccc1)=O)c2)=O)c1c(OCC)cccc116.9 NA NA VU0116810S(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCC(C)C)=O)(Nc1ccc(cc1)C(C)C)(=O)=O17.7 NA NA
VU0081336S(N1CCC(CC1)C)(c1cc2C(\C(\C(N3CCN(c4c(ccc(c4)C)C)CC3)=O)=C/Nc2cc1)=O)(=O)=O16.9 NA NA VU0004714 c1(c2ncccc2O)cc(c(cc1)O)O 17.8 NA NA
VU0117912N1(C(c2c(C1=O)ccc(c2)Cl)=O)c1c(cc(NC(CN2C(Oc3c2ccc(c3)Cl)=O)=O)cc1)C16.9 NA NA VU0040765 c1(C(Cc2cc3c(OCCO3)cc2)=O)c(cc(cc1O)O)O 17.8 NA NA
VU0121430n c(oc2c1cc(NC(c1oc([N+]([O-])=O)cc1)=O)cc2)c1cc(I)ccc117.0 NA NA VU0144658S(c1cc2C(\C(=C/Nc2cc1)\C(NCC1OCCC1)=O)=O)(Nc1ccc(cc1)CC)(=O)=O17.9 NA NA
VU0032772N1C(C(Nc2c1cccc2)CC(Nc1c(F)cccc1)=O)=O17.1 NA NA VU0111492S(c1cc2C(\C(=C/Nc2cc1)\C(NCc1occc1)=O)=O)(Nc1ccc(cc1)OCC)(=O)=O17.9 NA NA
VU0122624N1c2c(C\3C(C1c1ccc(cc1)Br)C\C=C3)cccc2I17.2 NA NA VU0115411S(N(c1c(C)cccc1)C)(c1cc2C(\C(\C(NC(CC)C)=O)=C/Nc2cc1)=O)(=O)=O18.0 NA NA
VU0007148c1(n(c2c(n1)cccc2)Cc1c(O)cccc1)c1c(O)cccc1 7.2 NA NA VU0100428S(Nc1cc2c(OC3C2CC(C(C)(C)C)CC3)c2c1cccc2)(c1cc([N+]([O-])=O)ccc1)(=O)=O18.0 NA NA
VU0079952C\1/2=C(\C(N(\C(=N1)\SCC(Nc1nccs1)=O)c1cc(c(cc1)OC)OC)=O)/SC(N2c1ccccc1)=S17.5 NA NA VU0105577N1(\C(=N/c2c(C1=O)ccc(C(Nc1cc(c(cc1)OC)OC)=O)c2)\SCc1nc2c([nH]1)cccc2)c1ccccc118.0 NA NA
VU0014378N1(c2nc(cs2)c2ccccc2)C(\C=C(/N1)\C)=O 17.5 NA NA VU0112701 N/1(C(N/C(=C1)/c1ccc(cc1)Cl)=S)c1c(Br)cccc1 18.1 NA NA
VU0081509S(c1cc(C(Nc2ccc(Br)cc2)=O)ccc1F)(N1CCN(c2ccc(cc2)F)CC1)(=O)=O17.5 NA NA VU0056444S(Nc1nccs1)(c1ccc(NC(=O)COc2c(C(C)(C)C)cc(cc2)Br)cc1)(=O)=O18.1 NA NA
VU0129851C\1(=C(\C(N(C1c ccc(cc1)C)Cc1cnccc1)=O)/O)/C(c1cc(c(cc1)OCC=C)C)=O7.6 NA NA VU0032672N1C(C2C(c3c1ccc(c3)C(=O)O)\C=C/C2)c1cc(Br)ccc118.1 NA NA
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VU0108788S(c1cc2C(\C(=C/Nc2cc1)\C(=O)O)=O)(Nc1ccc(NC(=O)C)cc1)(=O)=O18.1 NA NA VU0098218c1(nc2c([nH]1)cccc2)c1cc(NC(c2cc(c(cc2)OCC)Br)=O)c(cc1)C18.7 NA NA
VU0036021C=1(\c2nc3c(s2)cccc3)/C(Oc2c(c(ccc2\C1)O)CN(CC)CC)=O18.3 NA NA VU0126775c12c(n(c(n1)S)Cc1cc(Cl)ccc1)C(N(C(N2C)=O)C)=O 18.8 NA NA
VU0099192S(Nc1nc(cc(n1)C)C)(c1ccc(Nc2nc(cs2)c2cc(c(cc2)O)O)cc1)(=O)=O18.3 NA NA VU0115402S(N(c1cc(ccc1OC)Cl)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCC\C\1=C\CCCC1)=O)(=O)=O18.8 NA NA
VU0116788S(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCC(C)C)=O)(Nc1ccc(cc1)CC)(=O)=O18.3 NA NA VU0144648S(c1cc2C(\C(=C/Nc2cc1)\C(NCc1ccc(cc1)C)=O)=O)(Nc1cc(OC)ccc1)(=O)=O18.8 NA NA
VU0039979C\1(=C(\C(N(C1c1ccc(cc1)Br)Cc1cnccc1)=O)/O)/C(c1sccc1)=O18.3 NA NA VU0063850n1c(oc2c1cc(NC(c1cc(c(cc1)OC)Br)=O)cc2)c1ccncc118.9 NA NA
VU0014482c1(c(cc(cc1OC)\C=N\NC(c1cc(F)ccc1)=O)I)O18.4 NA NA VU0115337S(N(c1ccc(cc1)CC)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCC=C)=O)(=O)=O19.0 NA NA
VU0123289c1(nc2c(s1)cc(NC(=O)C)cc2)NC(c1ccc(NC(=O)C2CCCCC2)cc1)=O18.4 NA NA VU0013754c1(c(cc(cc1)O)O)C(N/N=C/c1c(c(Cl)ccc1)Cl)=O 19.1 NA NA
VU0111452S(Nc1c(F)cccc1)(c1cc2C(\C(\C(NC3CCCCC3)=O)=C/Nc2cc1)=O)(=O)=O18.5 NA NA VU0096454N1(c2nc3c(s2)cccc3)C(/C(=C(\C1c1cc2c(OCO2)cc1)/C(=O)c1ccccc1)/O)=O19.1 NA NA
VU0117197S(N(c1ccccc1)CC)(c1cc2C(\C(=C/Nc2cc1)\C(NCC1OCCC1)=O)=O)(=O)=O18.5 NA NA VU0129861C\1(=C(\C(N(C1c1ccc(cc1)Br)Cc1cnccc1)=O)/O)/C(c1cc(c(cc1)OCC=C)C)=O19.1 NA NA
VU0006754c1(n(c2c(c1C)cccc2)Cc1ccccc1)/N=C/c1occc1 8.6 NA NA VU0123064 n1(c2cc(c(C(=O)O)cc2)O)c(ccc1C)C 19.1 NA NA
VU0003020N1(C(c2c(C1=O)ccc(C(Nc1ccncc1)=O)c2)=O)c1c(c(ccc1)C)C18.6 NA NA VU0096640S(Nc1cc(c2c3c(ccc2O)cccc3)c(cc1)O)(c1ccc(cc1)C)(=O)=O19.2 NA NA
VU0111483S(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCCC)=O)(Nc1cc2c(OCCO2)cc1)(=O)=O18.6 NA NA VU0121419n1(nc2c(n1)ccc(c2)NC(c1cc(c(c(c1)OC)OC)OC)=O)c1ccc(cc1)C19.4 NA NA
VU0124864S(N1CC(CC(C1)C)C)(c1ccc(C(Nc2cc(c3nc4c([nH]3)cccc4)ccc2)=O)cc1)(=O)=O18.7 NA NA VU0013046C1(C(c2c(C1=O)cccc2)=O)C(CC(=O)CCC)c1ccccc119.4 NA NA
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VU0077925C=1(/C(c2cc(S(Nc3ccc(cc3)CC)(=O)=O)ccc2N\C1)=O)\C(N(Cc1occc1)C)=O19.5 NA NA VU0073548N1(C(c2c(NC1=O)ccc(c2)Br)(C(NCc1ccc(F)cc1)=O)O)c1cc(c(cc1)C)C21.1 NA NA
VU0126110C\1(=C(\C(N(C1c1ccc(cc1)Cl)c1cnccc1)=O)/O)/C(c1ccc(cc1)Cl)=O19.8 NA NA VU0006654 N1(C(O/C(/C1=O)=C/c1c(O)cccc1)=S)C 21.2 NA NA
VU0129368N1(C(/C(=C(\C1c1cc(Oc2ccccc2)ccc1)/C(c1ccc(cc1)Br)=O)/O)=O)c1nccs119.9 NA NA VU0129435N1(c2sc(nn2)C)C(/C(=C(\C1c1ccc(cc1)Br)/C(c1sccc1)=O)/O)=O21.2 NA NA
VU0107217n1c(cc(c2c1ccc(NC(=O)Cc1ccc(Cl)cc1)c2)C)N(CC)CC19.9 NA NA VU0052922S(c1cc(C(Nc2cc(C(=O)O)ccc2)=O)ccc1C)(Nc1ccc(Br)cc1)(=O)=O21.3 NA NA
VU0012474c1(c(cc(cc1Br)/C=N/NC(c1c2c(ccc1)cccc2)=O)Br)O20.0 NA NA VU0123478N1(C2C(N(C2c2sccc2)c2cc(C(F)(F)F)ccc2)=O)C(c2c(C1=O)ccc([N+]([O-])=O)c2)=O21.3 NA NA
VU0122895N\1(C(c2c(\N=C1\C=C\c1c(ccc(c1)Br)O)cccc2)=O)c1c(OC)cccc120.1 NA NA VU0007198C/1(=C(/N/C(=C(\C1)/C(=O)OCC)/C)\C)\C(=O)OCC 21.4 NA NA
VU0140504c (nc2c(c(c1)C)cc(NC(c1cc(Cl)ccc1)=O)cc2)N1CCC(CC1)C20. NA NA VU0057227c12n(nc(c1Cl)C(Nc1cc(ccc1O)Cl)=O)C(C(F)(F)F)CC(N2)c1sccc121.4 NA NA
VU0107207n1c(cc(c2c1ccc(NC(c1cc(cc(c1)OC)OC)=O)c2)C)N(CC)CC20.1 NA NA VU0081513[N+](c cc(C(Nc2ccc(C(F)(F)F)cc2)=O)ccc1NCCc1ccccc1)([O-])=O21.4 NA NA
VU0096208C\1(=C(\C(N(C1c1ccc(N(C)C)cc1)Cc1ccncc1)=O)/O)/C(c1ccc(cc1)OC)=O20.3 NA NA VU0098283c12n(nc(n1)NC(=O)c1ccccc1)C(/C=C(\N2)/C)c1ccc(cc1)Cl21.5 NA NA
VU0101667c1(c(sc(c1C)C(OC(C)C)=O)NC(C1c2c(Oc3c1cccc3)cccc2)=O)C(OC(C)C)=O20.6 NA NA VU0117902N1(C(Oc2c1ccc(c2)Cl)=O)CC(Nc1c(cc(cc1)Br)C)=O 21.5 NA NA
VU0121695c1(C(Cc2oc(C(=O)OCC)cc2)=O)c(cc(cc1O)O)O20.7 NA NA VU0040105C\1(=C(\C(N(C1c1cc(c(cc1)Cl)Cl)Cc1cnccc1)=O)/O)/C(c1sccc1)=O2 .5 NA NA
VU0103752C(c1cc(Oc2c(cc(cc2)Cl)C)c(NC(c2cnccc2)=O)cc1)(F)(F)F21.1 NA NA VU0144638S(c1cc2C(\C(\C(NC3CCCC3)=O)=C/Nc2cc1)=O)(Nc1cc(OC)ccc1)(=O)=O21.5 NA NA
VU0113020 21.1 NA NA VU0009666 N1\C(=N/Nc2ccccc2)\CCCc2c1cccc2 21.6 NA NA
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VU0126100C\1(=C(\C(N(C1c1c(F)cccc1)c1cnccc1)=O)/O)/C(c1ccc(cc1)Cl)=O21.6 NA NA VU0074030[N+](c1cc(C(Nc2cc3c(nc(N4CCN(CC4)C)cc3C)cc2)=O)ccc1)([O-])=O22.5 NA NA
VU0079943N1(/C(=C(/c2nc3c([nH]2)cccc3)\SC1=S)/N)c1cc(ccc1OC)Cl21.6 NA NA VU0096096N1(c2sc(nn2)C)C(/C(=C(\C1c1ccc(cc1)F)/C(c1ccc(cc1)OCC)=O)/O)=O22.8 NA NA
VU0116821C=1(/C(c2cc(S(Nc3cc(OC)ccc3)(=O)=O)ccc2N\C1)=O)\C(N1CCN(CC1)c1ccccc1)=O21.7 NA NA VU0144689S(Nc1c(c(Cl)ccc1)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCCOC)=O)(=O)=O22.9 NA NA
VU0073595n1c(snc1\C=C(\NCc1cc2c(OCO2)cc1)/C)Nc1ccc(Cl)cc121.8 NA NA VU0041042C\1(=C(\N\C\2=C(/C1c1ccc(cc1)O)\C(CC(C2)c1c(OC)cccc1)=O)/C)/C(OC1CCCC1)=O22.9 NA NA
VU0138061N1(c2nc3c(s2)cccc3)C(\C(=C(/N1)\CSc1ccc(Cl)cc1)\C=N\CCCN1CCOCC1)=O21.8 NA NA VU0098292c1(c([nH]c(n1)c1cc(c(cc1)O)OC)c1sccc1)c1sccc1 22.9 NA NA
VU0034579c12n(nc(c1c(cc(n2)C(F)(F)F)O)C)c1ccccc1 21.9 NA NA VU0131180N1(c2nc c(s2)cccc3)C(/C(=C(\C1c1cc(c(cc1)O)OCC)/C(c1ccc(cc1)Cl)=O)/O)=O22.9 NA NA
VU0017272C\1(/NC(/C(/S1)=C\c1c(cc(cc1)O)O)=O)=N\c1ccccc121.9 NA NA VU0145035c12c(n(nc1c1cc(c(cc1)OC)OC)C)sc(c2)C(NC1C(C(CCC1)C)C)=O22.9 NA NA
VU0096660S(Nc1cc(C(C(OC(C)C)=O)C(C(F)(F)F)=O)c(c2c1cccc2)O)(c1c(cc(cc1C)C)C)(=O)=O22.0 NA NA VU0100692c12c(sc(n1)/N=C/c1ccc(cc1)C)Cc1c2c(ccc1Br)OC 23.0 NA NA
VU0129392N1(C(/C(=C(\C1c1cc(Br)ccc1)/C(c1ccc(cc1)OCC)=O)/O)=O)c1nccs122.2 NA NA VU0073581C/1\2=C(/C(N/C(=N1)/SCc1c(F)cccc1)=O)\C(/C(=C(\N2)/C)/C(OC(C)C)=O)c1ccc([N+]([O-])=O)cc123.1 NA NA
VU0118672 C1(c2c(Oc3c1ccc(c3)O)cc(cc2)O)=O 22.2 NA NA VU0073600C/1\2=C(/C(N/C(=N1)/SCc1c(Cl)cccc1)=O)\C(/C/1=C(\N2)/CC(CC1=O)(C)C)c1ccc(cc1)O23.2 NA NA
VU0123062n1c(oc2c1cc(NC(c1cc(cc(c1)OC)OC)=O)cc2)c1ccc(C(C)(C)C)cc122.2 NA NA VU0034723N1(C(\C(\SC1=S)=C\c1c(cc(cc1)Cl)Cl)=O)NC(c1cnccc1)=O23.3 NA NA
VU0146006c12c(NC(N(C1=O)CCc1ccc(S(=O)(=O)N)cc1)=S)c1c(s2)ccc([N+]([O-])=O)c122.3 NA NA VU0138545c1(c(c2c(s1)CC(CC2)C)C#N)NC(c1cc(S(Nc2ccc(Br)cc2)(=O)=O)ccc1)=O23.3 NA NA
VU0144670C=1(\C(N2c3c(CC2)cccc3)=O)/C(c2cc(S(Nc3cc(cc(c3)C)C)(=O)=O)ccc2N\C1)=O22.4 NA NA VU0122993n1c(oc2c1cc(NC(c1cc(cc(c1)OC)OC)=O)cc2)c1cc(c(cc1)OC)Br23.4 NA NA
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VU0006922n12C(\C(=C(/c3c1c(c1c2cccc1)ccc3)\O)\Cl)=O23.5 NA NA VU0039282N1(C(/C(=C(\C1c1ccc(cc1)C)/C(c1ccc(cc1)OCC)=O)/O)=O)c1nccs124.9 NA NA
VU0013989 c1(nc2c(s1)ccc(c2)N)c1c(cc(cc1)N)O 23.5 NA NA VU0107063C/1\2=C(/C(N/C(=N1)/SCc1c(F)cccc1)=O)\C(/C/1=C(\N2)/CCCC1=O)c1ccncc124.9 NA NA
VU0002472C/1(\c2c(c3c1cccc3)cccc2)=N\N=C\c1c(cc(cc1)O)O23.5 NA NA VU0108757C=1(/C(c2cc(S(NCc3c(OC)cccc3)(=O)=O)ccc2N\C1)=O)\C(=O)O24.9 NA NA
VU0129358N1(C(/C(=C(\C1c1ccc(cc1)F)/C(c1ccc(cc1)Br)=O)/O)=O)c1nccs123.6 NA NA VU0126155c12c(n(c(n1)S)Cc1c(Cl)cccc1)C(N(C(N2C)=O)C)=O 25.1 NA NA
VU0072340c1(c(C(=O)OCC)cnc2c1cc(cc2)OCC)Nc1cc2c(OCO2)cc124.0 NA NA VU0101576C/1\2=C(/Nc3c(NC1c1cc([N+]([O-])=O)c(c(c1)OCC)O)cccc3)\CC(CC2=O)c1cc(c(cc1)OCC)OC25.1 NA NA
VU0068654c1(sc2c(c1N)ccc(n2)c1cc(c(cc1)OC)OC)C(Nc1cc(C(F)(F)F)ccc1OC)=O24.1 NA NA VU0117005c1(c(sc2c1CCC(C2)C)NCc1oc(cc1)C)C(Nc1c(OC)cccc1)=O25.4 NA NA
VU0077976C=1(/C(c2cc(S(Nc3cc(cc(c3)C)C)(=O)=O)ccc2N\C1)=O)\C(N1CCCC1)=O24.1 NA NA VU0142741c12c(/N=C/3\N(C1=O)\C=C/C=C3/C)sc(c2)C(Nc1ccc(S(Nc2c(c(no2)C)C)(=O)=O)cc1)=O25.5 NA NA
VU0010417N1C(S\C(\C1=O)=C/c1c(c(CC=C)ccc1)O)=S24.2 NA NA VU0358733c1(c(C(C)(C)C)cc(\C=C\c2nc3c(OC)cccc3cc2)cc1C(C)(C)C)O25.6 NA NA
VU0006925 N(\Nc1c2ncccc2ccc1)=C(/C(C)(C)C)\C 24.3 NA NA VU0112721 C1(N(/C=C(\N1)/c1ccc(cc1)Br)c1ccccc1)=S 25.7 NA NA
VU0115360S(N(c1ccc(cc )Cl)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCC\C\1=C\CCCC1)=O)(=O)=O24.6 NA NA VU0111442S(Nc c(F)cccc1)(c1cc2C(\C(=C/Nc2cc1)\C(NCC1OCCC1)=O)=O)(=O)=O25.9 NA NA
VU0034696N1(C(\C(\SC1=S)=C\c1ccc(Br)cc1)=O)NC(c1cnccc1)=O24.8 NA NA VU0115383S(N(c1ccc(cc1)F)C)(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCOC)=O)(=O)=O26.0 NA NA
VU0129961S(Nc1cc(c2c3c(ccc2O)cccc3)c(cc1)O)(c1ccc(cc1)OCC)(=O)=O24.8 NA NA VU0039141S(Nc1c(c(c(c(c1)Cl)O)Cl)C)(c1ccc(cc1)C)(=O)=O 26.2 NA NA
VU0138186C\1/2=C(\Nc3c(C1c1c(Cl)cccc1)c1c(nccc1)cc3)/CC(CC2=O)(C)C4.8 NA NA VU0005198c12c(c3c([nH]1)cccc3)CC(NC2c1cc(c(cc1)Cl)Cl)C(=O)O26.4 NA NA
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VU0070650C\1(=C(\C(N(C1c1c([N+]([O-])=O)cccc1)c1cc(C(F)(F)F)ccc1)=O)/O)/C(=O)c1ccccc126.6 ND
VU0126943c1(sc2c(c1N)cc1c(n2)CCCC1)C(Nc1ccc([N+]([O-])=O)cc1)=O26.7 ND
VU0014486c1(c(cc(cc1OC)\C=N\NC(c1cc(F)ccc1)=O)Br)O26.9 ND
VU0069013N1C(C2C(c3c1ccc(c3)C(=O)O)\C=C/C2)c1cc(F)ccc126.9 ND
VU0017645N1(C(NC(CC1=O)=O)=O)Cc1ccc(F)cc1 26.9 ND
VU0077927S(c1cc2C(\C(=C/Nc2cc1)\C(=O)NCCOC)=O)(Nc1cc2c(OCCO2)cc1)(=O)=O27.0 ND
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Appendix E 
 
Gametocyte Culturing Protocol 
 
 Under normal culturing conditions (Appendix B), the parasite is observed almost 
exclusively in the asexual form.  However, procedures exist that allow manipulation of 
culture conditions to encourage sexual forms of the parasite to dominate.
67
  The D6 strain 
was successfully cultured to promote gametocyte development using a combination of 
different reported methods.  The idea is to take advantage of the differential life cycles of 
sexual v asexual forms.  Asexual forms of the parasite complete a life cycle every 48 h, 
whereas sexual forms (gametocytes) take 7-10 days to mature.  Since merozoites do not 
reinfect old red blood cells very well, the sexual form of the parasite will slowly start to 
dominate as the asexual form begins to die.  
 Culture medium and 50% Hct blood should be prepared as described in Appendix 
B except rather than adding 4.5 mL of medium, 7 mL of medium should be added (Final 
volume of 7.5 mL).  The blood should be as fresh as possible, preferably obtained from a 
donor no more than 7 days from beginning the gametocyte culture schedule.  To promote 
gametocyte production/survival, medium must be prewarmed to 37⁰C and exchanged 
daily at the same time each day.  Medium exchange must be performed quickly as a 
decrease in culture temperature will compromise gametocyte survival.  Also, after day 5, 
be careful not to agitate the erythrocytes in the bottom of the flask. 
 After five days of exchanging the medium, the culture should be stained every 
other day to monitor gametocyte production.  Also, the amount of media in culture was 
 181 
reduced from 7.5 mL to 5mL.  Using the procedure described here, the first gametocyte 
was observed on day 9 (day 1 = the day cultures were initiated).  The gametocytes are 
elongated relative to asexual forms of the parasite and exist as stage I-V gametocytes.  
(Note - Stage I-III gametocytes resemble the asexual form of the parasite)  The 
population of gametocytes increased and by day 16, both male and female gametocytes 
were observed.  Importantly, mature gametocytes (Stage IV, Figure 40) were observed on 
this day.  As CQ is not toxic to mature gametocytes, the culture was treated with 50 nm 
CQ overnight to selectively kill the asexual forms of the parasite without disturbing the 
gametocytes.   
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Figure 40.  On day 16, gametocytes were the primary form of the parasite in culture.  
The blobs that do not resemble the parasite are crystals of hemozoin which visible 
accumulated in the culture flask by Day 9. 
 
 
 On day 18 of using this protocol, gametocytes dominated the culture and 50% 
parasitemia was observed.   
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Appendix F 
 
Top 250 β-Hematin Inhibitors Identified in the GSK In vitro antimalarial Library 
 
The compounds inhibiting >90% β-hematin formation are listed here and 
identified by the TCMDC number supplied by GSK.  The % Inhibitory activity of each 
compound in the β-hematin formation assay is included.  SMILES information for each 
of the TCMDC identifiers is available free online at: 
(http://www.nature.com/nature/journal/v465/n7296/full/nature09107.html#/supplementar
y-information) 
Refer to supplementary Table 1 for a complete list. 
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(reported in 
ChemBL) 
Identifier
Average % 
Inhibition in beta-
hematin assay
uM Parasite Activity 
(reported in 
ChemBL) 
TCMDC-140344 104 0.514 TCMDC-132862 100 0.910
TCMDC-124423 104 0.378 TCMDC-136243 100 0.888
TCMDC-139205 103 0.530 TCMDC-137983 100 0.395
TCMDC-137481 103 0.152 TCMDC-132558 100 0.194
TCMDC-137869 103 0.168 TCMDC-132135 100 0.633
TCMDC-123680 103 0.267 TCMDC-138432 100 0.237
TCMDC-134493 103 0.860 TCMDC-125364 100 0.646
TCMDC-137446 102 0.628 TCMDC-141388 100 0.121
TCMDC-137059 102 0.735 TCMDC-132846 100 0.119
TCMDC-137072 102 0.651 TCMDC-140319 100 1.168
TCMDC-140347 102 0.894 TCMDC-125274 100 1.090
TCMDC-141560 102 0.801 TCMDC-138898 100 0.925
TCMDC-123692 102 0.814 TCMDC-132571 100 0.396
TCMDC-138197 102 0.174 TCMDC-135405 100 0.138
TCMDC-136853 102 1.087 TCMDC-141338 100 0.978
TCMDC-141332 102 1.321 TCMDC-136152 100 0.828
TCMDC-125530 102 0.659 TCMDC-141609 100 0.272
TCMDC-132178 102 0.793 TCMDC-138486 100 0.132
TCMDC-132167 102 0.313 TCMDC-139550 100 0.114
TCMDC-132419 101 0.090 TCMDC-138911 100 0.751
TCMDC-141585 101 0.531 TCMDC-137092 100 0.958
TCMDC-138391 101 0.208 TCMDC-136781 100 0.731
TCMDC-132130 101 0.161 TCMDC-137212 100 0.035
TCMDC-125671 101 0.614 TCMDC-142308 100 0.873
TCMDC-133941 101 0.153 TCMDC-136965 100 0.236
TCMDC-136993 101 0.627 TCMDC-135688 100 0.832
TCMDC-136966 101 0.497 TCMDC-135945 100 0.840
TCMDC-132201 101 0.410 TCMDC-136287 100 0.122
TCMDC-138752 101 0.278 TCMDC-138696 99 0.716
TCMDC-136862 101 0.733 TCMDC-132192 99 0.323
TCMDC-136831 101 0.265 TCMDC-135250 99 0.975
TCMDC-138520 101 0.335 TCMDC-124969 99 0.647
TCMDC-138446 101 0.110 TCMDC-132141 99 0.789
TCMDC-139618 101 0.788 TCMDC-137180 99 1.477
TCMDC-139725 101 0.117 TCMDC-139008 99 1.161
TCMDC-141612 101 0.736 TCMDC-136998 99 0.596
TCMDC-125788 101 0.761 TCMDC-136145 99 0.804
TCMDC-137087 101 0.630 TCMDC-136859 99 0.585
TCMDC-139498 101 0.314 TCMDC-141611 99 0.859
TCMDC-132710 100 0.148 TCMDC-138557 99 0.776
TCMDC-132159 100 0.302 TCMDC-125505 99 0.774
TCMDC-124421 100 0.718 TCMDC-136830 99 0.065
TCMDC-131238 100 0.927 TCMDC-123466 99 0.277
TCMDC-137063 100 0.167 TCMDC-133257 99 0.630
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TCMDC-136923 99 0.612 TCMDC-133194 98 0.104
TCMDC-138451 99 0.186 TCMDC-141399 97 0.762
TCMDC-135507 99 0.174 TCMDC-137135 97 0.715
TCMDC-124526 99 1.588 TCMDC-137125 97 0.182
TCMDC-136194 99 1.510 TCMDC-139410 97 0.256
TCMDC-141000 99 0.135 TCMDC-136195 97 0.669
TCMDC-138298 99 0.048 TCMDC-132915 97 0.062
TCMDC-136382 99 0.621 TCMDC-132131 97 0.889
TCMDC-132898 99 0.184 TCMDC-135373 97 0.616
TCMDC-125529 99 0.830 TCMDC-132829 97 0.772
TCMDC-132729 99 0.130 TCMDC-141610 97 0.287
TCMDC-132753 99 0.956 TCMDC-138430 97 0.770
TCMDC-132910 99 0.200 TCMDC-136906 97 1.088
TCMDC-133171 99 0.756 TCMDC-136951 97 0.688
TCMDC-139502 99 0.063 TCMDC-135456 97 0.832
TCMDC-137120 99 0.552 TCMDC-133699 97 0.738
TCMDC-135054 99 0.930 TCMDC-124972 97 1.054
TCMDC-137137 99 0.505 TCMDC-135305 97 0.213
TCMDC-133702 99 0.534 TCMDC-136992 97 0.635
TCMDC-132188 98 0.577 TCMDC-139871 96 0.776
TCMDC-138686 98 0.818 TCMDC-141978 96 0.983
TCMDC-125577 98 0.524 TCMDC-133935 96 0.147
TCMDC-133932 98 0.142 TCMDC-133940 96 0.142
TCMDC-132145 98 0.452 TCMDC-137503 96 0.661
TCMDC-137034 98 0.857 TCMDC-132997 96 0.867
TCMDC-137582 98 0.104 TCMDC-136922 96 0.363
TCMDC-133009 98 0.308 TCMDC-123506 96 0.134
TCMDC-140797 98 0.895 TCMDC-132897 96 0.138
TCMDC-137094 98 0.289 TCMDC-137902 96 0.376
TCMDC-124146 98 0.871 TCMDC-136820 96 0.204
TCMDC-136837 98 0.726 TCMDC-132160 96 0.557
TCMDC-142040 98 0.202 TCMDC-123486 95 0.512
TCMDC-132405 98 0.119 TCMDC-125415 95 0.258
TCMDC-136193 98 0.941 TCMDC-137131 95 0.232
TCMDC-140681 98 0.464 TCMDC-140367 95 0.734
TCMDC-139268 98 0.158 TCMDC-133007 95 0.167
TCMDC-137480 98 0.104 TCMDC-134151 95 0.149
TCMDC-132566 98 0.255 TCMDC-141392 95 0.617
TCMDC-137129 98 0.185 TCMDC-132844 95 0.139
TCMDC-138205 98 0.111 TCMDC-133042 95 0.146
TCMDC-139559 98 1.006 TCMDC-125600 95 0.168
TCMDC-132189 98 0.829 TCMDC-132849 95 0.117
TCMDC-133701 98 0.240 TCMDC-136940 95 1.025
TCMDC-132320 98 0.519 TCMDC-132028 95 0.167
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Identifier
Average % Inhibition 
in beta-hematin 
assay
uM Parasite Activity 
(reported in 
ChemBL) 
Identifier
Average % 
Inhibition in beta-
hematin assay
uM Parasite Activity 
(reported in 
ChemBL) 
TCMDC-136818 95 0.990 TCMDC-139406 92 0.695
TCMDC-135557 95 0.279 TCMDC-131914 92 0.601
TCMDC-138256 94 0.445 TCMDC-140827 92 0.759
TCMDC-133460 94 0.978 TCMDC-133136 92 0.170
TCMDC-132845 94 0.099 TCMDC-136824 92 0.134
TCMDC-142335 94 0.253 TCMDC-136954 92 0.789
TCMDC-138660 94 0.608 TCMDC-140540 91 0.684
TCMDC-124127 94 1.117 TCMDC-137037 91 0.581
TCMDC-133422 94 0.086 TCMDC-132821 91 0.607
TCMDC-133550 94 0.837 TCMDC-137793 91 0.143
TCMDC-133705 94 0.572 TCMDC-135248 91 0.570
TCMDC-133044 94 0.140 TCMDC-133052 91 0.215
TCMDC-135478 94 0.197 TCMDC-134161 91 0.981
TCMDC-132143 94 1.743 TCMDC-133155 91 0.715
TCMDC-132906 94 0.156 TCMDC-124822 91 0.874
TCMDC-142048 94 0.030 TCMDC-136941 91 0.797
TCMDC-125220 94 0.799 TCMDC-123601 91 0.890
TCMDC-136913 94 0.643 TCMDC-135542 91 0.109
TCMDC-139383 93 0.573 TCMDC-136927 91 0.228
TCMDC-136970 93 1.045 TCMDC-137067 91 0.670
TCMDC-138659 93 0.915 TCMDC-137110 90 0.413
TCMDC-137068 93 0.645 TCMDC-132695 90 0.907
TCMDC-133135 93 0.277 TCMDC-136819 90 0.238
TCMDC-140218 93 0.911 TCMDC-140889 90 1.172
TCMDC-141561 93 1.018 TCMDC-136960 90 0.681
TCMDC-141584 93 0.344 TCMDC-133158 90 0.231
TCMDC-132958 93 0.157 TCMDC-136957 90 0.719
TCMDC-135406 93 0.111 TCMDC-132840 90 0.670
TCMDC-138467 93 0.557 TCMDC-140648 90 1.120
TCMDC-136914 92 0.454 TCMDC-133177 90 0.199
TCMDC-132144 92 0.767
TCMDC-137136 92 0.388
TCMDC-135912 92 0.754
TCMDC-132854 92 0.115
TCMDC-132947 92 0.156
TCMDC-137304 92 1.144
TCMDC-135247 92 0.698
TCMDC-136946 92 0.806
TCMDC-132120 92 1.244
TCMDC-135360 92 0.906
TCMDC-132857 92 0.170
TCMDC-136961 92 0.278
TCMDC-133210 92 0.351
TCMDC-137065 92 0.560
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